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Summary 
Cytochrome P450 (CYP) is a multigene family of constitutive and inducible 
enzymes which catalyze oxidative metabohsm of a wide variety of xenobiotics, of both 
endogenous and exogenous origin. Though several distinct CYP gene families are 
expressed in mammals, four of these CYP gene families (CYP 1-4) are recognized to be 
the major forms of CYPs that metabolize foreign chemicals including drugs, 
environmental chemicals and other xenobiotics. Alteration in the expression of these 
CYPs has been often found to be associated with exposure of drugs and environmental 
chemicals. Specific and selective expression profiles of these CYPs are observed 
following treatment of specific drugs and environmental chemicals. Genetic 
polymorphism is reported for several of the xenobiotic metabolizing CYPs and the 
susceptible genotypes are reported to be at increased risk to the toxicity of drugs and 
chemicals. Genetic variations in the CYPs are often an emerging resource for studying 
various complex diseases and have been identified as biomarker of susceptibility. Much 
of the variability in the CYPs is in the form of stable substitution of a single base termed 
as the single nucleotide polymorphism (SNP). Although SNPs in CYPs have been found 
to be present in all the population, the frequencies of these polymorphisms differ between 
populations. In general, SNPs occurring in the coding region have the potential to alter 
protein structure and function and therefore could be the causative factor influencing 
disease susceptibility, drug efficacy and xenobiotic response. SNPs in CYPs can cause 
abolished, quantitatively altered or enhanced xenobiotic metabolism leading to enhanced 
or diminished toxicity of a chemical or adverse drug effects. In addition, recent studies 
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have shown that CYPs are expressed in blood lymphocytes and could be used as a 
phenotypic tool and biomarker to predict exposure of drugs and environmental changes. 
Cytochrome P450 2E1 (CYP2E1) is a major component of the microsomal ethanol 
oxidizing system in the liver. It exhibits a high degree of inter-individual variability in its 
catalytic activity. To date, several mutations have been described in CYP2E1 gene which 
are well characterized in the Caucasian as well as in Oriental population. Further, these 
SNPs in CYP2E1 play a major role in determining individual's susceptibility to alcoholic 
liver diseases such as alcoholic liver cirrhosis, a chronic liver disease results from 
damage to liver cells from heavy alcohol consumption. As compared to the data available 
in other population worldwide, not much is known about the SNPs in CYP2E1 in Indian 
population. Only few case-control studies are available while no population based study 
have been carried out to investigate the genotype status of CYP2E1 gene in Indian 
populations. Studies have shown that Indian population has more human diversity than 
any other comparable global population in the world. It is likely that the SNPs found in 
the genes involved in the ethanol metabolism pathway may be conserved and these could 
be exploited to identify the risk factors for the environment induced diseases. Further the 
CYP2E1 protein activity and mRNA expression is also known to increase several fold in 
the liver of experimental animals following alcohol administration suggesting that 
CYP2E1 is regulated at various levels such as pretranscriptional, pretranslational, 
translational, and posttranslational. This increase in CYP2E1 activity results in 
accumulation of toxic acetaldehyde and reactive oxygen species in the cell which may 
lead to mitochondrial damage, DNA modification and lipid peroxidation. Studies have 
also shown that freshly isolated peripheral blood lymphocytes of human and laboratory 
animal express measurable levels of CYP2E1 mRNA and protein. Expression of CYP2EI 
mRNA and protein in the peripheral blood lymphocytes is known to be influenced by the 
same factors that affect the concentration of hepatic enzymes including exposure to 
xenobiotics and certain physiological states particularly those associated with higher 
plasma cholesterol. Since expression of CYP2E1 is altered by many factors affecting 
chemical metabolism and toxicity, monitoring of CYP2E1 levels in individuals, who are 
regular alcohol users could help in identifying individuals who are at risk to develop 
alcohol induced toxicity. 
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The candidate in the present dissertation has therefore attempted to identify the 
SNPs, including novel ones in CYP2E1 gene in the different sub-population of India. 
Attempts were also made by the candidate in a case-control study to investigate 
association of functionally important SNPs in CYP2E1 gene identified in Indian 
population along with the other candidate genes such as glutathione S-transferases 
(GSTs) and manganese superoxide dismutase (MnSOD), responsible for detoxifying 
electrophilic intermediates including free radicals generated during the ethanol 
metabolism. Studies were also initiated by the candidate to develop peripheral blood 
lymphocyte CYP2E1 expression as a possible biomarker of alcoholic liver cirrhosis by 
investigating mRNA and protein expression of CYP2E1 and associated catalytic activity 
in freshly prepared blood lymphocytes isolated from alcoholic cirrhotic patients. 
To identify SNPs in Indian population, different population were identified based 
on diverse geographical zones (North, South, East, West, Central and North-East) and 
linguistic backgrounds (Indo Europeans-IE, Dravidians-DR, Tibeto Burmans-TB and 
Austro Asiatics-AA) to maximize novel SNP discovery. Molecular diversity studies have 
revealed that Austro-Asiatic (AA) language speakers are exclusively tribals and are likely 
to have been the most ancient inhabitants of India. Populations of Indo-European (IE) and 
Dravidian (DR) lineage groups account for almost 85% of the total Indian population, 
while the Tibeto-Burman (TB) lineage groups are supposedly immigrants to India from 
Tibet and Burma. These diverse set of sub-population does increase the heterogeneity in 
terms of SNP discovery as compared to a set of samples from a single sub-population. 
These population were identified after consultation with the expert anthropologists. 
Blood samples were collected from different sub-population of India by the Indian 
Genome Variation (IGV) Consortium members including IITR, Lucknow. Genomic 
DNA samples were provided by IGV Consortium for identifying SNPs in CYP2EL Five 
pairs of primers for CYP2E1 gene were designed with the aim to cover the exonic region 
as well as the regions carrying functionally important SNPs using the DNA Star software. 
The first step involved discovering SNPs in CYP2E1 gene in one representative 
DNA sample drawn from 43 different sub-populations and designated as SNP Discovery 
Panel, Though 43 individuals per se do not represent the entire Indian population, such a 
diverse set does increase the heterogeneity in terms of SNP discovery as compared to a 
set of samples from a single sub-population. The SNPs identified in these Discovery 
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panel samples were than validated in the second step in a larger sample size of these 
populations. SNPs in CYP2E1 gene in SNP Discovery Panel were identified by 
bidirectional sequencing of PCR products using primer pairs that covered functionally 
important polymorphism of CYP2E1 gene. Five polymorphic sites including a novel one 
were identified in CYP2E1 gene and were designated as SNPl (-930A/G; rs3813870) in 
5'UTR, SNP2 (6396G/A; Novel) in exon 6, SNP3 (7126G/A; rs8192775), SNP4 
(7632T/A; rs6413432) and SNPS (8057C/A; rs2864984) in intron 6. Out of these five 
SNPs, SNP2 (6396G/A) was considered as novel because no information or any literature 
was available in any existing databases about this SNP. SNPl was found to be 
polymorphic in all the four major sub-population (AA DR, IE and TB) with minor allele 
frequency (MAP) of 0.26. SNP2 was found to be novel and polymorphic in only one sub-
population (DR) with very low minor allele frequency (0.01). SNP3 which is present in 
intron-6 was found to be polymorphic in the three sub-population (AA, DR and IE) with 
the minor allele frequency of 0.05. Similarly, SNP4 commonly known as Dral 
polymorphism or CYP2E1*6, was found to be polymorphic only in IE population with 
minor allele frequency of 0.01. Likewise, SNPS also located at intron-6 was found to be 
polymorphic in three sub population (AA, DR and IE) with minor allele frequency of 
0.05. SNPs identified as SNPl-5 at -930A/G (S'UTR), 6396G/A (exon 6), 7126G/A 
(intron 6), 7632T/A (intron 6) and 8057C/A (intron 6) in CYP2E1 gene were considered 
for further validation in a larger sample size because of their higher minor allele 
frequency. Interestingly, one of the major functionally important SNP, designated as Rsal 
or CYP2E1*5B was not present in any of the 43 representative DNA sample. Since the 
frequency of this polymorphism is very rare in Indian population (1%), it may be possible 
that the 43 representative DNA sample from different sub-population of India may not be 
carrying this SNP. It may be possible that if larger samples were screened, this SNP could 
have been identified. 
Validation data of SNPs in CYP2E1 gene in different Indian sub-population further 
provided evidence that CYP2E1 gene is polymorphic in all the Indian sub-population. The 
five SNPs discovered in Discovery Panel were found to exist in Indian population with 
varied frequency. SNPl was found to be present in all the linguistically and 
geographically diverse population of India. As the SNPl was present in most of the 
population of India, it can be concluded that this SNP was conserved in almost all the 
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population of India and must be the oldest SNP present in CYP2E1 gene in Indian 
population. This SNP has also been shown to be present in other world population though 
there is no frequency data available in NCBI or HapMap databases. Similarly, SNP2 
which is novel and results in amino acid substitution from Glycine to Serine was also 
found to be polymorphic in AA, DR and IE lineages. Minor allele frequency of this SNP 
was found to be similar in AA, DR and IE population. As this SNP is novel, no allele or 
genotype frequency data is available in the HapMap or NCBI database. However, as this 
SNP is located at coding region and resulted in amino acid substitution from Glycine to 
Serine, it might be responsible for alteration in protein activity and need to be further 
studied. SNP3 was also found to be polymorphic in all sub-population of India belonging 
to different linguistic lineages. This polymorphism was found to be reported in 
Caucasians with comparable minor allele frequency with IE lineage. Interestingly, the 
MAP reported in Oriental population (Chinese and Japanese) was almost similar to 
Dravidian but found to be higher than other sub population of India. However, the minor 
allele frequency of this polymorphism in Sub-Saharan African is lower than minor allele 
frequency observed in all the sub population of India. Likewise, our validation data have 
shown that SNP4 (Dral polymorphism) of CYP2E1 was found to be polymorphic in most 
of the sub-population of India except for few IE and one TB lineages. The MAP of Dral 
polymorphism observed in various sub-population of India was quite comparable to 
Caucasian population. However, this SNP was found to be present in African, Hispanic and 
Pacific Rim with higher minor allele frequency than found in different sub-population of 
India. Similarly, SNP5 was found to be polymorphic in all sub-population of India with 
varied frequency of minor allele. This polymorphism has also been reported in 
Caucasian, African American and Chinese population. Minor allele frequency reported in 
Caucasian and African American was found to be lower than found in different sub 
population of India whereas its frequency in Chinese population is similar to the found in 
AA and Out-group population but higher than IE and TB population. Haplotype analysis 
revealed the formation of nine major haplotypes. Some of these haplotypes were found to 
be present in all the four major linguistic groups and in one Out-group population though 
the frequency was found to vary between these groups. Haplotype analysis of SNPs of 
CYP2E1 also revealed that most of the SNPs did not exhibit Linkage Disequilibrium 
(LD) in majority of Indian population. However few SNPs (SNPS & SNPS; SNPl & 
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SNP3; SNP3 & SNP4) exhibit LD in few sub-population of India. The differences in the 
frequencies of these haplotypes could be of significance in determining the individual's 
susceptibility towards the environment induced diseases. 
To further identify the involvement of these SNPs with alcoholic liver disease, a 
case-control study was carried out to investigate the association of functionally important 
SNPs in CYP2E1 gene and other candidate genes with alcoholic liver cirrhosis in North 
Indian population. Even though Rsal {CYP2E1 *5E) and Mspl polymorphism of CYP2E1 
gene were not identified in SNP Discovery Panel of 43 samples, they were also included 
in the study as they were reported to be functionally important in Caucasians and Oriental 
population. Due to their very rare frequency in Indian population, these SNPs were not 
detected in 43 representative samples of Discovery Panel. However, because of their 
clinical significance, they were included in the case-control study to investigate their 
association with the disease. Along with CYP2E1, polymorphism in glutathione S-
transferases (GSTs) and manganese superoxide dismutase (MnSOD), involved in 
scavenging free radicals, were also studied for their association with alcoholic liver 
cirrhosis. The study group consisted of 175 patients suffering from alcoholic liver 
cirrhosis and 140 number of patients suffering from non-alcoholic liver cirrhosis visiting 
the OPD facility of Gastroenterology Department of Sanjay Gandhi Post Graduate 
Institute of Medical Sciences (SGPGIMS), Lucknow, India was included in the study. 
Patients with alcoholic and non-alcoholic liver cirrhosis were diagnosed on the basis of 
their liver biopsy. Control group consisted of non-alcoholic (n=255) and alcoholic 
(n=I40) healthy men having no evidence of liver disease as judged by physical 
examination and normal liver function test. All the patients and controls included in the 
study belonged to same geographical location (Northern India) and same ethnicity. 
It was found that the frequency of minor allele (1%) of CYP2E1*5B (Rsal) was 
almost similar to that reported earlier in North Indian population but slightly higher than 
South Indian controls. Similar frequency of the minor allele of CYP2E1*5B was also 
reported in the Caucasians population while the Oriental population carry much higher 
frequency of the minor allele. Similarly, the minor allele frequency (16%) of CYP2E1*6 
(Dral) was quite similar to that reported earlier in the North Indian or South Indian 
population. This polymorphism is also reported in the Caucasians, though its frequency 
was relatively less when compared to our study or Oriental population. Our data further 
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revealed that Mspl polymorphism is present in North Indian population, though its minor 
allele frequency (6%) is quite higher than reported in Caucasians population. Similar to 
the CYP2E1, the frequency of null genotype of GSTMl (31.5%) was found to be similar 
to that reported earlier in the North Indian population. However, this was much lower 
than found in other Asian populations, Caucasians and Pacific-Rims. Likewise, the 
GSTTl null genotype frequency was found to be 17% in the controls which was similar 
to that seen in other North Indian, Caucasians and African- Americans but lower than 
reported in Orientals and Pacific Rim. Similarly the frequency of minor alleles oiGSTPl 
was found to be 22% which was equal to that observed with other North Indian and 
Caucasians but more than that reported with Japanese and African-Americans and less 
than Hispanics and Pacific-Rim population. Likewise, the frequency of Alanine encoding 
allele of MnSOD in our study was found to be 43% which is slightly lower than that 
reported in Caucasian but much higher than that found in Orientals. 
It was also found that Rsal polymorphism (CYP2E1 *5B) of CYP2E1 gene were 
observed with higher frequency in alcoholic liver cirrhotic patients when compared with 
non-alcoholic controls or alcoholic controls or non-alcoholic cirrhotic patients. The 
higher frequency of Rsal polymorphism of CYP2E1 was found to be significantly 
associated with alcoholic liver cirrhosis risk. Interestingly, Dral and Mspl polymorphism 
of CYP2E1 did not show statistically significant risk for alcoholic liver cirrhosis. 
Haplotype analysis has revealed that Rsal and Dral polymorphism of CYP2E1 do not 
exhibit LD in either controls or cases. Haplotype approach further revealed that haplotype 
T-A-T was found to be associated with more than 5-fold increase in risk for alcoholic 
liver cirrhosis. As observed with CYP2E1 *5B, the present study also demonstrated that 
polymorphism in GSTs modifies the susceptibility to alcoholic liver cirrhosis. An 
elevated risk to alcoholic liver cirrhosis was observed in the patients with null genotype 
of GSTMl when compared with the non-alcoholic controls. Similar significant risk was 
also observed in alcoholic cirrhotic patients carrying variant genotype (Ile/Val + Val/Val) 
of GSTPl when compared with the non-alcoholic controls. Interestingly, no significant 
increase in the frequency of null genotype in GSTTl was observed in alcoholic cirrhotic 
patients when compared with the non-alcoholic controls or non-alcoholic cirrhotic 
patients or alcoholic controls. As observed with GSTs, a statistically significant risk was 
observed in alcoholic cirrhotic patients with variant genotype of MnSOD, an enzyme 
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specifically involved in the detoxification of mitochondrial reactive oxygen species such 
as superoxide anion, when compared with non-alcoholic controls. 
It was also found that combination of null genotypes of GSTMl and GSTTl or 
variant genotype of GSTPl with null genotype of GSTMl or GSTTl confer an even 
higher risk to alcoholic liver cirrhosis. Likewise, a much greater risk for alcoholic 
cirrhosis was also detected in the patients carrying the combination of null genotype of 
GSTMl, GSTTl and variant genotype of GSTPl. Our data also demonstrated that 
combination of SNPs particularly those which are involved in generating free radicals 
such as CYP2E1, a phase I enzyme, and GSTs or MnSOD, which detoxify there free 
radicals increase the risk in alcoholic cirrhotic patients. Several fold increase in risk was 
observed in the alcoholic liver cirrhosis patients with the combination of variant 
genotypes of CYP2E1*5B and GSTPl or null genotype of GSTMl or GSTTl. Similarly, 
several fold increase in the risk was observed in patients with alcoholic liver cirrhosis 
carrying combination of variant genotypes of CYP2E1 *5B and MnSOD when compared 
with non-alcoholic controls or alcoholic controls or non-alcoholic cirrhotic patients. 
Further evidence for the importance of genotypic combinations in the development of 
alcoholic liver cirrhosis was provided by the present study indicating significantly 
increased risk in the cases simultaneously carrying the null or variant genotypes of GSTs 
and MnSOD when compared to the patients with the risk genotypes of GSTs or MnSOD 
alone. 
In addition to identify the association of susceptibility genotypes of CYP2E1 with 
alcoholic liver cirrhosis, attempts were also made to develop and validate CYP2E1 as a 
phenotypic marker which can eventually be used in monitoring studies to screen 
individuals for alcohol exposure. Since exposure to alcohol has been shown to result in 
increased hepatic and blood lymphocyte CYP2EI levels in laboratory animals, these 
studies have been extended to humans who are regular alcohol users and suffering from 
alcoholic liver cirrhosis with the aim to validate blood lymphocytes CYP2E1 levels as a 
possible biomarker of exposure. Study was therefore initiated to investigate mRNA and 
protein expression of CYP2E1 and associated catalytic activity in freshly prepared blood 
lymphocytes isolated from non-alcoholic healthy controls, non-alcoholic cirrhotic and 
alcoholic cirrhotic patients. Eight patients suffering from alcoholic liver cirrhosis (non-
cholestatic) and equal number of patients suffering from non-alcoholic liver cirrhosis, 
8 
Stanmary 
diagnosed on the basis of their Hver biopsy and hepatitis B surface antigen and antibodies 
against hepatitis C virus, visiting the OPD faciUty of Gastroenterology Department of 
Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India 
was included in the study. Eight healthy non-alcoholic individuals were also enrolled in 
the study and served as controls. Semi-quantitative, quantitative RT-PCR, ELISA and 
NDMA-d activity were used for studying mRNA and protein expression of CYP2EI and 
associated catalytic activity in freshly prepared blood lymphocytes of non-alcoholic 
healthy controls, non-alcoholic cirrhotic and alcoholic cirrhotic patients. Significant 
increase in the CYP2E1 mRNA and protein expression was observed in the freshly 
prepared blood lymphocytes isolated from non-cholestatic alcoholic liver cirrhotic 
patients when compared to non-alcoholic controls and non-alcoholic cirrhotic patients. 
This increase in blood lymphocyte CYP2EI expression was associated with an increase 
in NDMA-d activity in blood lymphocytes isolated from alcoholic liver cirrhotic patients 
when compared to non-alcoholic controls and non-alcoholic cirrhotic patients. Our data 
indicating increase in CYP2E1 expression and catalytic activity in freshly prepared blood 
lymphocytes of alcoholic liver cirrhotic patients with early stage of alcoholic cirrhosis 
have suggested suitability of using blood CYP2E1 mRNA expression profile as a 
biomarker to detect the hepatic level of CYP2E1. 
In conclusion, the present dissertation had demonstrated that CYP2E1 is highly 
polymorphic in Indian population. Indian population when stratified either on language 
basis or on the basis of geographical zones, were found to exhibit polymorphism in 
CYP2E1. The presence of SNPs in CYP2EI even in the tribal population, have further 
provided evidence that these SNPs in CYP2E1 were conserved during evolution and may 
have a physiological role in addition to metabolizing drugs and environmental chemicals. 
Case-control studies have further shown that polymorphism in CYP2EJ particularly 
CYP2E1*5B and the phase II genes such as GSTs, MnSOD, are associated with an 
increased susceptibility to alcoholic cirrhosis. Risk to alcoholic cirrhosis was further 
found to increase several fold in the alcoholic cirrhotic cases carrying combinations of 
risk genotype of GSTs or CYP2E1 *5B or MnSOD demonstrating the role of gene-gene 
interactions in modulating the risk to alcoholic liver cirrhosis. The candidate in the 
present dissertation has further showed a significant increase in the CYP2E1 mRNA and 
protein expression and associated NDMA-d activity in the freshly prepared blood 
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lymphocytes isolated from non-cholestatic alcoholic liver cirrhotic patients indicating 
suitability of using blood CYP2E1 mRNA expression profile as a biomarker to predict 
the hepatic level of CYP2E1. 
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INTRODUCTION 
Introduction 
Cytochrome P450s (CYPs) are an important superfamily of phase I xenobiotic 
metabolizing enzymes that are involved in the biotransformation of majority of the drugs 
and chemicals including chemicals present in the environment. CYP dependent 
biotransformation often determines to a large extent whether a chemical will be 
detoxified or activated to a reactive species to produce toxicity. A potential relationship 
between CYP activation in target tissues and diseases such as cancer has been shown. 
Genetic polymorphism has also been reported for several of the xenobiotic metabolizing 
CYPs and the susceptible genotypes are reported to be at increased risk to the adverse 
effects/toxicity of drugs and chemicals. Genetic variations in the CYPs are often an 
important resource for studying various complex diseases and have been identified as 
biomarker of susceptibility. Much of the variability in the CYPs is in the form of stable 
substitution of a single base termed as the single nucleotide polymorphisms (SNP). SNPs 
create an extraordinary degree of variability among genomes of different individuals. 
SNPs in general serve as markers with those occurring in the coding region (cSNP) 
having the potential to alter protein structure and fianction and, therefore, to be the 
causative gene alteration influencing disease susceptibility, drug efficacy, and toxicity of 
xenobiotics. There has been an increased interest in identifying the role of SNPs in the 
human genome in modifying the effect of exposures to environmental health hazards, 
which might render some individuals or groups in the population more or less susceptible 
to develop disease after exposure. Since SNPs may vary among populations it is essential 
to discover and /or validate them in the population of interest for disease association or 
pharmacogenetic study. Since the complex diseases are not caused by a mutation in 
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single gene but by interaction of multiple genes, so called susceptibility genes, as well as 
environmental factors, it is important to identify genes that influences individual's 
susceptibility to environmental factors. Genetic polymorphism in genes encoding drug-
metabolizing enzymes, drug transporters and receptors contribute, at least in part, to the 
inter-individual variability in drug response. In recent years there has been an interest to 
develop biomarkers that predict the susceptibility and exposure of the toxic agents. SNP 
in CYPs has been used as biomarker of susceptibilify to predict the toxicity of 
environmental chemicals including carcinogens as well as adverse drug effects. 
Cytochrome P450 2E1 (CYP2E1) is a major component of microsomal ethanol 
oxidation system, involved in the activation of many procarcinogens and several drugs to 
highly reactive metabolites. It also metabolizes various endogenous substrates, such as 
ethanol, acetone, and acetal, as well as exogenous substrates including benzene, carbon 
tetrachloride, ethylene glycol and nitrosamines. Genetic polymorphism has been reported 
for CYP2E1 gene which has a clinical importance. The molecular genetic basis for the 
different phenotypes has been well characterized for this gene in Caucasians and Oriental 
population. However, not much information is available about the polymorphism in 
CYP2E1 gene in Indian population. The Indian population is unique due to its population 
structure and is subdivided into a multitude of large endogamous ethnic groups which are 
genetically less heterogeneous than conglomerate populations, enabling greater success in 
genomic and epidemiological studies on them. Thus the vast and diverse Indian genetic 
pool provides a unique opportunity to discover functional significance of the genetic 
variations. It is likely, that the SNPs found in the genes involved in the toxication-
detoxication pathways may be conserved and these could be exploited to find the risk 
factors for the environment induced diseases. As the CYP2E1 enzyme is responsible for 
the metabolism of ethanol, and its activity increases up to 20-fold following continuous 
alcohol consumption, the polymorphisms in CYP2E1 may consequently modulate the risk 
of developing alcoholic liver diseases involving alcoholic liver cirrhosis. 
Alcoholic liver cirrhosis, a chronic liver disease, results from damage to liver cells 
from chronic ethanol intake where damaged and dead liver cells regenerate in an 
abnormal pattern primarily forming nodules that are surrounded by fibrous tissue. 
Alcoholic liver cirrhosis is most common in the western world and its occurrence is 
increasingly seen in countries such as India and Japan which traditionally had a low 
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prevalence of the disease. The development of alcoholic cirrhosis depends upon the 
amount and regularity of alcohol intake and usually occurs after 10 to 15 years of heavy 
drinking. Though, alcohol consumption is one of the main factors responsible for 
alcoholic liver cirrhosis, only 20% of habitual drinkers develop cirrhosis. Genetic 
polymorphisms (SNPs) in alcohol metabolizing enzymes such as CYP2E1 and 
detoxification enzymes for example glutathione-S-transferases (GSTs) and manganese 
superoxide dismutase (MnSOD), may play a major role in determining individual's 
susceptibility to cirrhosis and thus may act as useful markers to predict the susceptibility 
for cirrhosis in individuals and populations at large. Though the pathogenesis of alcoholic 
liver cirrhosis involves oxidative stress, the disease seems to be multifactorial involving 
gene-environment interaction. It would be therefore interesting to focus on 
polymorphisms in the genes that are involved in ethanol metabolism particularly CYP2E1 
and detoxification of reactive oxygen species generated during metabolism of ethanol 
such as GSTs and MnSOD. 
As compared to genotyping, phenotyping studies have shown to provide more 
clinically relevant information because it is a reflection of the combined effects of 
genetic, environmental and endogenous factors on CYP activity. In recent years, there 
has been great interest in developing assays that can be used as biomarkers of the extent 
and persistence of effects caused by exposure to toxic agents. As blood cells are easily 
available these cells can be used as surrogate for the status of CYP in the target tissues 
and changes in CYP levels in blood cells could be used to predict xenobiotic induced 
alterations in the target tissues. CYP2E1 protein activity and mRNA expression is also 
known to increase several fold in the liver of experimental animals following alcohol 
administration suggesting that CYP2E1 is regulated at various level such as 
pretranscriptional, pretranslational, translational, and posttranslational. Studies have also 
shown that freshly isolated peripheral blood lymphocytes of human and laboratory 
animal express measurable levels of CYP2E1 mRNA and protein. Expression of CYP2E1 
mRNA and protein in the peripheral blood lymphocytes is known to be influenced by the 
same factors that affect the concentration of hepatic enzymes including exposure to 
xenobiotics and certain physiological states particularly those associated with higher 
plasma cholesterol. Since expression of CYP2E1 is altered by many factors affecting 
chemical metabolism and toxicity, monitoring of CYP2E1 levels in individuals, who are 
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regular alcohol users could help in identifying individuals who are at risk to develop 
alcohol induced toxicity. 
The candidate in the present dissertation has therefore carried out studies with the 
following objectives: 
> To identify and validate Single Nucleotide Polymorphisms (SNPs) in cytochrome 
P450 2E1 (CYP2E1) gene in Indian population, stratified on linguistic and 
geographical basis. 
> Using case-control studies identify functional significance of SNPs in CYP2E1, a 
phase I genes and glutathione S-transferases (GSTs), and manganese superoxide 
dismutase (MnSOD), phase II genes by studying their association with alcoholic liver 
cirrhosis in North Indian population. 
> To explore the importance of possible genotypic combinations in the above 
mentioned genes involved in the pathogenesis of alcoholic liver cirrhosis. 
> To develop peripheral blood lymphocyte CYP2E1 expression as a possible biomarker 
of alcoholic liver cirrhosis by investigating CYP2E1 mRNA and protein expression in 
blood lymphocytes isolated from alcoholic cirrhotic patients. 
CaEIAPTER-l 
REVIEW OF LITERATURE 
(Review of Literature 
Cytochrome P450s (CYPs) are an important superfamily of phase I xenobiotic 
metaboHzing enzymes which are ubiquitously distributed and found from bacteria to 
humans (Nelson et al., 1996). The term 'cytochrome P450' was coined because of its 
unusual spectral properties which displayed a typical absorption maximum of the reduced 
CO-bound complex at 450 nm (Omura and Sato, 1962). In cytochrome P450, cytochrome 
stands for a hemoprotein, P for pigment and 450 reflects the absorption peak of the CO 
complex at 450 nm. Most of these CYPs are found in the endoplasmic reticulum and 
some are localized primarily in mitochondria. They are involved in the metabolism of a 
wide variety of xenobiotics (drugs, environment pollutants, food additives, pesticides, 
and other xenobiotics) as well as endobiotics including eicosanoids, cholesterol, bile 
acids, vitamin D3, steroid etc. The CYP enzymes often referred to as heme thiolate 
proteins are the monooxygenases (mixed fuction oxidases) that catalyze the incorporation 
of an oxygen atom in to the substrate and converts them to more water soluble products 
(Vaz, 2001; Yan and Caldwell, 2001; Coon, 2005). 
Cytochrome P450 systems catalyzes the following reaction: 
RH + O2 + NAD(P)H + H^ ^ ROH + H2O + NAD(P)^ 
Where R represents a substrate sucji as a steroid, fatty acid or compound with an alkene, 
aromatic ring or heterocyclic ring substituent that serves as a site for oxygenation. They 
are involved in reactions as diverse as e.g. hydroxylation, N-, O- and S-dealkylation, 
sulphoxidation, epoxidation, deamination, desulphuration, dehalogenation, peroxidation, 
and N-oxide reduction. Their substrates include fatty acids, steroids, prostaglandins, as 
well as a multitude of foreign compounds such as drugs, anaesthetics, organic solvents, 
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ethanol, alkylaryl hydrocarbon products, pesticides, and carcinogens. This diversity of 
catalyzed reactions including large intra- and interspecies variability in catalytic activity 
and in regulation attracted researchers from different fields to study CYP systems. 
Despite their occasionally minimal sequence similarity, all CYPs have a similar structural 
fold with a highly conserved core (Graham and Peterson, 1999). 
Sladek and Mannering (1966) for the first time provided evidence for the presence 
of multiple forms of cytochrome P450 in liver microsomes. Their studies demonstrated 
that phenobarbital (PB) inducible isoforms are different from the 3-methylcholanthrene 
(MC) induced isoenzymes of CYP. Purification and characterization studies later on 
indicated that many different forms of CYPs exist in the liver which has narrow but 
overlapping substrate specificities (Ryan and Levin, 1990). Humans are estimated to have 
at least 57 different genes and 58 pseudogenes (Nelson, 2006; 
http://dmelson.utmem.edu/CytochromeP450.html). Till date, 18 families and 44 
subfamilies of CYP genes have been identified (Nelson, 2006). To add uniformity to 
CYP enzyme classification, a nomenclature system was adapted in 1996 (Nelson et al., 
1996). Based on amino acid sequence homologies, the CYP superfamily has been 
categorized into several families and subfamilies (Nebert et al., 1989, 1991; Nelson et al., 
1996). Sequence that are greater a 40% identical at the amino acid level belong to the 
same family (designated by Arabic number) and sequence that are greater than then 60% 
identical are in the same subfamily (designated by a capital letter) where the individual 
genes are numbered arbitrarily. To illustrate this naming system, CYP2C9*1*2 is taken as 
an example. In this isozyme designation, CYP is the standard abbreviation for 
mammalian cytochrome P450. Families of the isozyme which share greater than 40% 
protein sequence homology with each other are designated by the first number following 
the cytochrome P450 designation e.g., 2. Subfamilies which share greater than 55% 
homology with each other are differentiated by the letter following the family designation 
e.g., C. Single members of subfamilies represent a particular gene and are designated by 
the number following the subfamily description e.g., 9. An asterisk and a number 
following the member description designate an allele e.g. *1 and *2. The *1 allele for 
CYP2C9, and most others, is known as the wild type and denotes normal enzyme activity. 
The enzymes in the families 1-3 are mostly active in the metabolism of 70-80% of 
all phase I dependent xenobiotics including drugs and environmental chemicals, whereas 
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the other families have important endogenous substrates (Table 1.1). The expression of 
the CYPs belonging to families 1-3 is often increased several fold following exposure to 
the chemicals which are metabolized by these enzyme systems. For example, expression 
of CYPIA can be elevated 100-fold or more in liver and many extrahepatic tissue 
following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 3-
methylcholanthrene (MC), or other polycyclic aromatic hydrocarbons (Lewis, 1996, 
Kondraganti et al., 2002). Likewise, phenobarbital (PB) as well as a large number of 
structurally unrelated chemicals termed 'PB-like' inducers induce the expression of 
CYP2A, 2B & 2C subfamilies both in laboratory animal and in the humans (Waxman and 
Azaroff, 1992; Xiong et al., 2002). Similarly, ethanol and other substrates of CYP2E1 
increases the expression of CYP2E1 several fold in the liver and other extra hepatic 
tissues in experimental animals as well as humans (Song et al., 1990; Raucy et al., 1995; 
Dey et al., 2002, 2005). Likewise the 3A subfamily can be induced effectively by 
macrolide antibiotics (rifampicin) and synthetic steroids such as dexamethasone or by 
pregnenolone-16a-carbonitrile, PCN (Waxman and Azaroff, 1992; Lewis, 1996; Cui et 
al, 2005). 
1.1 CYTOCHROME P4502E1 (CYP2E1) 
Cytochrome P450 2E1 belongs to CYP2 family which is the largest family 
consisting of eight subfamilies 2A, 2B, 2C, 2D, 2E, 2F, 2G & 2H (Nebert et al 1989; 
Gonzalez et al 1996). This enzyme is constitutively expressed and can metabolize 
substrates such as ethanol, acetone, acetol, benzene, pyridine etc. Its activity towards 
acetone and acetol oxidation suggests that CYP2E1 is involved in the pathway of 
gluconeogenesis during the fasting state. This feature, combined with the ability of 
CYP2E1 to convert dioxygen into reactive oxygen radicals which can promote lipid 
peroxidation suggests important toxicological implications for this enzyme. It is involved 
in metabolism of many toxicologically important substrates including ethanol, carbon 
tetrachloride, acetaminophine and N-nitrosodimethyamine (Guengerich et al., 1991; 
Koop, 1992), exogenous substrates such as benzene, ethylene glycol and nitrosamines as 
well as endogenous substrates including lipid peroxidation products, ketones such as 
acetone and polyunsaturated fatty acids such as linoleic, linolenic and arachidonic acid. 
(Novak and Woodcraft, 2000). 
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Table 1.1: Human CYP families and their main functions 
CYP 
Family 
CYPl 
CYP2 
CYP3 
CYP4 
CYP5 
CYP7 
CYP8 
CYPll 
CYP17 
CYP19 
CYP20 
CYP21 
CYP24 
CYP26 
CYP27 
CYP39 
CYP46 
CYP51 
Number of 
sub-families 
2 
13 
1 
6 
1 
2 
2 
2 
1 
1 
1 
1 
1 
3 
3 
1 
1 
1 
Number 
of genes 
3 
16 
4 
12 
1 
2 
2 
3 
1 
1 
1 
1 
1 
3 
3 
1 
1 
1 
Main function 
PAHs metabolism 
Drug metabolism, Arachidonic acid 
metabolism 
Xenobiotic and steroid metabolism 
Fatty acid hydroxylation 
Throboxane synthesis 
Cholesterol 7 a - hydroxylation 
Prostaglandin synthesis 
Cholesterol side-chain cleavage, Steroid 11 P 
-hydroxylation. Aldosterone synthesis 
Steroid -17a hydroxylation 
Androgen aromatization 
Expressed in gastrula, neural patterning and 
somatgenesis, fetus and nasopharynx 
Steroid 21-hydroxilation 
Steroid 24-hydroxilation 
Retinoic acid hydroxylation 
Steroid 27-hydroxilation 
Unknown 
Cholesterol 24- hydroxylation 
Steroid biosynthesis 
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Acetone is the most important endogenous substrate of CYP2E1, which is 
converted to acetol and methylglyoxal and these three carbon intermediates can 
ultimately produce glucose (Koop and Casazza, 1985). Blood levels of acetone under 
fasting conditions were elevated up to 50-fold in transgenic mice lacking CYP2E1 as 
compared to wild type mice, indicating the critical role of CYP2E] in acetone 
metabolism (Bondoc et al., 1999). Other endogenous compounds that can be metabolized 
by CYP2E1 include fatty acids such as linoleic and arachidonic (AA) acids (Laethem et 
al., 1993). With respect to exogenous substrates, CYP2E1 metabolizes a variety of small, 
hydrophobic substrates including solvents such as chloroform and carbon tetrachloride, 
aromatic hydrocarbons such as benzene and toluene, alcohols such as ethanol and 
pentanol, aldehydes such as acetaldehyde, halogenated anesthetics such as enflurane and 
halothane, nitrosamines such as A ,^A^dimethylnitrosamine, and drugs such as 
chlorzoxazone and acetaminophen (Kopp, 1992; Lieber, 1999; Tanaka et al., 2000; Boh 
et al., 2003) (Table 1.2). Chlorzoxazone is important drug and its hydroxylated product 
can readily be assayed in the blood, and the 6-hydroxychlorzoxazone/chlorzoxazone ratio 
is widely used to assess the approximate levels of CYP2E1 in humans, including 
alcoholics (Girre et al., 1994). Procarcinogens, including nitrosamines and azo 
compounds are the effective substrates for CYP2E1 (Yang et al., 1990). 
1.1.1 CYP2E1 and ethanol metabolism 
Until three decades ago, it was believed that alcohol dehydrogenase (ADH) was the only 
significant pathway for ethanol metabolism which catalyzes the conversion of ethanol to 
acetaldehyde (Lieber, 1992, 1998). Later on it was reported that microsomal ethanol 
oxidizing system (MEOS) plays the major role in ethanol metabolism (Lieber, 1999). The 
Km for ethanol oxidation by the MEOS (10 mM) was about an order of magnitude 
greater than that for ethanol oxidation by alcohol dehydrogenase and represents a minor 
pathway of ethanol oxidation, probably accounting for less than 10% of the liver capacity 
to oxidize ethanol (Lieber, 1972). It is now well established that there are three enzyme 
systems in the hepatocytes which are able to metabolize ethanol and these are located in 
three different cellular compartments (Figure 1.1). 
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Table 1.2: Substrates of CYP2E1 
Alcohols, 
aldehydes, 
ketones 
Acetaldehyde 
Butanol 
2-Butanone 
Ethanol 
Glycerol 
Isopropanol 
Methanol 
Pentanol, 
Propanol 
Aromatic 
compound 
Acetaminophen 
Aniline 
Benzene 
BromoBenzene 
Caffeine 
Capsaicin 
Chlorzoxazone 
Phenol 
Isoniazid 
/?-Nitrophenol 
Pyrazole 
Pyridine 
Styrene 
Toluene 
Ethers 
Diethyl ether 
Methyl t-
butyl ether 
Fatty acids 
Arachidonic 
acid 
(co-land co-2 
hydroxylation) 
Laurie acid 
(co-1-
hydroxylation) 
Halogenated 
& non-
balogenated 
alkanes & 
alkenes 
Acetoacetate 
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i) Alcohol dehydrogenase (ADH) located in the cytosol and is major enzyme 
pathway for ethanol oxidation, 
ii) Microsomal ethanol oxidizing system (MEOS) situated in the endoplasmic 
reticulum and represents a minor pathway for ethanol oxidation, 
iii) Catalase located in the peroxisomes, capable of oxidizing ethanol in vitro 
in the presence of hydrogen peroxide generating system and plays a very 
small role in ethanol metabolism. 
Each of these systems causes specific metabolic and toxic alterations which all 
lead to the formation of acetaldehyde, the toxic metabolite of ethanol. Acetaldehyde is 
subsequently oxidized to acetate by aldehyde dehydrogenase (ALDH). Activity of MEOS 
enhances significantly after chronic ethanol exposure, due to an increased total content of 
CYPs, in particular the induction of CYP2E1, which show high catalytic activity for 
ethanol (Lieber, 1972, 1999). The purification of an ethanol-inducible form of CYPs 
from rabbit liver microsomes firmly established the role of CYP2E1 in MEOS (Koop et 
al., 1982). Ethanol-inducible CYPs have been isolated from many species (Raucy et al., 
1995, 1999; Soh et al., 1996; Dey et al., 2002) and while several CYPs may be induced 
by ethanol, the major ethanol inducible CYPs is now referred to as CYP2E1. 
1.1.2 CYP2E1 localization and tissue specific expression 
CYP2E1 is an enzyme expressed primarily in the hepatocytes, but significant 
amounts are also found in the Kupffer cells. CYP2E1, like other xenobiotic-metabolizing 
CYPs, is mainly located in the membrane of the endoplasmic reticulum, where it is 
anchored and retained through its hydrophobic NH2- terminus, leaving the large COOH-
terminal domain, including the catalytic site exposed to the cytosol. CYP2E1 was shown 
to be transported out of the endoplasmic reticulum to the Golgi apparatus, with 
subsequent transfer to the plasma membrane where it may play a role in the autoimmune 
hepatotoxicity (Lytton et al., 1999; Neve and Ingelman-Sundberg, 2000). Removal or 
modification of the hydrophobic NH2-terminal transmembrane domain of CYP2E1 
results in the exposure of a mitochondrial-targeting signal that directs the protein to the 
mitochondria. Essentially two forms of CYP2E1 are present in the mitochondria, a 
highly phosphorylated form mediated via cAMP-dependent protein kinase A and a 
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shortened 40-kDa amino-terminal-truncated form, which lacks the N-terminal amino 
acids and which can be further truncated at amino terminal to produce a mature 
mitochondrial form of CYP2E1 lacking about 100 amino acids. The mitochondrial 
CYP2E1 is catalytically active with typical substrates but requires, as do the other 
mitochondrial P450s, adrenodoxin and adrenodoxin reductase (and NADPH) as electron 
donors(Neve and Ingelman-Sundberg, 2000; Robin, 2001). 
Evidence suggests that CYP2E1 is also expressed in extrahepatic tissues, 
including lung, kidney, brain and blood lymphocytes (Wheeler et al., 1992; Amet et al., 
1997; Raucy et al., 1999; Yadav et al., 2006). Several studies have shown that freshly 
isolated peripheral blood lymphocytes of human and laboratory animal express 
measurable levels of CYP2E1 mRNA and protein (Song et al., 1990; Soh et al., 1996; 
Raucy et al., 1997, 1999; Dey et al., 2002, 2005; Haufroid et al., 2003). CYP2E1 has been 
also identified in kidney microsomes and its expression was increased by chronic ethanol 
treatment (Ding et al., 1986; Ding and Coon, 1988), but basal levels of CYP2E1 were 
lower in kidney than in liver. Hakkak et al. (1996a) showed that CYP2E1 is present in 
colonic epithelial cells. Yadav et al. (2006) also showed that ethanol-inducible CYP2E1 
is constitutively expressed in the rat brain. Catalytic activity, and inducibility, of CYP2E1 
in the rat nervous system was also described by others (Bhagwat et al., 1995; Tindberg 
and Ingelman-Sundberg, 1996). CYP2E1 mRNA was also identified in the rat prostate 
and testis by reverse transcription PCR, southern blotting, and DNA sequencing (Jiang et 
al., 1998). 
1.1.3 CYP2E1 regulation 
Regulation of CYP2E1 is complex process involving transcriptional, 
posttranscriptional and posttranslational events. Ethanol and other agents (acetone, 
imidazole, 4-methylpyrazole, pyrazole, and pyridine) acting on CYP2E1 have little effect 
on CYP2E1 transcript content in liver (Song et al., 1986, 1987; Khani et al., 1987; 
Johansson and Ingelman-Sundberg, 1988; Porter et al., 1989). A posttranslational 
mechanism, namely protein stabilization, has been shown to be involved in CYP2E1 
induction as ethanol and imidazole were found to prevent the rapid decrease in CYP2E1 
enzyme levels in rat hepatocytes cultures (Eliasson et al., 1988), and acetone treatment 
was shown to prolong the in vivo half-life of CYP2E1 in rat liver by eliminating the fast-
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phase component associated with the enzyme's normal degradation (Song et al., 1989). 
Furthermore, in a HepG2 cell line which stably and constitutively expresses the coding 
sequences of human CYP2E1, addition of ethanol (2 to 100 mM) for 2 days resulted in an 
increased CYP2E1 content as determined by Western blotting, whereas Northern blot 
analysis did not reflected increased steady-state CYP2E1 mRNA level. These results 
indicated that ethanol increases the content of CYP2E1 in this experimental model 
probably by stabilization of the protein against degradation (Carroccio et al., 1994). 
Similarly, a FGC-4 hepatoma cell line exhibited basal levels of CYP2E1 apoprotein that 
were inducible by ethanol treatment but there was no observed rise in CYP2E1 mRNA 
levels again suggesting that CYP2E1 is increased by ethanol through posttranscriptional 
mechanisms (McGehee et al., 1994). 
Kubota et al. (1988) found that induction of CYP2E1 protein in hamsters by 
ethanol and pyrazole was associated with an increase in translatable CYP2E1 mRNA, 
while elevated levels of hepatic CYP2E1 mRNA were also described in alcohol-treated 
rats (Ingelman-Sundberg et al., 1988; Diehl et al., 1991), and enhanced levels of both 
hepatic CYP2E1 protein and mRNA were found in actively drinking patients (Takahashi 
et al., 1993). Cellular levels of CYP2E1 protein and its mRNA were significantly 
correlated (Tsutsumi et al., 1993), which indicated that mRNA stabilization and/or 
transcriptional activation are involved in ethanol-mediated CYP2E1 induction in humans. 
Indeed, CYP2E1 induction appears to occur via two steps: a posttranslational mechanism 
at low ethanol concentrations and an additional transcriptional one at high ethanol levels 
(Badger et al., 1993; Ronis et al., 1993). 
1.1.4 CYP2E1 induced oxidative stress 
Oxidative stress is the result of an increase in intracellular pro-oxidant species 
such as H2O2, hydroxy radicals (OH) and superoxide anion radical (02' )High 
intracellular levels of these molecules, collectively called reactive oxygen species (ROS), 
can lead to damaged mitochondria, DNA modification, lipid peroxidation, elevated 
cytokine production and even cell death. In mammals, ROS can result in a number of 
pathological conditions including Alzheimer's disease, atherosclerosis, cancer, diabetes, 
rheumatoid arthritis, various neurological disorders and alcoholic liver diseases (Mates et 
al., 1999). Oxidative stress has been proposed to be critically involved in alcoholic liver 
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diseases (Di Luzio, 1966; Shaw et al., 1981) and is most probably not due to an increase 
in pro-oxidant formation alone. Alcoholics replace up to 50% of their total daily calories 
with ethanol (Patek, 1979), leading to nutritional deficiencies that can be further 
complicated by nutrient malabsorption (Bujanda, 2000) and the net effect is that 
alcoholics often have lower levels of key dietary antioxidant molecules and a decreased 
overall antioxidant status. Therefore, oxidative stress in alcoholic liver diseases is most 
probably mediated by both an increase in pro-oxidant production and a decrease in 
antioxidant defenses. 
The pathway of CYP2E1 dependent oxidative stress and toxicity is shown in 
figure 1.2. Ethanol induces the level of CYP2E1 upto 20-fold (Stickel and Osterreicher, 
2006), largely by a posttranscriptional mechanism involving enzyme stabilization against 
degradation. During the metabolism of ethanol by CYP2E1, reactive oxygen species 
(ROS) such as O2' , H2O2 and reactive nitrogen species (RNS) are generated and in 
presence of iron, which is increased after ethanol consumption, produces more powerful 
oxidants including OH, ferryl species, and 1-hydroxyethyl radical. Initially, the liver 
cells respond to the CYP2E1 related oxidative stress by transcriptionally inducing various 
antioxidant enzymes glutathione-S-transferase (GST), glutamate cysteine ligase (GCL), 
manganese superoxide dismutase (MnSOD) via their antioxidant response elements. 
However, these protective mechanisms are soon overwhelmed and the cells become 
sensitive to the CYP2E1 generated oxidants. These generated oxidants promote toxicity 
by protein oxidation, enzyme inactivation, oxidative damage to the DNA, disturbing cell 
membranes via lipid peroxidation and production of reactive lipid aldehydes, such as 
malondialdehyde (MDA) and 4-hydroxynonenal (HNE). Mitochondria seem to be among 
the critical cellular organelles damaged by CYP2E1 derived oxidants. A decrease in 
membrane potential (A4^m) of mitochondria due to the mitochondrial membrane 
permeability transition causes the release of proapoptotic factors, resulting in apoptosis 
and a decrease in ATP levels further causes necrosis. Some CYP2E1 derived ROS, such 
as H2O2, lipid hydroperoxide (LOOH), and 4-hydroxynonenal (HNE), are diffusible and 
may exit hepatocytes and enter other liver cell types such as stellate cells and stimulate 
these cells to produce collagen and elicit a fibrotic response which ultimately leads to 
alcoholic liver diseases (Nieto et al., 2002). 
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Like superoxide anion for ROS, it is likely that NO' serves as the 'parent' 
molecule for other RNS. Unlike superoxide anion, NO' has pleotropic effects which has 
protective as well as damaging role in liver disease (Hon et al., 2002). For example, it is 
well known that the disregulation of vascular tone after acute alcohol intake and in 
alcoholic cirrhosis is mediated, in part, by a decrease in NO" production (Oshita et al., 
1994; Wiest and Groszmann, 2002). It is also been shown that NO' is anti-apoptotic in 
hepatocytes and is required for normal liver regeneration (Rai et al., 1998; Kim et al., 
2000). However, high levels of NO' can also play a potentially damaging role in 
alcoholic liver diseases by the production of RNS, such as ONOO". RNS derived from 
NO' can cause nitration (e.g. 3-nitrotyrosine formation) and nitrosation reactions (e.g. 
nitrosothiol formation), as well as oxidation reactions during alcohol exposure. Thus, 
NO' may play a dual role in alcoholic liver diseases, mediating both protective effects 
and tissue damage by overproduction of RNS. 
1.2 ALCOHOLIC LIVER DISEASE 
Alcohol consumption is a major public health problem, and contributes to about 
4% of the global burden of disease, a proportion similar to that of tobacco and 
hypertension (Room et al., 2005). Not only volumes of consumption, but also patterns of 
drinking, especially irregular heavy drinking, have been shown to determine burden of 
disease (Rehm et al., 1996, 2003; McKee and Britton, 1998). Rates of alcohol 
consumption in the general population have been known to be associated with those of 
alcoholic liver disease. Nearly all heavy drinkers reveal fatty liver and approximately 10-
20% develops alcoholic liver cirrhosis (Teli et al., 1995). In addition, alcoholics with 
chronic hepatitis C virus infection or obesity display more severe liver damage (Wiley et 
al., 1998; Raynard et al., 2002). Alcohol has been shown to be causally related to more 
than 60 different medical conditions (Rehm et al., 2003). 
Alcoholic liver disease develops due to chronic alcohol consumption and is one of 
the major medical complications of alcohol abuse. It accounts for more than 50% of all 
chronic liver diseases and responsible for more than 50,000 annual death worldwide 
(Corrao et al., 1997; John and Hanhe 2002; Kim et al., 2002). Ethanol consumption 
induces oxidative stress in liver and extrahepatic tissues and is linked to an imbalance 
between the pro-oxidant and the antioxidant systems (Nordmann, 1994; Kurose et al.. 
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1996). This oxidative stress induces peroxidation of lipids leading to by-products which 
have been shown to promote collagen production (Tsukamoto et al., 1995) and to form 
adducts with proteins. They have been suggested to be initiators of inflammatory 
response and fibrosis and therefore play an important role in disease (Ingelman-Sundberg 
etal., 1993). 
The risk for the development of alcoholic liver diseases increases with the time 
and dose dependent consumption of alcohol (Lelbach, 1966). In order to develop liver 
disease, a 'threshold' regarding daily amount and length of time of alcohol intake has to 
be exceeded. Daily intake of alcohol for 10-12 years with doses in excess of 40-80 g/day 
for males and of 20-40 g/day for females are generally needed to cause alcoholic liver 
diseases (Fuchs and Stampfer, 1995; Becker et al., 1996; Thun et al., 1997; Grant et al., 
1988) .Women had greater susceptibility to these diseases at any given level of intake. 
Kwo et al. (1998) have shown that men and women have equivalent alcohol elimination 
rates. The gender differences in susceptibility to liver injury may be due to 
pharmacokinetic reasons such as differences in ethanol absorption or alternatively 
differences in the response of the liver to alcohol induced injury that may be caused by 
oxidative by-products of ethanol metabolism in the liver. The pattern of drinking is also 
important as alcoholic liver diseases increases in those who drink without accompanying 
food and also in those who drink multiple different alcoholic beverages (Bellentani et al., 
1997). It is well known that food delays gastric emptying and intestinal absorption of 
alcohol and thus intake of food before drinking will decrease the rise of blood alcohol 
concentrations. 
Detection of the 1-hydroxyethyl radical in the bile after administration of ethanol 
to rodents has been a most valuable assay for determining ethanol-induced radical 
formation and oxidant stress in vivo (Reinke et al., 1987). Formation of the I-
hydroxyethyl radical may play a role in the development of alcoholic liver diseases 
produced by ethanol, perhaps via formation of protein adducts with subsequent 
autoantibody formation (Clot et al., 1996). During chronic ethanol consumption the level 
of CYP2E1 increases several fold and catalyzes the two-electron-oxidation of ethanol to 
acetaldehyde and produces reactive oxygen species (ROS). The generated acetaldehyde is 
subsequently oxidized to acetate by aldehyde dehydrogenases. The kinetics of this 
reaction are sufficiently slow to allow the accumulation of detectable increases in 
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acetaldehyde which form adducts with reactive residues on proteins or small molecules 
(e.g. cysteines) and alter or interfere with normal biological processes that may be 
directly toxic to the cell. Modified biological molecules may also stimulate the host's 
immune response and cause an autoimmune-like disease. Antibodies against such 
oxidatively modified proteins have been reported in both humans and animal models of 
alcoholic liver diseases (Klassen et al., 1995; Niemela, 2001). For example, hybrid 
adduct of malondialdehyde and acetaldehyde (MMA) unique to alcohol exposure has 
been shown to induce an immune response both in human alcoholics and in animal 
models of these disease (Thiele et al., 2001). CYP2E1 can also promote the one-electron 
oxidation of ethanol to the 1-hydroxyethyl radical (Albano et al., 1991). The mechanism 
for this oxidation is not clear but appears to involve the oxidase activity of CYP2E1 
rather than a direct metabolism by CYP2E1, since production of the 1-hydroxyethyl 
radical is inhibited by ROS scavengers such as superoxide dismutase and catalase 
(Knecht et al., 1993; Rao et al., 1996). 
Alcohol probably works as a 'potential hepatotoxin', with the development of 
liver disease depending on the balance of host attributes and co-existing external factors, 
such as gender, polymorphism of alcohol-metabolizing enzymes, immunological factors, 
exposures to other substances/drugs, hepatic viral infections, nutritional deficiencies, 
obesity, etc. Despite the need for a threshold with respect to dose and length of time for 
development of alcoholic liver disease, there is not a particular amount of alcohol that 
will predictably cause the disease. Among heavy, long term alcohol drinkers, 90-100% 
develops fatty liver, 10-35% develops alcoholic hepatitis and only 8-20% of heavy 
drinkers develop alcoholic liver cirrhosis (Teli et al., 1995). 
1.3 ALCOHOLIC LIVER CIRRHOSIS 
Alcohol liver cirrhosis is most common in the western world and its occurrence is 
increasingly seen in countries such as India and Japan which traditionally had a low 
prevalence of the disease (Walsh and Alexander, 2000). The development of alcoholic 
cirrhosis depends upon the amount and regularity of alcohol intake and usually occurs 
after 10 to 15 years of heavy drinking (Becker et al., 1996; Walsh and Alexander, 2000). 
The amount of alcohol consumption required to cause cirrhosis varies from person to 
person, and not everyone who drinks excessively gets cirrhosis. However, nearly 
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everyone who drinks excessively suffers some liver damage, and between 10 and 20 
percent of heavy drinkers develop cirrhosis (Teli et al., 1995). An alcoholic individual's 
risk to develop cirrhosis is governed by a complex interplay of numerous genes with 
several known or unknown environmental factors. For example, it is well established that 
the amount of alcohol consumption is highly correlated with evolution of cirrhosis 
(Bellentani et al., 1997). 
In alcoholic liver cirrhosis, damaged and dead liver cells regenerate in an 
abnormal pattern primarily forming nodules that are surrounded by fibrous tissue. In 
alcoholic cirrhosis there are distortion of the hepatic vasculature which leads to shunting 
of the portal and arterial blood supply directly into the hepatic outflow (central veins), 
compromising exchange between hepatic sinusoids and the adjacent liver parenchyma 
i.e., hepatocytes. The hepatic sinusoids are lined by fenestrated endothelia that rest on a 
sheet of permeable connective tissue in the space of Disse, which also contains hepatic 
stellate cells and some mononuclear cells. The other side of the space of Disse is lined by 
hepatocytes that execute most of the known liver functions. In cirrhosis, the space of 
Disse is filled with scar tissue and endothelial fenestrations are lost, a process known as 
sinusoidal capillarisation (Schaffner and Popper, 1963). Histologically, alcoholic 
cirrhosis is characterized by vascularised fibrotic septa that link portal tracts with each 
other and with central veins, resulting in hepatocyte islands surrounded by fibrotic septa 
and that are devoid of a central vein (Figure 1.3). If the process of cirrhosis is not slowed 
or stopped, the liver will no longer be able to perform its critically important functions 
such as neutralizing poisons from the blood, producing immune agents to control 
infection, removing germs and bacteria from the blood, making proteins that regulate 
blood clotting and producing bile to help absorb fats and fat-soluble vitamins. Cirrhosis 
leads to jaundice and also changes the biochemical function of liver which can lead to 
several complications. In men, breast enlargement (gynecomastia) sometimes occurs due 
to decrease metabolism of estrogen in the liver. Likewise, decreased production of blood 
clotting factors can lead to bleeding complications, derangements in the metabolism of 
triglycerides, cholesterol and sugar can occur. In earlier stages, cirrhosis frequently can 
cause insulin resistance and diabetes mellitus whereas in later stages, blood glucose may 
be low because it cannot be synthesized from fats or proteins. Cirrhosis of the liver can 
also cause abnormalities in other organ systems such as immune system dysfunction 
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pensinusoidal hepatic stellate cells and portal or central-vein fibroblasts proliferate and 
produce excess extracellular matrix (ECM). 
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causing an increased risk of infection, ascites fluid in the abdomen often becomes 
infected with bacteria normally present in the gut (spontaneous bacterial peritonitis). 
Cirrhosis can also lead to profound abnormalities in the brain, kidney dysfunction and 
failure. 
In addition, alcoholics with chronic hepatitis C virus infection or obesity display 
more severe liver damage (Wiley et al., 1998; Raynard et al., 2002). However, these 
factors are not sufficient to explain the wide diversity of hepatic damage suggesting a role 
of certain host factors. Evidence has accumulated supporting the concept that genetic 
factors unrelated to gender contribute to the emergence of alcoholic liver disease (Hrubec 
and Omenn, 1981). For example, twin studies have shown that the concordance for 
alcoholic cirrhosis is significantly greater in monozygotic than in dizygotic twins, leading 
to the conclusion that 50% of the phenotypic variation of alcoholism can be attributed to 
genetic modifiers (Reed et al., 1996). Some diseases, such as cystic fibrosis, alpha-1 
antitrypsin deficiency, and phenylketonuria, are related to mutations of single gene loci 
inherited according to Mendelian rules, while cirrhosis and the majority of other liver 
disease are polygenic and represent 'complex traits'. 
Apart from chronic alcohol consumption there are other factors which cause 
cirrhosis. Chronic hepatitis C, hepatitis B infection is also leading cause of cirrhosis. 
Cirrhosis can develop much faster in certain people who have chronic viral hepatitis and 
drink excessively. Sometimes excess fat in the liver leads to inflammation, a condition 
called nonalcoholic steatohepatitis (NASH) and this inflammation may lead to cirrhosis. 
This type of hepatitis appears to be associated with diabetes, protein malnutrition, 
obesity, coronary artery disease, and treatment with corticosteroid medications. This 
disorder is similar to that of alcoholic liver disease but patient does not have an alcohol 
history. Certain medications (for example, acetaminophen, tylenol), poisons, and 
environmental toxins can also lead to cirrhosis. Long-term infections with various 
bacteria or parasites can also damage the liver and cause cirrhosis. Inherited disorders can 
also result in the accumulation of toxic substances in the liver which lead to tissue 
damage and ultimately lead to cirrhosis. Examples include the abnormal accumulation of 
iron (hemochromatosis) or copper (Wilson's disease). In hemochromatosis, patients 
inherit a tendency to absorb an excessive amount of iron from food. Over time, iron 
accumulation in different organs throughout the body causes cirrhosis. In Wilson disease. 
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there is an inherited abnormality in one of the proteins that controls copper in the body 
and as a result copper accumulates in the liver and causes cirrhosis. 
1.3.1 Pathogenesis of alcoholic liver cirrhosis 
The mechanisms by which alcohol consumption causes liver damage involves a 
number of physiological and biochemical changes that lead to liver pathology. The 
oxidation reactions involving conversion of alcohol to acetaldehyde by alcohol 
dehydrogenase and further oxidation of acetaldehyde to acetate by acetaldehyde 
dehydrogenase are associated with the formation of NADH and NAD that alter the redox 
state of the cell. This has harmful effects on lipid and carbohydrate metabolism. When 
tissue alcohol levels exceed 10 mmol/L concentration, the microsomal enzyme, CYP2E1 
is induced and participates in alcohol metabolism. It has been proposed that CYP2E1 
induction plays a major role in alcoholic liver disease and this enzyme is a source of 
oxidative stress that results in direct damage to hepatocytes, contributing to inflammation 
and is also responsible for production of acetaldehyde (Arteel et al., 2003). 
Acetaldehyde produced by the oxidation of ethanol has toxic effects, inhibiting 
the repair of alkylated nucleoproteins (Espina et al., 1988), decreasing the activity of key 
enzymes, and markedly reducing oxygen use in mitochondria (Baraona et al., 1988; 
Lieber et al., 1989). This impaired oxidation capacity of the mitochondria may, in turn, 
interfere with the oxidation of acetaldehyde (Hasumura et al., 1976), leading to a vicious 
circle of progressive acetaldehyde accumulation and greater mitochondrial injury. 
Moreover, acetaldehyde promotes cell death by depleting the concentration of reduced 
glutathione (GSH), inducing lipid peroxidation, and increasing the toxic effect of free 
radicals. Acetaldehyde-protein adducts promote collagen production and may also act as 
neoantigens, which stimulate an immune response (Hoemer et al., 1986; Niemela et al., 
1987). Oxidative stress also promotes inflammation, which is aggravated by an increase 
of the proinflammatory cytokine tumor necrosis factor-alpha (TNF-a) in the Kupffer 
cells, a major source of cytokines (Figure 1.4). Indeed, in both acute and chronic liver 
diseases, Kupffer cells become activated to produce cytokines and reactive oxygen 
radicals (Batey et al., 1998). 
In human alcoholics, lipopolysaccharids (LPS) levels are increased in the blood 
and in the portal circulation (Urbaschek et al., 2001). As it enters the liver, LPS is 
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recognized by the Tolllike receptor 4 complex expressed on the resident macrophages, 
Kupffer cells in the liver induces downstream activation of intracellular pathways that 
result in activation of various proinflammatory genes including TNFa, IL-8, and MCP-1 
(Nagy, 2003). The increased production of TNFa by Kupffer cells is thought to be of 
particular importance in the pathogenesis of alcoholic liver disease, as TNFa is one of the 
principal mediators of the inflammatory response transducing differential signals that 
regulate cellular activation, proliferation, cytotoxicity, and apoptosis (Beutler et al., 
1995). The continued presence of increased inflammatory mediators and activation of 
Kupffer cells in the liver contribute to the stimulation of hepatic stellate cells (HSCs) into 
an activated myofibroblast (MFB) (Dataller and Brenner, 2001). Activated HSCs/MFBs 
markedly increase the production and deposition of extracellular matrix (ECM) 
molecules which comprise collagen glycoproteins (coUagens type I, III and IV), non-
collagenous glycoproteins (fibronectin and laminin), proteoglycans, and 
glycosaminoglycans which leads to fibrosis and progresses to cirrhosis (Figure 1.4). In 
normal liver tissue, balance is maintained between matrix synthesis and degradation. 
Degradation is exerted by a group of matrix metalloproteinases (MMPs) released by 
various liver cells. MMPs process a wide range of ECM substrates (Benyon and Arthur, 
2001) and their activity is regulated by a group of specific inhibitors produced by 
activated HSCs/MFBs termed tissue inhibitors of matrix metalloproteinases (TIMPs). 
Upregulation of TIMP-I and TIMP-2 is responsible for the loss of MMP expression 
during fibrogenesis in the liver (Herbst et al., 1997) which causes deposition of ECM on 
liver and leads to liver damage (Figure 1.4). 
The risk for the development of alcoholic liver disease increases with the time and 
dose dependent consumption of alcohol (Lelbach, 1966). However, even in populations 
that consume high levels of ethanol (e.g. .80 g/day), only a fraction of individuals 
develop severe forms of the disease (e.g. alcoholic hepatitis and cirrhosis). Even when 
other risk factors (e.g. diet composition, concomitant hepatitis C virus (HCV) or hepatitis 
B virus (HBV) infection, etc) are taken into account, there is no combination of 
environmental risk factors that leads to a 100% incidence of the disease. Furthermore, 
some individuals develop alcoholic liver disease while consuming much less alcohol. 
Though, alcohol consumption is one of the main factors responsible for alcoholic 
cirrhosis, only 20% of habitual drinkers develop cirrhosis. Genetic polymorphisms 
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(SNPs) in alcohol metabolizing enzymes, such as CYP2E1 and ADH, play a major role in 
determining individual's susceptibility to cirrhosis and thus may act as useful markers to 
predict the susceptibility for cirrhosis in individuals and populations at large. For these 
reasons, it has long been proposed that in addition to environmental risk factors, there are 
genetic risk factors that increase the risk for the development of alcoholic liver disease 
(Day, 2000). 
1.4 BIOMARKERS FOR PREDICTING EXPOSURE, EFFECT AND 
SUSCEPTIBILITY TO ALCOHOLIC LIVER DISEASES 
In recent years there has been great interest in developing assays that can be used 
as biomarkers to detect effect as a consequence of exposure of environmental chemicals 
and persistence of effects caused by exposures to toxic agents. Ideally these assays 
should be relatively non-invasive, should be specific for a given toxic agent, and should 
be capable of detecting effects caused by exposures to low concentrations of toxicants. 
As blood is easily available, it is often used as biomarker for predicting exposure of the 
toxicants and consequences of exposure. The degree to which the concentration in the 
blood reflects levels in different organs vary widely between different chemicals, and 
usually also depends upon the length of the exposure as well as time since exposure. The 
life time of the relevant cell types is a major determinant of the persistence of biomarkers. 
Lymphocytes have an average life span of upto several years (Kriek et al 1998). 
Furthermore, effects in the peripheral blood lymphocytes due to smoking and 
environmental pollution are much larger than in the other blood cells (Savela and 
Hemminki 1991; Grzybowska et al 1993). In several human and animals studies, effects 
on biomarkers in blood cells have been shown to be associated with known or suspected 
exposure to genotoxic carcinogens (Raucy et al., 1995, 1999; Dey et al., 2002, 2005). 
The induction of genes whose products function in detoxification processes is a 
well-characterized cellular response to chemical challenge (Wattenberg, 1985). 
Advantage has been taken of this response by developing molecular assays that will 
detect inducible gene expression in peripheral blood lymphocytes. Lymphocytes have 
been shown to possess a full complement of genes whose products are involved in the 
metabolism and detoxication of xenobiotic compounds. Several members of the CYP 
gene family are expressed by both animal and human lymphocytes, as well as the 
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glutathione-S-transferase gene family (Raucy et al., 1999). Due to easy availability of 
these cells, lymphocytes have been used to develop noninvasive bioassays for CYP 
dependent enzyme activities to screen human population for toxicant exposure and these 
cells have been used to determine exposure and susceptibility to the toxicants. Further, 
these cells could be used to monitor the hepatic status of CYP enzymes and could be used 
as a biomarker of exposure to predict the alterations in the enzyme expression on 
exposure to environmental toxicants. 
1.4.1 Blood Lymphocyte CYPs: Biomarker of exposure and effect 
It has been shown that several of the CYPs and phase II enzymes are present in 
the whole cell fractions of human and animal blood, though considerable variations exist 
in literature in identifying xenobiotic metabolizing CYPs in human peripheral blood 
lymphocytes (Raucy et al., 1997, 1999). Hoffbauer and Goedde (1972) for the first time 
reported the presence of aryl hydrocarbon hydroxylase (AHH) in human blood 
lymphocytes, though very low levels of AHH activity was observed in the lymphocytes. 
Measurable amounts of AHH activity was reported in monocyte cultures (Bast et al., 
1976; Gelboin et al., 1976; Lake et al., 1977) and was also found to be present in mouse 
peritoneal macrophages (Ptashne et al., 1974). A low AHH activity was reported in a 
granular leucoyctes (Busbee et al., 1972). Burke et al. (1977) and Kouri et al. (1974) 
demonstrated the responsiveness of lymphocyte CYPs by reporting the inducibility of 
AHH activity in blood lymphocytes by 3-methylcholanthrene (MC) and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), CYPIA inducers respectively. A good correlation 
was also observed between AHH activity in pulmonary alveolar macrophages and its 
inducibility in lymphocytes. Further studies proved that the 3-MC or TCDD inducible 
CYP associated with AHH activity in human lymphocytes was in fact a P448 like CYP 
isoform (CYP 1A1/1A2) and the MC induced lymphocytes catalyzed the 0-deethylation 
of ethoxyresorufin, an activity specific for P-448 in liver (Burke and Meyer, 1975; Burke 
et al., 1977). Low ethoxyresorufin 0-deethylase (EROD) activity was found in 
lymphocytes which might indicate the total absence or the presence of very low levels of 
CYP in the untreated cells. Kouri et al. (1974) also suggested that no constitutive AHH 
activity was present in human lymphocytes. Burke et al. (1977) reported that the 
hydroxylation of benzo[a]pyrene was carried out in lymphocytes which exhibited poor 
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metabolic capacity for 0-deethylation of ethoxyresorufin. Bast et al. (1976) also reported 
the presence of benzo[a]pyrene hydroxylating ability of CYP in unstimulated monocyte 
cultures. Since benzo[a]pyrene hydroxylation is primarily catalyzed by CYPlAl in liver, 
these studies indicate that CYPlAl might be present in uninduced lymphocytes, although 
in insignificant levels (Aoyama et al., 1989). Pretreatment with MC may have induced 
the levels of CYPlAl in lymphocytes thereby resulting in significant benzo[a]pyrene 
hydroxylation activity in human lymphocytes. Radioimmunoassay using monoclonal 
antibody have also shown that CYPlAl expression in lymphocytes increases 
significantly after treatment with benz[a]anthracene, a CYPlAl inducer (Song et al., 
1985). 
As opposed to measuring CYPlAl induction in cultured mitogenised cells, 
Omiecinski et al. (1990) presented the first report for the constitutive CYPlAl mRNA 
expression in non cultured adult human lymphocytes. Clark et al. (1992) compared the 
sensitivity of human and murine lymphocytes to TCDD by analyzing the dose response 
relationships of lymphocytes for induction of EROD activity and found that humans are 
at least as sensitive to rats to CYPlAl enzyme induction produced by transcriptional 
activation of the CYPlAl gene. They also demonstrated that humans exhibit 
interindividual differences in their responsiveness to TCDD and related compounds by 
quantifying EROD activity in lymphocytes from different individuals and this 
interindividual variation could be attributed to the genetic differences found in CYPlAl. 
Vanden Heuvel et al. (1993) reported CYPlAl mRNA expression in freshly prepared 
cultured human blood lymphocytes by sensitive reverse transcriptase polymerase chain 
reaction (RT-PCR) studies and were also able to measure EROD activity in these cells. 
Krovat et al. (2000) were able to detect low levels of CYPlAl mRNA in fresh human 
lymphocyte cultures using Quantitative Competitive Reverse Transcriptase Polymerase 
Chain Reaction (QC RT-PCR) assay. They also compared the expression pattern of 
CYPlAl in fresh lymphocytes with human blood cell lines. Low levels of interindividual 
variation existed and the mRNA profile was essentially conserved across different 
established human blood cell lines and highly analogous to the basal expression patterns 
identified in freshly isolated lymphocytes. 
Previous studies from our laboratory also reported the catalytic activity and 
expression of CYPlAl in rat blood lymphocytes (Dey et al., 2001). Freshly prepared, 
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unstimulated rat blood lymphocytes revealed significant activity of CYPlAl dependent 
7-ethoxyresorufin-O-deethylase (EROD). Pretreatment with MC and P-naphthoflavone 
(NF), CYPIA inducers, resulted in significant induction in the activity of lymphocyte 
EROD suggesting that like the liver enzyme, EROD activity in lymphocytes is inducible 
and is mediated by the MC inducible isoenzymes of CYP. The increase in the activity of 
EROD was associated with a significant increase in the apparent Vmax and affinity of the 
substrate towards EROD. That this increase in the activity of EROD could be primarily 
due to the increase in the expression of CYPlAl isoenzymes was demonstrated by RT-
PCR and western immunoblotting studies indicating an increase in the expression of 
CYPlAl in blood lymphocytes after MC pretreatment. Significant inhibition in the 
EROD activity of MC induced lymphocyte by anti-CYPlAl/IA2 and a-naphthoflavone 
further provided evidence that the CYP1A1/1A2 isoenzymes are involved in regulating 
the activity of EROD in blood lymphocytes (Dey et al., 2001). 
Hanaoka et al. (2002) reported a significantly higher level of CYPlBlmRNA in 
workers at the polycyclic aromatic hydrocarbons (PAHs) work site than in controls. 
Several studies have suggested that elevated CYPIBI gene expression was associated 
with occupational, but not environmental, exposure to PAH/dioxins (Hanaoka et al., 
2002; Toide et al., 2003; Tuominen et al., 2003; Baccarelli et al., 2004). Dassi et al. 
(1998) demonstrated the presence of CYPIBI mRNA in blood mononuclear cells 
through a competitive RT-PCR assay. A substantial overlap in the expression of CYPIBI 
mRNA was found in nonsmokers and smokers indicating that smoking does not seem to 
be potent in inducing CYPIBI transcription in mononuclear cells. Baron et al. (1998) 
also reported the mRNA expression of CYPIBI in human blood monocytes and 
macrophage subsets. This observation was confirmed by Northern blot analysis, 
immunoblotting and immunohistochemical studies. His data further indicated that this 
enzyme is the main CYP in human monocytes and monocyte-derived macrophages under 
constitutive conditions and that it is not induced by benzanthracene (BA), which binds to 
Ah receptor, suggesting another regulation of this mRNA expression in these cells. 
Mahnke et al. (1996) provided the first immunochemical evidence for the 
presence of CYP3A in rat leukocyte microsomes. They however reported that CYP3A 
was not present constitutively in white blood cells. In vivo administration of prototypic 
CYP3A inducers (dexamethasone, clotrimazole, phenobarbital, pregnenolone 16a-
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carbonitrile) led to the increased expression of CYP3A, although the induction observed 
in lymphocytes was several fold (upto 1000 fold) lower than that observed in liver. 
Janardan et al. (1996) reported the presence of constitutive CYP3A5 protein in human 
lymphocytes. Krovat et al. (2000) reported the presence of very low abundance of 
CYP3A4 mRNA in fresh human lymphocytes and human blood cell lines which was also 
confirmed by Western blot analysis. Nguyen et al. (2000) also found a weak expression 
of CYP3A5 mRNA in human blood mononuclear cells using DNA-array. Kikuta et al. 
(1993) isolated and sequenced cDNA of CYP4F3, which catalysis hydroxylation of 
leukotriene B4, from human polymorphonuclear leukocytes. Other CYPs reported to be 
present in blood lymphocytes include CYP2B6/7, CYP 4A11, CYP2D6, CYP2J2, 
CYP2F1 etc. (Krovat et al., 2000; Nguyen et al., 2000). These studies indicating the 
presence and inducibility of CYPs in lymphocytes from human and animals is highly 
speculative at present. The occurrence of their mRNA does suggest the possibility of 
using this more readily available tissue as an indicator of changes in the status of certain 
hepatic enzymes. 
1.4.2 Blood Lymphocytes CYP2E1: A biomarker of alcohol exposure 
Monitoring of CYP2E1 levels in individuals exposed to environmental agents, 
known to be inducers of CYP2E1 or pathophysiologic conditions resulting in induction of 
CYP2E1 could help in the identification of individuals who may be at an increased risk. 
The use of metabolic markers like 6-hydroxylation of chlorzoxazone or N-1 and N-7 
demethylation of caffeine may be used to assess in vivo CYP2E1 expression but these 
methods have disadvantages since these probes may not be solely metabolized by 
CYP2E1. Under certain circumstances or induction of other CYPs may occur which may 
contribute significantly to the reaction that is being monitored (Raucyet al., 1995; 
Streetman et al., 2000). Furthermore, the use of metabolic probes requires multiple 
sampling of urine and blood and an extended assessment period, usually in a hospital 
setting. Instead of using metabolic markers to assess CYP2E1 level peripheral blood 
lymphocytes could be used to monitor CYP2E1 level and blood lymphocyte provided the 
levels of CYP2E1 parallel to those observed in liver (Song et al., 1990; Raucy et al., 
1995; Soh et al., 1996; Dey et al., 2002, 2005). CYP2E1 has been shown to expressed in 
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the peripheral blood lymphocytes of humans (Song et al., 1990), rabbits (Raucy et al., 
1995), and rats (Soh et al., 1996; Dey et al., 2002, 2005). 
To show the similarities in the expression and catalytic activity of CYP2E1 blood 
lymphocyte with the liver isoenzymes Dey et al. (2002) characterized, NADPH 
dependent lipid peroxidation and activity of N-nitrosodimethyamine demethylase 
(NDMA-d), regulated by CYP2E1 in rat blood lymphocytes. Pretreatment with ethanol or 
pyrazole or acetone resulted in significant increase in the NADPH dependent lipid 
peroxidation and the activity of NDMA-d in blood lymphocytes and liver microsomes. In 
vitro addition of CCI4 to the blood lymphocytes isolated from control or ethanol 
pretreated rats resulted in an increase in the NADPH dependent lipid peroxidation. 
Significant inhibition of the basal and CCI4 supported NADPH dependent lipid 
peroxidation and NDMA-d activity in blood lymphocytes isolated from control or ethanol 
pretreated rats by dimethyl formamide or dimethyl sulfoxide or hexane, solvents known 
to inhibit CYP2E1 catalyzed reactions in liver and anti- P450 2E1, have indicated the role 
of CYP2E1 in the NADPH dependent lipid peroxidation in rat blood lymphocytes. The 
data indicated the similarities in the NADPH dependent lipid peroxidation and NDMA-d 
activity in blood lymphocyte with the liver microsomes. 
Significant mRNA expression of CYP2E1 was observed in control rat blood 
lymphocytes (Dey et al., 2005). RT-PCR studies showed that as observed in liver, acute 
treatment of ethanol resulted in increase in the mRNA expression of CYP2E1 in freshly 
isolated rat blood lymphocytes. Western blotting studies using polyclonal antibody raised 
against rat liver CYP2E1 demonstrated significant immunoreactivity, comigrating with 
the liver isoenzymes, in freshly isolated control rat blood lymphocytes. Similar to that 
seen in liver, pretreatment of ethanol was found to produce an increase in the CYP2E1 
isoenzymes in the blood lymphocytes. Soh et al. (1996) also identified CYP2E1 in 
freshly isolated lymphocytes and cultured cells isolated from rats. Immunoreactive 
CYP2E1 level in the homogenate and S-9 fraction of fresh lymphocytes was elevated 
about 5-fold by fasting, comparable to the induction observed in cuhured conditions. 
This induction was evidenced by the increase in mRNA level, confirmed by nested RT-
PCR, Southern blot and DNA sequence analysis. They suggested that CYP2E1 in 
lymphocytes is induced pretranslationally by fasting, as observed in liver. In all, these 
studies provided convincing evidence for the catalytic activity & mRNA and protein 
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expression of CYP2E1 in freshly isolated rat blood lymphocytes. Further, similarities of 
the blood lymphocyte CYP2E1 with the liver enzyme suggest that lymphocyte CYP2E1 
levels in freshly isolated rat blood lymphocytes could be used to monitor tissue enzyme 
levels (Dey et al., 2005). 
Song et al. (1990) identified very low level of CYP2E1 in normal human blood 
lymphocytes. However the levels were elevated in lymphocytes of poorly controlled 
insulin dependent diabetic patients. Only one major form (M.W. 48 KDa) of CYP2E1 
was detected with a specific polyclonal antibody against CYP2E1. Immunoblotting 
studies in peripheral lymphocytes from diabetic patients indicated the reversibility of the 
induction of a CYP isoform. A positive correlation was obtained between the elevated 
levels of CYP2E1, as evidenced by immunoblot analysis and the levels of Hemoglobin 
Al, a metabolic indicator in diabetic subjects. However, Scobbie et al. (1999) using 
western blot studies in human lymphocytes observed slightly different results than that 
reported earlier with the immunoreactive lymphocyte CYP2E1 having higher molecular 
weight than the liver enzyme. Raucy et al. (1995, 1997) reported the presence of 
immunochemically detectable CYP2E1 in freshly isolated rabbit and human blood 
lymphocytes. Quantification of immunoreactive bands revealed that levels of CYP2E1 in 
the lymphocytes were 2.3-fold higher in alcoholics than the control subjects. This 
increase in lymphocyte CYP2E1 content in alcoholic subjects coincided with a 2.1-fold 
increase in chlorzoxazone clearance indicating that there was a good correlation between 
human lymphocyte CYP2E1 content and chlorzoxazone clearance rates and monitoring 
lymphocyte CYP2E1 expression may provide a substitute for estimating hepatic activity 
of CYP2E1. Raucy et al. (1999) further detected that constitutive levels of peripheral 
blood lymphocyte CYP2E1 protein, mRNA, and CZX pharmacokinetic parameters were 
similar among the three ethnic groups of non-alcoholic and alcoholic subjects (White, 
Navajo, and Mexican American) indicating that ethnicity does not appear to play a major 
role in the levels of expression of CYP2E1 in lymphocyte. However, Chalasani et al. 
(2003) studied the CYP2E1 expression in patients with non-alcoholic steatohepatitis 
(NASH) concluded that CYP2E1 activity and CYP2E1 mRNA expression in PBLs was 
significantly enhanced in comparison with a matched control group but no correlation 
was detected between chlorzoxazone hydroxylase activity and lymphocytes mRNA. 
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Using RT-PCR, CYP2E1 mRNA was identified in human blood lymphocytes 
(Raunio et al., 1998; Krovat et al., 2000; Nguyen et al., 2000). Yano et al. (2001) reported 
that CYP2E1 mRNA expression in mononuclear cells increases during drinking which 
subsequently declined when subject abstained from drinking for 3 to 4 days. This 
increase in CYP2E1 mRNA level of mononuclear cells in alcoholic healthy subjects was 
approximately 100 times when compared with nonalcoholic healthy subjects and may be 
used as an effective marker for alcoholic intake. Haufroid et al. (2003, 2005) measured 
the CYP2EI expression in patients suffering from hepatitis C infection and poorly 
controlled insulin dependent diabetes (IDD) subjects in peripheral blood lymphocytes and 
liver and found that measurement of CYP2E1 expression in PBLs is not useful in liver 
diseases. However, in a systemic insulin dependent diabetes condition, this measurement 
can be proposed for monitoring the CYP2E1 induction in a relatively noninvasive 
manner. Haufroid et al. (2003) further reported that expression of CYP2E1 in hepatitis C 
patients was 7000-fold lower level in peripheral blood lymphocytes than in the liver. 
Finnstrom et al. (2001) found 1000-fold lower expression level of CYP2E1 mRNA in 
peripheral blood lymphocytes of alcoholic liver disease patients when compared to liver 
of patients suffering from the disease. Almost 27-fold inter-individual variation of 
CYP2E1 expression in peripheral blood lymphocytes of alcoholic liver disease patients 
was also observed when compared to liver enzyme which shows 18-fold variation. 
1.4.3 Biomarker of susceptibility for alcoholic liver diseases 
Even though induction of enzymes involved in the metabolism of ethanol play a 
major role in development of alcoholic liver diseases, interindividual differences exist in 
levels of expression of these enzymes and are thought to be critical in understanding the 
basis of individual differences involved in ethanol metabolism and predicting 
susceptibility to the disease. The race-related differences in the several types of 
polymorphisms in the ethanol metabolism genes such as CYP2E1, ADH, catalase and 
ALDH have been reported in several studies (Caballeria, 2003). It has been demonstrated 
in many studies that allele frequency of the metabolic genes are not randomly distributed 
throughout the human population but follow diverse ethnic and/or geographic specific 
region (Caballeria, 2003). In addition to differences in population frequencies, the various 
polymorphisms in ethanol metabolizing enzymes have been found to be differentially 
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associated with increased risk of alcoholic liver diseases in different specific ethnic 
groups (Stickel and Osterreicher, 2006). There are several possible explanations for why 
a particular genotype might be differentially associated with alcoholic cirrhosis in 
different ethnic populations. A statistical consideration based on differences in allele 
frequencies, known to exist between populations, may explain certain apparent 
differences found in several studies. The second explanation may be related to 
differences in linkage or genetic associations between alleles in different populations. It 
IS important to note that such genes may also be in linkage disequilibrium with various 
metabolic gene polymorphisms in certain populations and not in others. It is also possible 
that different ethnic groups have different modifiers of gene function, not necessarily 
linked to specific polymorphisms. In this case, a complex ethnic-specific pattern of gene 
function and disease association would be observed, including differential effects of the 
polymorphisms. Finally it may be possible that certain alleles actually have different 
functions in different populations. This possibility seems less likely than the other two, 
since it is difficult to conceive of a mechanism that would cause such differences other 
than differences related to linkage with other genes whose functions have impact on the 
target gene product (Garte et al., 1998). The genes responsible for development of 
alcoholic liver disease are summarized in table 1.3 and polymorphisms in these genes 
may be the basis of the apparent genetic risk for the development of the ALD. 
1.5 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) 
A single nucleotide polymorphism, or SNP (pronounced "snips"), is a small genetic 
change or variation, that can occur within a person's DNA sequence and are the most 
common source of variation, accounting for about 90% of sequence differences at an 
overall frequency of about one per 300 bases (www.ncbi.nih.gov). The genetic code is 
specified by the four nucleotide "letters". A (adenine), C (cytosine), T (thymine) and G 
(guanine). SNP variation occurs when a single nucleotide such as A, replaces one of the 
other three nucleotide letters-C, G, or T. 
For example a SNP might change the DNA sequence CGGTACTTGAGGCTA to 
CGGTACTCGAGGCTA, where the "T" in the first snippet is replaced with a "C" 
(Figure 1.5). Thus SNPs are single base differences in the DNA sequence that can be 
observed between individuals in the population (Zhao et al., 1998; Brooks, 1999; Hacia et 
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Table 1.3: Genetic polymorphisms involved in alcoholic liver disease 
s. 
No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Gene 
CYP2E1 
ADH 
ALDH 
GSTs 
(GSTMl, 
GSTTl, 
GSTPl) 
MnSOD 
CYPlAl 
TGF-pi 
TNF-P 
IL-10 
ApoE 
Etiology 
of liver 
disease 
ALD 
ALD 
ALD 
ALD 
ALD 
ALD 
HCV 
HCV/ 
ALD 
HCV/ 
ALD 
HCV 
Function of 
the gene 
product 
Ethanol 
metabolism 
Ethanol 
metabolism 
Ethanol 
metabolism 
Free radical 
Scavanding 
Free radical 
Scavanding 
Ethanol 
metabolism 
Profibrogenic 
Proinflammato 
-ry 
Immune 
modulation 
Viral entry to 
cells 
Implicated 
genotype 
cl/cl,c2/c2 
alleles 
ADH2 
cl,c2,c3 
alleles; ADH3 
cl, c2, c3 
alleles 
ALDH2 c2/c2 
alleles 
Null genotype 
(GSTMl & 
GSTTl) 
GSTPl Ile/Val 
Val/Ala 
m2/m2 allele 
Codon 25 
(pro/arg) 
-308 G/A 
-1082 A/A;-
627 C/A 
E4 allele 
Effect on 
gene 
product 
Increased 
activity 
Abnormal 
function 
Abnormal 
function 
Decreased 
activity 
Increased 
activity 
Increased 
activity 
Increased 
transcription 
Increased 
transcription 
Decreased 
transcription 
Abnormal 
function 
References 
Yamauchietal. (1995) 
Okamotoetal. (2001) 
Frenzeretal.(2002) 
Yamauchietal. (1995) 
Frenzer et al. (2002) 
Yamauchietal. (1995) 
Okamotoetal. (2001) 
Savolainen et al. 
(1996) 
Ladero et al. (2005) 
Ghobadloo et al. 
(2004) 
Degouletal.(2001) 
Nahon et al. (2005) 
Burim et al. (2004) 
Powell et al. (2000) 
Yeeetal.(2000) 
Grove etal. (1997) 
Grove et al. (2000) 
Knapp et al. (2003) 
Wozniak et al. (2002) 
CYP2E1 = cytochrome P450 2E1; ADH = alcohol dehydrogenase; ALDH = aldehyde dehydrogenase; GSTs = 
glutathione-S-transfrerases; MnSOD = Manganese superoxide dismutase; CYPlAl = cytochrome P450 lAl; 
TGF-P = transforming factor beta; AT = angiotensinogen; HFE = hereditary haemochromatosis gene; NASH = 
non alcoholic steatohepatitis; TNF-P = tumor necrosis factor beta; IL-10 — interleukin 10; NAFLD — non 
alcoholic fatty liver disease; MPO = myeloperoxidase; ApoE = apolipoprotein E. 
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"The most common sources of variation between humans are single 
nucleotide polymorphisms (SNPs)—single base differences between 
genomic sequences." 
Aravinda Chakravarti, Nature, 409 (Feb 2001), 822-823 
Figure 1.5: schematic representation of single nucleotide 
polymorphism (SNP). Strings of nucleotides at which 
individuals 1 and 2 differ are shown. 
lifview of Literature 
al., 1999). SNPs are associated with diversity in tlie population, individual susceptibility 
to disease, and individual response to therapeutic treatment or environmental exposure. 
Apart from SNPs, other naturally occurring DNA variation include variable numbers 
randomly repeats (microsatellite or minisatellite), insertion or deletion of single base and 
duplication (including insertion or deletion) of large DNA segments known as copy 
number polymorphisms. 
SNPs are found throughout the genome, e.g. in exons, introns, intergenic regions 
in promoter or enhancers etc (Figure 1.6). SNPs present in protein coding regions can 
give rise to a protein that has an amino acid substitution, or is truncated, which may alter 
catalytic activity, localization, enzyme stability, and/or substrate specificity. Basically, 
there are two types of SNPs: non-synonymous and synonymous. Synonymous SNPs does 
not result in amino acid change and this is also called as silent mutation. Non-
synonymous SNPs are those which resuh in the change of a codon giving rise to a 
different amino acid. SNPs that fall near intron-exon junctions may cause alterations in 
mRNA splicing resulting in truncated or alternatively spliced protein products. SNPs in 
promoter regions may change the regulation and level of expression of a protein and this 
nucleotide alteration in the regulatory regions of a gene can also have a significant impact 
on the integrity of protein function. Mutations in other noncoding regions may affect 
mRNA stability or mRNA splicing (Figure 1.6). 
1.5.1 SNPs in CYP2E1 
SNP in CYPs has been shown to predispose individuals to variety of environment 
induced toxicity including diseases such as cancers (Hirvonen, 1999). CYPs have been 
identified and established as biomarkers of susceptibility. Polymorphisms in various 
CYPs like CYPlAl, CYP1A2, CYPIBI, CYP2E1, etc have been implicated in the 
development of cancers of various regions like head and neck, lung, esophagus, liver, etc. 
Polymorphic CYPIA is particularly involved in the metabolic activation of PAHs, 
nitrosamines and aromatic amines resulting in the production of carcinogenic 
intermediates that may produce carcinogenicity and mutagenicity (Nebert, 1991; Osawa 
et al., 2007; Pavanello et al., 2007). Similarly, CYPIBI metabolizes carcinogens present 
in tobacco such as N-nitrosamines and it has been implicated in physiological and 
chemical induced cancers (Shimada et al., 1996; Thier et al., 2002; Li et al., 2005). Ko et 
32 
II s 
o 
m Hi 
'M 
C 
2 
^ 
c S 
o a. 
w a. 
"1 
'i 
*^  or -i 
E 
O 
O c 
Q. Z 
w 
o 
u 
I 
c 
o 
Q. 
z 
> 
s 
o 
a. k. 
o ^ 
ra C/) 
raO. 
tu Z 
DC C/) 
£ = 
3) 3 
TJ _ 
•B 5 
0) it: 
_ LU 
0) (A 
n 
0) 
<J 
0) 
T3 
(A 
5^  
u 
y 2 
© 
e 
o 
S 
a 
on 
O 
61) 
-3 
O 
I 
e 
o 
e 
M) 
o 
S 
a 
o g 
^ WD 
%-< 
o 
4> 
3 
61) 
S 
CM 
o (/! 
0) 
U 
e 
a 
s 
o-
</) 
e 
© 
• • 
s 
6X) 
^Rfview of Literature 
al. (2001) have shown that tobacco-specific compounds relevant for etiology of head and 
neck cancers are probably metabolically activated through CYPIBI. Thus polymorphism 
in PAH metabolizing genes may modulate the risk for various cancers such as head and 
neck, lung etc. 
Polymorphism in CYP2E1 has been shown to be associated with alcohol and 
environment induced diseases (Danko and Chaschin, 2005). CYP2E1 gene is located on 
the long arm of chromosome 10 (qlO 24.3-qter), containing nine exons (Kolble, 1993) 
and span 11754 bp of genomic DNA. In humans, CYP2E1 is genetically polymorphic and 
the presence of genetic variants in the CYP2E1 may affect the inducibility of the enzyme 
which consequently modulates the risk of developing various diseases such as cancers 
and alcoholic cirrhosis (Danko and Chaschin, 2005). Currently, more than ten different 
polymorphic sites of CYP2E1 are identified in 5'-regulatory, intron and transcribed 
regions (Ingeiman-Sundberg et al., 2001) and out of these polymorphisms only few are 
commonly studied using Restriction Fragment Length Polymorphism (RFLP) (Table 
1.4). PstI polymorphism consist of G to C substitution at -1293bp in the 5'noncoding 
region of the CYP2E1 gene that creates PstI restriction enzyme cleavage site whereas 
Rsal polymorphism constitute C to T substitution at -1053 in 5'noncoding region of the 
CYP2E1 gene that delete Rsal restriction enzyme cleavage site. These two polymorphism 
(Rsal and PstI) were found to be in linkage disequilibrium and together called as 
CYP2E1*5B, giving rise to the cl and c2 allele (Watanabe et al., 1990). Hayashi et al. 
(1991) classified the genotypes as type A (homozygous "normal" alleles; cl,cl), type C 
(homozygous alleles with the nucleotide exchanges; c2,c2) and type B (heterozygous, 
having a normal and an altered allele; cl,c2). The CYP2E1 c2 (mutated) allele that lacks 
the Rsal restriction site is associated with an upto 10-fold higher gene transcription, 
protein level, and enzyme activity than the cl allele and could result in a higher exposure 
of acetaldehyde and ROS in the liver (Hayashi et al., 1991; Tsutsumi et al., 1994; 
Watanabe et al., 1994). Another polymorphism present at 5' flanking region at position 
from -2270 to -1672bp, a two-allele insertion, was identified using DNA restriction 
endonuclease Xbal. Allele containing 6 repeats with length of 42-60 bp is designated as 
CYP2E1*1C, and a rare allele with 8 repeats as CYP2E1 *1D (McCarver et al., 1998; Hu 
et al., 1999). No differences were found in vitro in constituent expression for these two 
gene variants (Hu et al., 1999). However, CYP2E1*1D polymorphism is supposedly 
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Table 1.4: Polymorphisms reported in CYP2E1 
Polymorphism Protein Nucleotide changes RFLP References 
CYP2E1 *1A 
CYP2E1*1B 
CYP2E1*1C 
CYP2E1 "ID 
CYP2E1*2 
CYP2E1 *3 
CYP2E1U 
CYP2EI*5A 
CYP2EI *5B 
CYP2E1*6 
CYP2E1*7A 
CYP2E1*7B 
CYP2E1*7C 
Mspl 
CYP2E1.1 None 
CYP2E1.1 98960G 
CYP2E1.1 6 repeats in the 5' flanking 
region 
CYP2E1.1 8 repeats in the 5' flanking 
region 
CYP2E1.2 11320A 
CYP2E1.3 10023G>A 
CYP2E1.4 47680A 
Umenoetal, 1988 
Taql McBrideetal, 1987 
BrockmoUer et al, 1996 
Huetal, 1999 
Oral and Huetal, 1999 
Xbal McCarveretal, 1998 
Huetal, 1997 
Huetal, 1997 
Fairbrother et al, 1998 
CYP2E1.1 -1293G>C;-1053C>T(cl>c2); PstlRsa], Watanabe et al, 1990 
76321>A Oral Hayashi et al, 1991 
Perssonetal, 1993 
CYP2E1.1 -1293G>C;-1053C>T(cl>c2) Pstl,Rsal Watanabe et al, 1990 
Hayashietal, 1991 
CYP2E1.I 7632T>A 
CYP2E1.1 -333T>A 
CYP2E1.1 -71G>T;-333T>A 
CYP2E1.1 -333T>A;-352A>G 
CYP2E1.1 6827 A>G 
Oral Perssonetal, 1993 
Fairbrother et al, 1998 
Fairbrother et al, 1998 
Fairbrother et al, 1998 
Mspl Savolainen et al., 1997 
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associated with increased CYP2E1 metabolic activity in obese patients and chronic 
alcoholics. 
Several polymorphic sites were also identified in CYP2E1 intron region. One of 
the important polymorphism identified in intron region is Dral polymorphism which 
constitute T to A substitution at 7632bp in intron 6 that delete Dral restriction enzyme 
cleavage site and is represented as CYP2E1*6 allele (Persson et al., 1993). It has three 
genotypes, two homozygous designated as CC and DD and one heterozygous genotype, 
CD (Uematsu et al., 1991; Stephens et al., 1994). However, CYP2E1*6 does not 
influence the enzyme expression and catalytic activity (Persson et al., 1993). In contrast, 
Uematsu et al. (1991) reported altered CYP2E1 catalytic activity with CYP2E1*6 allele 
but did not find impact of this polymorphism on gene transcription. 
Another polymorphism present in intron 6 region of CYP2E1 gene is the Mspl 
polymorphism. This polymorphism constitutes A to G replacement at 6827bp causing 
deletion of Mspl restriction enzyme cleavage site. Little information is available about 
this polymorphism and is found not to be associated with increased expression or enzyme 
activity. There are several polymorphism of CYP2E1 which are present on coding region 
and lead to amino acid replacements (Danko and Chaschin, 2005). Out of these 
polymorphism only Tail polymorphism {CYP2E1*4) has been studied and can be 
identified using RPLP. This polymorphism is located at exon 4 (4804bp), resulting in 
nucleotide replacement G to A, which corresponds to amino acid replacement (Val—>lle) 
and can be identified by Tail restriction enzyme (Fairbrother et al., 1998). 
Ethnic variations have been reported in the distribution of CYP2E1 genotypes 
(Kato et al., 1993; Lieber, 1994). Most of the polymorphisms of CYP2E1 have been 
reported in Caucasians (Salvolainen et al., 1997; McCarver et al., 1998; Vidal et al., 
2004) as well as in the Oriental population (Tanaka et al., 1997; Hu et al., 1999). 
However, only two polymorphisms (Rsal and Oral) are reported in Indian populations 
(Mittal et al., 2005; Soya et al., 2005). The frequency of the Rsal c2 allele varies in 
different population (Stephens et al., 1994). The minor allele (c2) frequency of Rsal 
polymorphism was found to be 1% in Indian population (Mittal et al., 2005; Soya et al., 
2005) which is similar to that reported in the Caucasians (1% - 4%) (Grove et al., 1998; 
Wong et al., 2000). The Orientals (Chinese and Japanese) carry much higher frequency 
(20% - 30%) of the minor allele (Hildesheim et al., 1997; Chao et al., 1997). Similarly, 
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the minor allele frequency of Dral polymorphism {CYP2E1 *6) was also reported to be 
relatively high (19%) in the Indian population (Mittal et al., 2005). This polymorphism is 
also reported in the Caucasians (Savolainen et al., 1997; Wong et al., 2000; Garte et al., 
2001), though its frequency (7% - 12%) was relatively less when compared to Indian or 
Oriental (20%) - 30%)) population (Hildesheim et al., 1997; Garte et al., 2001). However, 
Mspl polymorphism is only reported in Caucasian (2%) population (Savolainen et al., 
1997). 
Since, CYP2E1 polymorphism is known to increase CYP2E1 enzyme activity, the 
polymorphisms in CYP2E1 may consequently modulate the risk of developing alcoholic 
cirrhosis. Significant association of CYP2E1*5B with alcoholic cirrhosis and other 
alcoholic liver diseases has been shown in the Oriental population (Tsutsumi et al., 1994; 
Tanaka et al., 1997). Piao et al. (2003) reported that the minor allele frequency of 
CYP2E1 *5B in Chinese population play a key role in the pathogenesis of fatty liver. 
Yamauchi et al. (1995b) also found the association of variant genotype of CYP2E1*5B 
with alcoholic liver disease in Japanese population. However, there are few reports which 
do not show the association between variant genotype of CYP2E] *5B with alcoholic liver 
disease in Oriental population (Carr et al., 1996; Lee et al., 2001). Chao et al. (1997) 
reported that the Rsal polymorphism is not associated with the predisposition to 
alcoholism or alcoholc liver diseases in Chinese men. However, Maezawa et al. (1994) 
compared 62 Japanese alcoholics with the diagnosis of liver cirrhosis and 20 alcoholics 
without cirrhosis using Rsal restriction fragment-length polymorphisms and found that 
the frequency of wild type genotype of CYP2E1*5B was higher in alcoholic liver 
cirrhotic patients when compared with controls. 
The risk for alcoholic liver disease with CYP2E1*5B was not found to be 
consistent in the Caucasians populations. Few studies in Caucasians populations show 
significant association of CYP2E1*5B with alcoholic liver diseases (Ingelman-Sundberg 
et al., 1993; Pirmohmad et al., 1995; Cicho-Lach et al., 2006). Pirmohmad et al. (1995) 
reported that the minor allele frequency of CYP2E1*5B is strongly associated with 
development of alcoholic liver disease in Caucasians populations. However, most of the 
study of Caucasians does not show any significant association of CYP2E1*5B with 
alcoholic cirrhosis and other alcoholic liver disease (Carr et al., 1995; Parsian et al, 1998; 
Wong et al., 2000; Vidal et al., 2004). Carr et al. (1995) compared the minor allele 
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frequency of CYP2E1*5B in a sample of 53 male alcoholics of Caucasians populations 
with clinical diagnosis of alcohol hepatitis or alcohol cirrhosis, 21 alcoholics without 
liver cirrhosis, and 32 healthy individuals and found no significant in the allele 
frequencies between these groups. Vidal et al. (2004) further reported that CYP2E1 
genetic variations are not related to alcoholism or susceptibility to alcoholic liver disease 
in Spanish population. 
Likewise, the association of Dral {CYP2E1*6) polymorphism with alcoholic liver 
disease is controversial and no significant association was observed with the disease in 
majority of the studies in Caucasians and Oriental population (Savolainen et al., 1997; 
Vidal et al., 2004). However, Lucas et al. (1996) reported a higher frequency of Dral 
minor allele in alcoholics compared with non-alcoholics. No association of Mspl 
polymorphism or Tail with alcoholic liver cirrhosis has been observed in any population 
(Savolainen et al., 1997). However, not much information is available on association of 
polymorphic variant of CYP2E1 with susceptibility to alcoholic liver disease in Indian 
population. 
1.5.2 SNPs in Alcohol Dehydrogenase (ADH) 
Genetic polymorphism is known for alcohol dehydrogenase (ADH) gene that 
metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic 
alcohols, hydroxysteroids, and lipid peroxidation products (Day et al., 1991; Kedishvili et 
al., 1997). Human ADH is a dimeric protein consisting of two subunits with a molecular 
weight of 40 kD each. Over 20 ADH isoenzymes are known which vary in their 
pharmacokinetic properties and can be divided into five major classes or distinct groups 
(1-V) according to their subunit and isoenzyme composition as well as their 
physicochemical properties (Crabb et al., 2004) (Table 1.5). Class I isoenzymes, which 
have a low Km for ethanol, are found in the liver and consist of homo or heterodimeric 
forms of three subunits: a, p, and y which is represented by ADHl, ADH2 and ADH3, 
respectively. Class II ADH is a homodimeric n n form, ADH4, with a relatively high Km 
for ethanol (34 mM) and is found in the liver. The class III isoenzyme, ADH5, has a very 
low affinity for ethanol and therefore, does not participate in its oxidation in the liver. 
The class IV isoenzyme, ADH7, is found in the stomach and has a very high Km for 
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Table 1.5: Types and properties of Alcohol Dehydrogenase (ADH) 
Gene locus Subunit Km for Vmax Tissue 
Type Ethanol (turnover Distribution 
(mM) number /min). 
Class I 
Class II 
ADHl 
ADH2 
ADH3 
ADH4 
a 
P 
Y 
71 
4 
0.05-34.0 
0.6-1.0 
34 
54 
40 
Liver 
Liver, Lung 
Liver, Stomach 
Liver, Cornea 
Class III 
ADH5 X 1000 Most tissues 
Class IV 
Class V 
ADH7 a, Yi 
ADH6 
20 
30 
1510 Stomach, 
Oesophagus 
Liver, Stomach 
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ethanol. Finally, the recently described class V isoenzyme, ADH6, is found in both the 
stomach and the liver (Table 1.5). 
Genetic variations are known for ADH2 and ADH3 encoded by different alleles. 
Alleles ADH2*1, ADH2*2 and ADH2*3 have subunits pi, p2 and p3 respectively 
whereas alleles ADH3*1 and ADH3*2 have subunits yl and Y2, respectively. The 
frequency of the different ADH alleles exhibit ethnic variations. The ADH2*1 allele 
predominates in black and white races, while the ADH2*2 allele in oriental subjects and 
the distribution of ADH2*3 is found in about 25% of black subjects (Caballeria, 2003). 
ADH3*1 and ADH3*2 alleles of ADH3 appear with about equal frequency among 
Caucasian subjects while the ADH3*1 allele predominates among black and oriental 
races (Caballeria, 2003). The affinity for alcohol and the metabolic rate among the 
different isoenzymes differ, and these genetic differences have been implicated in the 
pathogenesis of alcoholic liver disease (Day et al., 1991; Sherman et al., 1993; Caballeria, 
2003). According to the differences in the capacity to metabolize alcohol to acetaldehyde, 
it has been speculated that individuals with the more active ADH2*2 and ADH3*1 alleles, 
especially Asian population, are at increased risk of developing alcohol-related organ 
damage due to a higher acetaldehyde exposure (Couzigou et al., 1994) which in turn 
produces an uncomfortable sensation with facial flushing and tachy cardia (Shen et al., 
1997). Earlier studies identified the ADH2*2 allele and genotype ADH2*2/2 as a risk 
factor for alcoholic liver disease (Sherman et al., 1993; Chao et al., 1994; Yamauchi et 
al., 1995a, 1995b), whereas subsequent investigations found the allele ADH2*1 and 
genotype ADH2*1/1 to be associated with the disease (Tanaka et al., 1996, Tanaka et al., 
1997; Chao et al., 1997; Frenzer et al., 2002). While several investigators reported 
association between the ADH3*2 allele or the ADH3*2/2 genotype respectively and 
alcoholic liver disease (Monzoni et al, 2001; Frenzer et al., 2002), others suggested a 
role of the high turnover allele ADH3*1 to confer risk to the development of the disease 
(Day et al., 1991). However, a number of studies found no association at all (Couzigou et 
al., 1990; Cen et al., 1997; Grove et al., 1998). 
1.5.3 SNPs in Acetaldehyde Dehydrogenase (ALDH) 
Acetaldehyde is rapidly metabolized to acetate by the action of aldehyde 
dehydrogenase (ALDH). There are two classes of ALDH, ALDH I located in the cytosol 
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with a high Km for acetaldehyde and ALDH2 or mitochondrial ALDH with a low Km for 
acetaldehyde which is of the great importance in the metabolism of acetaldehyde. Genetic 
variations are known for ALDH2, encoded by two alleles, ALDH2*1 and ALDH2*2. 
ALDH2*2 is a physiologically inactive form (Bosron et al., 1993; Li et al., 2001) and 
there is slower elimination of alcohol in subjects with the ALDH2*2 genotype which is 
due to the inhibition of alcohol dehydrogenase activity by the accumulated acetaldehyde. 
ALDH2*1 is more active form and homozygotic subjects, oxidizes all the acetaldehyde 
produced by ADH in mitochondria. The cytosolic ADLHl is responsible for the 
oxidation of acetaldehyde in the ALDH2 homozygotic individual in which no 
mitochondrial ALDH activity is found (Farres et al., 1994). 
The prevalence of the different ALDH genotypes varies according to the 
populations. In Caucasian population, the ALDH2*2 genotype has not been detected 
while it is prevalent in Orientals ranging from 10% to 44% of the population (Crabb et 
al., 1989; Yoshida, 1992). The elevated levels of acetaldehyde achieved in ALDH2*2 
homozygotic subjects, even after the ingestion of a small or moderate amount of alcohol, 
produce circulatory changes which may be translated into a reaction of discomfort with 
tachycardia and facial flushing. All of this leads to aversion to alcohol and has a protector 
effect versus alcohol dependence in Orientals in which the prevalence of the ALDH2*2 
genotype is much lower in alcoholics than in the general population (Okamoto et al., 
2001). 
1.5.4 SNPs in antioxidant enzymes 
In order to survive it is necessary for living organisms to protect themselves from 
harmful xenobiotics and several detoxification systems are used this protection. The most 
efficient in elimination of electrophiles are reduced glutathione (GSH), glutathione S-
transferase (GSTs) and manganese superoxide dismutase (MnSOD). During ethanol 
metabolism reactive oxygen species are generated which are efficiently removed by 
antioxidant enzymes and if the generated ROS exceed the capacity of the antioxidant 
defense mechanisms it may contribute to the development of alcohol induced liver injury. 
Polavarapu et al. (1998) have shown that in rats with alcohol induced injury, these 
antioxidant enzymes are reduced and levels are inversely correlated with severity of liver 
injury. The capacity of CYP2E1 to oxidize ethanol is increased up to 10-fold in heavy 
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alcohol users which consecutively increases the pro-oxidative burden (Kessova and 
Cederbaum, 2003). Defense mechanisms such as antioxidant mitochondrial and cytosolic 
enzymes can offset some of the toxicity derived from oxidative stress but may become 
saturated as it persists, or down regulated as liver damage progresses. 
1.5.5 SNPs in Glutathione-S-transferases (GSTs) 
Glutathione-S-transferases (GSTs) are a family of phase 11 xenobiotic 
metabolizing enzymes that catalyze conjugation of reduced glutathione (GSH) to the 
electrophilic compound. GSTs are classified into five different families alpha (a), mu 
(l^), pie (7t), theta (9) and zeta (Q (Pemble et al., 1996) out of which four are cytosolic 
while one is microsomal. Cytosolic GSTs are involved in the conjugation of a wide range 
of electrophilic substrates with the abundant cellular nucleophile-glutathione (GSH), 
thereby facilitating their metabolism, detoxification and excretion (Chasseaud, 1979). 
Because these enzymes are involved in the detoxification of a wide variety of potentially 
toxic and carcinogenic substances, numerous molecular epidemiology studies have 
examined the association between GST polymorphism and increased risk for disease, 
especially cancer and cirrhosis. In alcoholic liver diseases, GSTs catalyses the 
conjugation of toxic acetaldehyde to GSH, and detoxification of oxygen radicals 
generated by phase I enzymes (Harada et al.,1987; Lieber, 1994) and thus play an 
important role in protecting hepatocytes against oxidative damage induced by metabolism 
ofethanol. 
GSTs are polymorphic with variable genotype frequency in different ethnic 
groups (Pemble, 1994). Out of five families oi GSTs only GSTMl, GSTTl and GSTPl 
are genetically polymorphic. Deletion polymorphisms (homozygous deletion of gene) of 
the GSTMl and GSTTl loci result in the loss of functional activity (Seidegaard, 1989). 
Two genetic variants are present in GSTPl gene, one at codon 105 with He to Val 
polymorphism (Osman et al., 1997) and the other at 114 (Ala to Val transition) which 
results in significant differences in catalytic activity (Osman et al., 1997). Homozygous 
gene deletion in GSTMl, GSTTl and variant genotypes of GSTPl may lead to the 
increase in the levels of potential reactive metabolites resulting from chronic ethanol 
intake (Ghobadloo et al., 2004; Ladero et al., 2005). 
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Ethnic variations have been reported in the distribution of GSTs (Singh et al., 
2008). Approximately 40-50% of the Caucasians are homozygous for a deletion that 
inactivates GSTMl gene (Seidegaard, 1989). However the frequency of null genotype of 
GSTMl gene was found to be 28%-33% in the Indian population (Sobti et al., 2004; 
Singh et al., 2008) which is quite lower than found in Oriental population (33-63% in 
Japanese, Chinese and Koreans) (Geisler and Olshan, 2001) and Pacific-Rims (approx. 
75%) but much higher than African-Americans (approx. 12.5%). Likewise, the GSTTl 
null genotype frequency was found to be approximately 20% in the Indian population 
(Sobti et al., 2004; Singh et al., 2008) which is similar to that reported in Caucasians and 
African- Americans (15-25% ) (Geisler and Olshan, 2001; Ladero et al., 2005). However 
higher frequency of GSTTl null genotype is reported in Oriental (approx. 42-58% in 
Chinese, Japanese and Korean) and Pacific Rim (33%) population. Similarly the 
frequency of minor alleles of GSTPl was found to be approximately 22% in Indian 
population (Jain et al., 2006; Singh et al., 2008) which was equal to that observed in 
Caucasians (Garte et al., 2001) but more than that reported with Japanese and African-
Americans and less than Hispanics and Pacific-Rim populations (Geisler and Olshan, 
2001) (www.snp500cancer.nci.nih.gov). 
Because of their important role in cellular defense against oxidative stress, GSTs 
have been considered candidates for association studies with alcoholic liver diseases. A 
loss or deficiency in GSTMl and GSTTl enzyme activity could potentially increase the 
levels of toxic intermediates generated along with chronic alcohol intake. GSTMl null 
genotype has been found to be associated with alcoholic liver diseases in several studies 
(Harada et al., 1993; Baranov et al., 1996; Savolainen et al., 1996; Ladero et al., 2005) 
though there are few reports which do not show significant association of GSTMl null 
genotype with the alcoholic liver diseases (Groppi et al., 1991; Rodrigo et al., 1999; 
Burim et al., 2004). Interestingly, the GSTMl null genotype has also been associated with 
other forms of liver disease including primary biliary cirrhosis (Davies et al., 1993) and 
autoimmune hepatitis (Fukagawa et al., 2001) as well as various cancers such as oral, 
lung, bladder and stomach (Harada et al., 1992; Bell et al, 1993; Shah et al., 2008; Singh 
et al., 2008). In contrast to GSTMl, there have been fewer studies on GSTTl and GSTPl 
and most of the studies did not find significant association of the deletion or variant 
genotypes with alcoholic liver diseases (Frenzer et al., 2002; Brind et al., 2004). 
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However, it has been found that GSTPl Val/Val genotype is associated with the 
development of cirrhosis in patients with hereditary hemochromatosis (Stickel et al., 
2005). A higher frequency of GSTPl Val/Val genotypes was found in alcohoHc 
pancreatitis as well as cryptogenic liver cirrhosis patients when compared to the controls 
(Burim et al., 2004; Ghobodloo et al., 2004). 
1.5.6 SNPs in Manganese Superoxide Dismutase (MnSOD) 
Hepatocyte mitochondria are prime targets of oxidative stress generated in 
chronic alcoholism and alterations of mitochondrial function and structure, such as the 
breakdown of mitochondrial membrane potential, have been recognized as key events in 
the onset of alcohol-driven apoptosis (Adachi and Ishii, 2002). The ability to resist 
oxidative pressure largely depends on the mitochondrial GSH content and antioxidant 
mitochondrial enzymes. Mitochondria-derived ROS are detoxified to hydrogen peroxide 
and water by the successive action of manganese superoxide dismutase (MnSOD) and 
GSH peroxidase, respectively (Wallace, 1999). MnSOD is synthesized with a cleavable 
N-terminal mitochondrial target sequence that enables its transport into mitochondria 
(Shimoda-Matsubayashi et al., 1996). A SNP within codon 16 of the precursor protein 
leads to either alanine (Ala) or valine (Val) at amino acid position 9 of the target 
sequence resulting in enhanced translocation into mitochondria and higher concentration 
of active MnSOD in cases with the Ala-sequence (Sutton et al., 2003). Degoul et al. 
(2001) have found that the Ala/Ala genotype occurs more frequently in patients with 
severe alcoholic liver disease further suggesting that the presence of at least one Ala 
MnSOD allele increases the risk for developing cirrhosis with the development of 
hepatocellular carcinoma and death due to cirrhosis (Nahon et al., 2005). However, other 
studies with larger numbers of patients and controls could not confirm these findings 
(Stewart et al., 2002; Brind et al., 2003). 
1.6 NEED FOR ASSOCIATION STUDIES FOR ALCOHOLIC LIVER 
DISEASES IN INDIAN POPULATION 
As the SNPs in genes involved in alcoholic liver diseases exhibit ethnic 
differences, it is of interest to study the distribution of these SNPs in Indian population. 
As compared to the Caucasians or Orientals, not much information is available on SNPs 
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involved in alcoholic liver diseases in Indian population. India is a land of enormous 
genetic, cultural and linguistic diversity and comprises about one-sixth of the world 
population, consisting of 4,693 communities with several thousands of endogamous 
groups 325 fixnctioning languages and 25 scripts which provide a unique resource for 
dissecting complex disease etiology and pathogenesis (Majumder, 1998; Singh, 2002). 
Historically, the Indian population is a conglomeration of multiple culture and 
evolutionary histories and exhibit a great genetic diversity than any other comparable 
global region, with the exception of Africa (Majumdar, 1998, 2001). The social structure 
of the Indian population is dominated by the hierarchical Hindu caste system. The origin 
of caste system in India is a matter of debate. Previous genetic studies on Indian castes 
and tribes failed to achieve a consensus on Indian origins and affinities. A few studies 
reported closer affinity of Indian castes with either the Europeans or the Orientals Asians. 
Studies of Bamshad et al. (2001) and Basu et al. (2003), support the genetic 
differentiation of caste and tribal populations, and the North Indian invasion of Indo-
European speaking Nomads, pushing the Dravidian tribes to Southern Peninsula. On the 
other hand, Kivisild et al. (2003) suggest that Indian tribal and caste populations were 
derived largely from the same genetic heritage of Pleistocene. Southern and Western 
Asians received limited gene flow from external regions since Holocene. Further, 
Cordaux et al. (2004) reported that the paternal lineages of Indian castes are more closely 
related to the Central Asians than to the Indian tribal groups, thereby supporting the view 
that Indian caste groups are primarily the descendents of the Indo-European migrants. In 
a study conducted on ranked caste populations sampled from one Southern Indian State 
(Andhra Pradesh), Bamshad et al. (2001) have found that the genomic affinity to 
Europeans is proportionate to caste rank, the upper castes being most similar to 
Europeans, particularly East Europeans, whereas the lower castes are being more similar 
to Asians. 
Indian population can be, to a large extent, sub-structured on the basis of their 
ethnic origin as well as linguistic lineages. All the four major morphological types— 
Caucasoid, Mongoloid, Australoid and Negrito are present in the Indian population 
(Malhotra, 1978). The "Caucasoid" and "Mongoloid" populations are mainly 
concentrated in the North and Northeastern parts of the country. The Mongoloids have 
come to India from different directions at different times and perhaps earlier than the 
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Caucasoids (Das et al., 1987). Mongoloids have migrated from Eastern, Southeastern 
(Dani, 1960), and Central Asian regions while the Caucasoids may have entered from 
Western and Northern boundaries of this region. Majority of the Mongoloids are tribes 
affiliated with the Tibeto-Chinese linguistic family. Except Khasi, most of the 
Caucasoids are caste groups and speak Indo-European languages. Both the Mongoloid 
and Caucasoid groups show a certain degree of differentiation within themselves in 
cultural and biological traits such as anthropometry, genetic markers, and 
dermatoglyphics (Phookan, 1974; Das, 1979; Das and Das, 1981; Bhasin and Walter, 
2001). The "Australoids" are mostly confined to the Central, Western and Southern 
India, while the "Negritos"are restricted only to the Andaman Islands (Cavalli-Sforza et 
al., 1994). Linguistically, Indian populations belong to four major language families: 
Indo-European, Dravidian, Tibeto-Burman and Austro-Asiatic. The Indo-European and 
Dravidian languages are spoken in the Northern and Southern parts of the subcontinent, 
respectively (Gadgil et al., 1998). The Tibeto-Burman speakers are supposedly 
immigrants to India from Tibet and Burma (now, Myanmar) and are concentrated in the 
Northeastern parts of the country (Guha, 1935). The Austro-Asiatic speakers are 
exclusively tribals and are dispersed mostly in the Central and Eastern parts of the 
country. Molecular diversity studies have revealed that the Austro-Asiatic speakers are 
likely to have been the most ancient inhabitants of India (Majumder, 2001; 
Roychoudhury et al., 2001). These tribes might have entered India through the 
Northwest, as they moved out of Africa following a path south of the Himalayas, while 
another ancestral group moved North, crossing the Himalayas, settling in Southern China, 
and entering South Asia later from the Northeast (Majumder, 2001; Basu et al., 2003). 
The Indian subpopulations exhibit wide diversity and extensive variations in 
frequencies of alleles and haplotypes of common polymorphisms (Bhattacharyya et al., 
1999; Roy et al, 2001, 2003; Chandak et al., 2002; Nagarkatti and Ghosh, 2002; Pasha et 
al., 2002; Nagarkatti et al., 2004a, 2004b; Batra et al., 2005) as well as occurrence of 
some private polymorphisms and mutations (Pramanik et al, 2000; Mukherjee et al, 
2004; Sengupta et al, 2004). Several studies on Indian subpopulations have revealed 
founders for disease mutations and helped in understanding the origins of monogenic 
diseases in India (Saleem et al, 2000, 2002, 2003; Bahl et al. 2005; Mittal et al, 2005). 
These findings suggest the significance of population stratification in designing case-
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control association studies. Case-control studies carried out in the Indian population 
sometimes reveal observations distinct from other world population (Ramana et al., 2000; 
Nagarkatti et al., 2002; Thangaraj et al., 2002; Sengupta et al., 2004; Batra et al, 2005; 
Rajput et al., 2005). Using SNPs and repeat polymorphisms, both novel and reported, 
studies have been successful in identifying at-risk markers or haplotypes for particular 
diseases (Choudhry et al., 2001; Ahsan et al., 2004; Nagarkatti et al., 2004a, 2004b; 
Sharma et al. 2004; Sharma and Ghosh, 2004; Verma et al., 2004). 
Alcohol consumption has been steadily increasing in developing countries like 
India and decreasing in developed. Around 15% to 20% of Indians consume alcohol and 
over the past twenty years, the number of drinkers has increased considerably and about 
80% of alcohol consumption in India is in the form of hard liquor or distilled spirits 
indicating that the majority drink beverages are with a high concentration of alcohol. 
Branded liquor accounts for about 40% of alcohol consumption while the rest is in the 
form of country liquor. The pattern of drinking in India has also undergone a change from 
occasional and ritualistic use (Deepawali and Holi) to being a social event like in 
marriages and other social parties. These developments have raised concerns about the 
health and the social consequences of excessive drinking which can ultimately leads to 
alcoholic liver diseases, the prevalence of which is increasing in India (Walsh and 
Alexander, 2000). The ethnic differences in the frequency of ethanol metabolizing genes 
such as CYP2E1, ADH and ALDH have been reported in several studies which revealed 
that allele frequency of the metabolic genes are not randomly distributed throughout the 
human population but follow diverse ethnic and/or geographic specific region 
(Caballeria, 2003). In addition to differences in population frequencies, the various 
polymorphisms in ethanol metabolizing enzymes have been found to be differentially 
associated with increased risk of alcoholic liver diseases in different specific ethnic 
groups (Stickel and Osterreicher, 2006). 
It is of interest to study the distribution of SNPs in the genes involved in alcoholic 
liver diseases in Indian population as India has a leading edge on the global scene due to 
its unique population structure. Several studies have shown that there is a significant 
genetic diversity among different ethnic groups of India which can be observed between 
different linguistic groups residing in different geographical locations and different caste 
and tribal populations. Studies in the Indian subpopulations provide an enormous 
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opportunity for complex disease such as alcoholic liver diseases. For instance, it has been 
reported (Majumder, 1998) that heterozygosity values at many genetic loci in several 
Indian ethnic groups are lower than those of the Icelandic population that is considered 
genetically isolated and homogeneous. However, between subpopulation, the extent of 
haplotype diversity is highly variable. Therefore, genomic diversity of the Indian ethnic 
groups coupled with an underlying genomic unity also provides an opportunity to 
replicate findings in groups of genetically similar populations (Sengupta et al., 2004). 
Thus, the analysis of sequence variation in the context of genomic diversity within Indian 
sub-population would help in identifying genetic substructures, which in turn would be 
invaluable for identification of markers for linkage or association studies, detecting 
candidate susceptibility regions for many common and complex diseases as well as drug 
response studies. 
Further, studies are needed in humans to validate the expression profiles of 
CYP2E1, involved in the metabolism of ethanol and progression of alcoholic liver 
diseases particularly alcoholic cirrhosis. As compared to genotyping, phenotyping studies 
provide more clinically relevant information because it is a reflection of the combined 
effects of genetic, environmental and endogenous factors on CYP activity. Development 
of cirrhosis is a step-by-step process and take years or decades to fully develop, and 
staging of hepatic fibrosis is therefore of paramount clinical importance for the 
prognostic assessment in the individual patient. In these patients liver biopsy represents 
the gold standard for evaluating presence, type and stage of liver fibrosis. This procedure, 
however, is invasive, costly and difficult to standardize. Recent studies from our 
laboratory have shown that CYP2E1 is express in peripheral blood lymphocyte and its 
regulation was similar to that found in the liver. As peripheral blood lymphocytes are 
easily available, it would be of interest to valid the expression profile of CYP2E1 in 
human blood lymphocyte and whether the levels in blood lymphocyte isolated from the 
patient suffering from alcoholic liver diseases are similar to that reported with the tissue 
enzyme. These studies will not only help in validating the use of blood lymphocytes 
CYPs as a surrogate to monitor tissue levels but also provide evidence for the use of 
expression profiles of CYPEl genes as a possible biomarker of alcoholic liver diseases 
including cirrhosis. 
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2.1 INTRODUCTION 
^--'ndians, comprise about one-sixth of the world population, consisting of several 
thousand of communities with thousands of endogamous groups, hundreds of functioning 
languages and numerous scripts (Singh, 2002). Such diversity in population provides a 
unique resource for dissecting complex disease etiology and pathogenesis. Indian 
population can be, to a large extent, substructured on the basis of their ethnic origin as 
well as linguistic lineages. All the four major morphological types Caucasoid, 
Mongoloid, Australoid and Negrito are present in the Indian population (Malhotra, 1978). 
The "Caucasoid" and "Mongoloid" populations are mainly concentrated in the north 
and northeastern parts of the country. Majority of the Mongoloids are tribes affiliated 
with the Tibeto-Chinese linguistic family. Most of the Caucasoids are caste groups and 
speak Indo-European languages. Both the Mongoloid and Caucasoid groups show a 
certain degree of differentiation within themselves in cultural and biological traits such as 
anthropometry, genetic markers, and dermatoglyphics (Phookan, 1974; Das, 1979; Das 
and Das, 1981; Bhasin and Walter, 2001). The "Australoids" are mostly confined to the 
central, western and southern India, while the "Negritos"are restricted only to the 
Andaman Islands (Cavalli- Sforza et al., 1994). Linguistically, Indian populations belong 
to four major language families: Indo-European, Dravidian, Tibeto-Burman and Austro-
Asiatic. The Indo-European and Dravidian languages are spoken in the northern and 
southern parts of the subcontinent, respectively (Gadgil et al., 1998). The Tibeto-Burman 
speakers are supposedly immigrants to India from Tibet and Burma (now, Myanmar) and 
are concentrated in the northeastern parts of the country (Guha, 1935). The Austro-
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Asiatic speakers are exclusively tribals and are dispersed mostly in the central and eastern 
parts of the country. Molecular diversity studies have revealed that the Austro-Asiatic 
speakers are likely to have been the most ancient inhabitants of India (Majumder, 2001; 
Roychoudhury et al., 2001). These tribes might have entered India through the northwest, 
as they moved out of Africa following a path south of the Himalayas, while another 
ancestral group moved north, crossing the Himalayas, settling in southern China, and 
entering South Asia later from the northeast (Majumder, 2001; Basu et al., 2003). 
The Indian subpopulations shows wide diversity and extensive variations in 
frequencies of alleles and haplotypes of common polymorphisms (Bhattacharyya et al., 
1999; Roy et al., 2001, 2003; Chandak et al., 2002; Nagarkatti and Ghosh, 2002; Pasha et 
al., 2002; Nagarkatti et al., 2004a, 2004b; Batra et al., 2005) as well as occurrence of 
some private polymorphisms and mutations (Pramanik et al., 2000; Mukherjee et al., 
2004; Sengupta et al., 2004). These findings suggest the significance of population 
stratification in designing case-control association studies. Case-control studies carried 
out in the Indian population sometimes reveal observations distinct from other world 
populations (Ramana et al., 2000; Nagarkatti et al., 2002; Thangaraj et al., 2002; 
Sengupta et al., 2004; Batra et al., 2005; Rajput et al., 2005). Using SNPs and repeat 
polymorphisms, both novel and reported, studies have been successful in identifying at-
risk markers or haplotypes for particular diseases (Choudhry et al., 2001; Ahsan et al., 
2004; Nagarkatti et al., 2004a, 2004b; Sharma and Ghosh, 2004; Sharma et al., 
2004;Verma et al., 2004). 
Cytochrome P450 2E1 (CYP2E1), a major component of the microsomal ethanol 
oxidizing system, is expressed in abundance in the human (Raucy et al., 1995) and is 
involved in the metabolism of endogenous substrates such as ethanol, acetone, acetal as 
well as exogenous substrate including benzene, carbon tetrachloride, ethylene glycol and 
nitrosamines (Novak and Woodcraft, 2000). It is also involved in metabolism of several 
drugs such as chlorzaxazone, acetaminophen and synthesis of endogenous substrate such 
as cholesterol, steroids and other lipids. Chronic ethanol consumption induces the 
expression of CYP2E1 up to 10-fold which metabolizes ethanol and generates free 
radicals and acetaldehyde which react with cell membrane leading to cell damage and 
development of alcoholic liver disease (Castillo et al., 1992; Koop, 1992). Several single 
nucleotide polymorphisms (SNPs) have been reported in CYP2E1 gene which may have 
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varied effect on the various processes such as glconeogenesis, cirrhosis and cancer. 
Restriction Fragment Length Polymorphism (RFLP) for the restriction enzyme Rsal and 
PstI have been detected in 5' upstream sequence of gene due to G/C and C/T mutation 
(Watanabe et al., 1990). The Dral polymorphism, another occurs at high frequency 
(Stephen et al., 1994). Polymorphism of CYP2E1 has been shown to be one of the 
potential indicators of a CYP associated susceptibility to cancer and cirrhosis in humans 
(Danko and Chaschin, 2005; Stickel and Osterreicher, 2006). 
Even though polymorphism in CYP2E1 may have functional consequences, not 
much information is available on the SNPs in CYP2E1 in India population. Identification 
of SNPs in CYP2E1 associated with environmental factors, may not only leads to 
understanding of variations in response amongst different endogamous group but also 
help in explaining the inter-individual differences in risk of disease and response to drugs 
or chemicals. 
2.2 MATERIALS AND METHODS 
2.2.1 Selection and Identification of Study Populations 
Population identification and collection of samples was carried out with the help of 
expert anthropologists and community health workers who were part of the Indian 
Genome Variation (IGV) Consortium formed during the CSIR Tenth Five Year Plan 
Network project entitled "Predictive medicine using repeat and single nucleotide 
polymorphisms". The populations for SNP discovery and validation panel were identified 
based on the following criteria; geographical zones, linguistic groups, practice of 
endogamy, presence of minority communities from different religious groups and 
existence of populations of different sizes. Four major linguistic lineages, namely, Indo-
European (IE), Dravidian (DR), Tibeto-Burman (TB), and Austro-Asiatic (AA) have 
been considered from six geographical zones namely North (N), South (S), East (E), 
West (W), Central (C) and North-East (NE) India (Table). Population were categorized as 
isolated if their size was <1 million and large if >10 million. In each grid of language and 
geography, at least two isolated (IP) and large populations (LP) were identified for 
collection, wherever applicable. These populations were selected with the aim for giving a 
fair representation of the wide spectrum of diversity within the Indian population including 
castes, tribes as well as religious groups. Instead of naming the populations because of 
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ethical issues, a convention was followed wherein each population was given a label of 
language, followed by geographical zone and ethnic categorization as LP, IP or SP. For 
e.g. lE-N-LP wherein IE means population of Indo-European lineage, N stands for North 
zone and LP for large population. LPs are caste groups - mostly large populations, IPs are 
tribal isolated populations and SPs are religious groups. Tribal populations can be large (a 
few of the IPs are also large groups). Endogamy for each population was established by 
taking extensive information about marriage patterns, gathered through pedigrees and 
interview of family members of the donor as well as published literature. 
To reduce the cost, a two step approach was followed wherein in the first step; 
SNPs were discovered in one representative DNA sample of the sub-population. This 
panel of representative DNA samples was known as Discovery SNP Panel. In the second 
step, the discovered SNPs were validated in a larger sample size of each population. The 
populations in this step were known to belong to Validation Panel. A selection criteria 
was evolved for prioritizing the SNPs for validation based on the data of novel and 
putative functional SNPs as well as minor allele frequencies (MAF>0.05) of the SNPs in 
the Discovery panel. Information on the frequencies of SNPs in different databases like 
dbSNP, Celera, Real SNP and HapMap along with the information on haplotype block 
structures and tag SNPs were taken into consideration during selection of SNPs for 
validation. SNPs with an overall minimal allele frequency (MAF>0.05) were used for 
further validation. 
2.2.2 Populations for SNP Discovery Panel 
With a view to discover novel SNPs as well as to determine the frequency of the 
reported SNPs in the Indian population, an initial panel was made comprising of 
representatives drawn from 43 different sub populations (Figure 2.1). A discovery panel 
of 43 DNA samples collected from different parts of India was made so as to capture the 
entire spectrum of genetic diversity of the Indian population. The discovery panel 
included samples of various castes, tribes as well as some religious groups, belonging to 
diverse geographical zones and linguistic backgrounds to maximize novel SNP 
discovery. Though 43 individuals per se do not represent the entire Indian population, 
such a diverse set does increase the heterogeneity in terms of SNP discovery as compared 
to a set of samples from a single sub-population. 
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Figure 2.1: Samples comprising the discovery panel (DSNP). The panel comprises of 43 
samples, representing the Indian population, consisting of linguistically diverse samples 
from both tribal and non-tribal population. This panel is used for SNP discovery. 
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2.2.3 Populations for Validation Panel 
Once the SNPs were identified, including the novel ones in the Discovery panel, 
they were further validated in a larger sample size of these sub-populations. The 
populations for validation panel were based on the suggestions of anthropologists and the 
extent of diversity and heterozygosity prevalent in Indian population. In all, twenty four 
subpopulations from all over India were identified and an average of 23 samples from 
each sub-population was collected to validate the SNPs (Table 2.1). Since the IE 
language family is mostly confined to Northern zone of the country, majority of the 
populations were identified from this zone. Out of five populations of Northern zone, 
three populations (lE-N-LPl, IE-N-LP5, IE-N-LP9) belonged to a large population 
group, one population (IE-N-SP4) belong to special group and one population (1E-N-1P2) 
belongs to isolated group. Only three populations were identified from Eastern zone 
where IE language is common. Two populations which were identified belonged to a 
large population group (IE-E-LP2, IE-E-LP4) and one to isolated (lE-E-IPl) population. 
Four populations were identified in Western region where IE language is common. All 
the four populations (lE-W-LPl, IE-W-LP2, IE-W-LP3, IE-W-LP4) belonged to large 
group. There were no samples from central and southern zone with IE language. Two 
populations from North-East zone (lE-NE-IPl and lE-NE-LPl) were identified in IE 
lineage category (Table 2.1). As Dravidian language was not common in Northern 
region, no populations of Dravidian lineage were identified from this region. Dravidian 
language group was also not identified in Eastern, Western and North-eastern region. One 
isolated population (DR-C-IP2) was identified in Central zone and three populations, two 
(DR-S-LP2, DR-S-LP3) and one isolated (DR-S-IP4) populations were included from 
Southern zone. Two populations in Northern zone, one special (TB-N-SPl) and one 
isolated population (TB-N-IPl) and one large population in north-east zone (TB-NE-
LPl) were identified in TB language group. Two populations were also identified from 
AA language group, one isolated population from Eastern zone (AA-E-IP3) and Central 
zone (AA-C-IP5) respectively (Table 2.1). In this way each SNP was genotyped in 552 
samples to confirm their status and measure their frequency. 
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Table 2.1: Indian population selected for the validation panel 
Zone/ 
Linguistic 
category 
North 
(N) 
East 
(E) 
West 
(W) 
Central 
(C) 
South 
(S) 
North-East 
(NE) 
Indo-European 
(IE) 
IE-N-IP2, 
IE-N-LP1,IE-N-LP5, 
IE-N-LP9, IE-N-SP4 
lE-E-IPl, IE-E-LP2, 
IE-E-LP4 
IE-W-LP1,IE-W-LP2, 
IE-W-LP3, IE-W-LP4 
lE-NE-IPl, 
lE-NE-LPl 
Dravidian 
(DR) 
DR-C-IP2 
DR-S-IP4, 
DR-S-LP2, 
DR-S-LP3 
Tibeto-
Burman 
(TB) 
TB-N-IPl, 
TB-N-SPl 
TB-NE-
LPl 
Austro-
Asiatic 
(AA) 
AA-E-IP3 
AA-C-IP5 
Out-
Group 
(OG) 
OG-W-IP 
IE, DR, TB and AA represent the Indo-European, Dravidian, Tibeto-Burman and Austro-Asiatic language 
families, respectively; OG represents out group population of African origin, N, E, W, C, S and NE represent 
the north, east, west, central and north-east zones of the country respectively; LP, IP and SP represent large 
endogamous population, isolated population and special population, respectively. 
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12A Field Work and Sample Collection 
In the current study, samples from 6 populations of Indo-European language were 
personally collected from the districts of Uttar Pradesh whereas samples from the 
remaining populations were provided by Indian Genome Variation (IGV) Consortium 
members participating in the CSIR network project. These 6 populations were identified 
in districts of Khatima, Agra, Firozabad, Barabanki, Unnao, Gonda, Faizabad, Raibareli, 
and Shahjhanpur. Before undertaking the field work, a pilot survey was done wherein 
information was collected on the distribution of the population in different villages in 
these districts. Information about the prevalence of diseases, if any, in the concerned 
population was collected from the Medical Officer (MO) of the Public Health Center 
(PHC) as well as the local health workers. The populations were then approached with 
the help of a Village-head, social workers and community health workers as their 
participation was essential for establishing rapport with the people. 
Endogamy of the populations was established by taking extensive information about 
the marriage pattern gathered through pedigrees and interviews of family members of the 
donor. A general template to obtain informed consent from the donors of the samples was 
used and in cases where the donor was illiterate, thumb impression was used. In addition, 
consent of the donors in writing was also taken. It was ensured that the individuals were 
unrelated at least to the first cousin level and both males and females were collected in 
equal numbers. Although large sample sizes would have added robustness to our 
inferences, it is expected that even small sample sizes in highly endogamous small cohorts 
would be equally informative with respect to allele frequency. About 10ml of intravenous 
blood was collected from each individual. Ethical clearance was obtained from the 
Institutional Bioethics Committee (IBC) for the collection of samples following the 
guidelines of Indian Council of Medical Research (ICMR), New Delhi 
(Tittp://icmr.nic.in/ethical.pdf). 
2.2.5 DNA Isolation 
Genomic DNA was isolated from the peripheral blood leukocytes by using a modified 
salting-out procedure (Miller et al., 1988). Briefly, four volumes of ice-cold CI buffer (IX) 
was added in 10ml blood, obtained from individuals to disrupt the cell membrane. The 
suspension was mixed by inverting the tubes several times until it became translucent and 
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incubated on ice for lOmin. This was followed by centrifugation at 2500 rpm for 15min 
at 4°C to pellet the nuclei. The supernatant was discarded and the pellet was washed with 
8ml of ice-cold cell lysis containing buffer. 12ml of nuclei lysis buffer was added with 
0.8ml of 10% SDS. 50|a.l of a 20|j.g/|j,l solution of proteinase K was added and the pellet 
was resuspended by brief vortexing. After incubation at 65°C for 2-3 hrs, the digested 
protein products were precipitated by the addition of 4ml of 6M NaCl. After 
centrifugation for 15min at 2500 rpm at room temperature, the supernatant was 
transferred to another tube at room temperature containing absolute ethanol to spool the 
DNA. The spooled DNA 
TE buffer and stored at 4°C. 
^ was then washed with 70% ethanol twice, air-4iie4 -dissolved in 
2.2.6 DNA Quantitation I v 
The quantity of the DNA was estimated by making appropriate dilutions W 
determine the optical density (OD) at 260nm and 280nm. DNA quality was assessed 
using the 260nm/280nm ratio. 2^1 of the stock DNA was electrophoresed on a 0.8% 
agarose gel and stained with ethidium bromide to determine the integrity of the genomic 
DNA. The stock solution of the DNA was diluted to 50ng/|.il for genotyping application. 
The stock DNA solution was stored at -20''C and deposited at the repository of IGV 
consortium. All the representative DNA samples from 43 population were then used for 
identifying SNPs in the SNP Discovery Panel. 
2.2.7 Primer Designing for CYP2E1 Gene 
Primer designing is the most critical parameter for successful PCR. Five pairs of 
primers were designed using DNASTAR Laser gene software (www.dnastar.com) which 
covered UTR, coding region and intron/exon boundaries of CYP2E1 gene where 
functionally important polymorphisms are known to exist in other populations (Fig: 2.2). 
The details of the primers and amplicon lengths are given in table 2.2. The primer pairs 
were selected to have theoretically the melting temperature of 60 C, primer length 
between 18 to 24 nucleotides, GC contents of 50%, product length less than Ikb, 5' end 
stability and 3' end specificity. Primers with four or more bases at the 3' end 
complementary to other pair of the primer was discarded or redesigned to avoid artifact 
due to hairpin or primer-dimer formation. In brief, the gene sequence of CYP2E1 was 
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Table 2.2: PCR primers used for CYP2E1 gene amplification and 
sequencing 
s. 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
FP 5'-
RP 5' 
FP 5'-
RP 5' 
FP 5'-
RP 5' 
FP 5'-
RP 5' 
FP 5'-
RP 5' 
Primer Sequence 
ACTGGCCACTGGAAAGGAAAGAGA -3' 
- CACATGAATGGGGCCAGAAGGAA -3' 
• CTTCTGCTGGCCCCTCTGC -3 
- CACCCCTCGAAGCTATGTTGTTTG -3' 
• GCTGGGAGGTGGCTGGTTCT -3' 
- AGCTCCCTTTCCTCCCCTTTACTT -3' 
GTGTGCCGCCCTCCTCCTG-3' 
- TTTGGCTCCTTCACCCTTCACATT-3' 
• TGGGCAGATGGATAAAAGCGTGAT-3' 
- GGAGGGGAGATGAGGAGTGTGG-3' 
Primer 
Length (nt) 
24 
23 
19 
24 
20 
24 
19 
24 
24 
22 
Product Location 
size 
925bp 
848bp 
896bp 
835bp 
999bp 
5'UTR 
Exon 3 
&4 
Exon 6 
& Intron6 
Intron 6 
Exon 7 
&8 
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downloaded in the FASTA format from gene bank database of NCBI (National Centre 
for Biotechnology Information, (www.ncbi.nlm.nih.gov'). Using the Repeat Masker 
programme fwww.repeatmasker.org') the repetitive sequences were masked and this 
masked sequence was then used for designing primer using primer select programme. 
The designed primer pairs were blasted using BLASTN software to search for homology 
with other loci in the genome. Primer pairs showing less than 70% homology with other 
loci in the genome were selected for amplification. 
2.2.8 Polymerase Chain Reaction (PCR) 
PCR reactions were carried out with an initial denaturation of 94°C for 5min, 
followed by 35 cycles of denaturation and extension at 94°C and 72°C respectively for 
30sec. The annealing step was carried out for SOsec and the annealing temperature varied 
with the locus amplified. The reaction was completed with a final extension at 72°C for 
lOmin. 5 )LI1 of PCR product was analyzed on 2.0% Agarose gel containing ethidium 
bromide and analyzed by VERSA DOC Imaging System (Model 1000, Bio-Rad). 
2.2.9 PCR Product purification for Sequencing 
In cases where some non-specific PCR products were observed along with the 
specific amplicon, the PCR product was purified using isolation kit available from 
Biological Industries (Israel). Two volumes of polyethyl glycol/ sodium acetate 
(PEG/NaOAc) solution were added to the PCR product and mixed properly by vortexing 
and incubated for lOmin at room temperature. The DNA was pelleted at 3,200 rpm for 30 
min. The supernatant was removed by inverting the PCR plate on tissue paper and 
centrifuging up to 500 rpm. Pellet was washed twice with two volumes of 70% ethanol 
and centriftiging at 3,200 rpm for lOmin. Ethanol was then completely removed and the 
pellet was air-dried and resuspended in 5-15^1 sterile MilliQ H2O. 
2.2.10 DNA Sequencing for SNP Discovery Panel 
Purified PCR product was gel quantitated prior to cycle sequencing reaction. Cycle 
sequencing reaction was carried out to incorporate the flourochrome labeled dideoxy 
terminators in the DNA strand. Briefly, sequencing primer (2pmol/^l) and 50-I50ng/|xl 
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amplicon were added to 4^ ,1 reaction mix containing Big dye terminator reaction mix, 
dilution buffer and volume made up to 10^1 with autoclaved MilliQ water as per the Big 
Dye Terminator kit instructions (version 3.1, Applied Biosystems, Foster City, CA, 
USA). The reaction was carried out for 30 cycles of denaturation at 96°C for lOsec 
followed by annealing step for 5 sec and an extension at 60°C for 4min. The annealing 
temperature was 50°C, 55°C or 60°C depending on the primers utilized for sequencing. 
2.2.11 Purification of Sequencing Products and Loading in Automated Sequencer 
After sequencing reaction, the products were precipitated using ethanol, EDTA and 
NaOAc to remove unincorporated primers and fluorescent ddNTPs. Briefly, 2^1 of 150mM 
EDTA and lOfil of water were added to 10|jl of the sequencing product and mixed well. To this 
mix, 2|il of 3M NaOAc (pH 4.6) and 50|il of absolute ethanol were added and incubated for 10 
min at room temperature. The pellet obtained after centrifijgation at 4000 rpm for 5 min, were 
washed twice with lOOfi of 70% ethanol. The pellets were air-dried and resuspended in 10^ 1 of 
100% Hi-Di formamide (Applied Biosystems). The tubes were incubated at 94°C for 5min and 
immediately plunged in ice for denaturing the samples. The sequencing samples were then 
loaded in the 3100 Automated Sequencer (ABI 3100 capillary sequencer. Applied 
Biosystems, Foster City, CA). 
2.2.12 SNP Validation Using Sequenom Mass ARRAY System 
Validation of the SNPs identified in the Discovery Panel samples were carried out 
using Matrix assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass 
spectrometry at TCGA facility, Okhala, New Delhi (www.tcga.org). The extended 
products were analyzed by SEQUENOM MALDI-TOF mass spectrometry, and the time-
of-flight is proportional to mass, permitting precise determination of the size of products 
generated, which can be converted into genotype information. The principle of the 
MassARRAY system is the extension of an oligonucleotide probe over a SNP site in a 
PCR product with a mixture of deoxynucleotides and dideoxynucleotides, to produce 
different size products for each allele of a SNP (Figure 2.3). The assay consists of a post-
PCR primer extension reaction that is carried out in the presence of one or more 
dideoxynucleotides (ddNTPs) resulting in allele specific terminated extension products. 
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Primers are designed to anneal adjacent to the SNPs of interest. The addition of a DNA 
polymerase, plus a cocktail mixture of nucleotides and terminators, allows extension of the 
primer through the polymorphic site. The resultant mass of the primer extension product is 
then analyzed and used to determine the sequence of the nucleotides at the polymorphic 
site. A homozygous genotype leads to one extension product of defined mass. In 
heterozygous samples, two products of distinguishable masses are generated. 
2.2.13 Statistical Methods 
All polymorphic alleles were tested for Hardy-Weinberg equilibrium using v2 tests 
with one degree of freedom. Haplotypes were determined computationally from unrelated 
individuals using haploview software and pair-wise linkage disequilibrium (LD) between 
the SNPs was calculated fi-om the genotype data of the populations with Haploview 
software version 3.2 (Barret et al., 2005). Principal component analysis of all SNPs such as 
genotype and allele frequency estimation was performed using SPSS software (version 
11.0 for Windows; SPSS Chicago, IL). 
2.3 RESULTS 
2.3.1 SNPs of CYP2E1 Identified in Discovery Panel Samples 
As evident from Table 2.3, CYP2E1 gene was found to be polymorphic in Indian 
sub-populations using the primers pairs mentioned in the methodology section. A total of 
five SNPs were identified in CYP2E1 in the representative DNA samples of SNP 
Discovery Panel (Figure 2.4, 2.5 & 2.6). Analysis of the sequencing data using primer 
pair I, covering 5'UTR revealed the presence of polymorphism at nucleotide position -
930 in CYP2Elg&[\Q. This polymorphism results in the substitution of nucleotide A with 
G in 5'UTR (-930A/G; rs3813870) (Table 2.3 & 2.4). As seen in table 2.4, eleven 
populations showed the presence of heterozygous genotype in 43 samples of Discovery 
Panel and five samples revealed the presence of homozygous mutant genotype. The 
minor allele frequency of CYP2EJ (-930A/G) polymorphism i.e. G allele was found to be 
0.26 and the expected genotype for -930A/G polymorphic site was almost equal to that of 
the observed genotypes following the Hardy-Weinberg equilibrium (HWE). Sequence 
analysis of PCR products using primer pair 2, covering exon 3 and 4, did not reveal the 
presence of any polymorphic sites. 
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Figure 2.4: DNA Sequence Electropherograms of SNPs (1&2) of 
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CYP2E1 gene 
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Table 2.3: Identified SNPs of CYP2E1 gene in SNP Discovery Panel Samples 
S. No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
28 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
Sample 
Id. 
DSNPl 
DSNP2 
DSNP3 
DSNP4 
DSNP5 
DSNP6 
DSNP7 
DSNP8 
DSNP9 
DSNPIO 
DSNPl 1 
DSNPl 2 
DSNPl 3 
DSNPl 4 
DSNPl 5 
DSNPl 6 
DSNPl 7 
DSNPl 8 
DSNPl 9 
DSNP20 
DSNP21 
DSNP22 
DSNP23 
DSNP24 
DSNP25 
DSNP26 
DSNP27 
DSNP28 
DSNP29 
DSNP30 
DSNP31 
DSNP32 
DSNP33 
DSNP34 
DSNP35 
DSNP36 
DSNP37 
DSNP38 
DSNP39 
DSNP40 
DSNP41 
DSNP42 
DSNP43 
Population 
code 
IE-N-LP9 
lE-NE-LPl 
IE-N-LP3 
lE-N-IPl 
IE-N-IP2 
1E-E-LP4 
1E-E-LP3 
lE-E-IPI 
DR-E-IPl 
AA-E-lPl 
AA-E-IP2 
TB-N-lPl 
IE-W-LP3 
lE-W-IPI 
AA-W-IPl 
lE-W-LPl 
IE-W-LP2 
DR-C-lPl 
AA-C-IPl 
lE-NE-IPI 
TB-NE-LPl 
TB-N-SP2 
lE-S-IPI 
DR-S-LPl 
DR-S-IPl 
AA-C-IP5 
AA-E-IP3 
AA-NE-lPl 
OG-W-IP 
DR-S-1P4 
IE-W-IP2 
IE-N-SP3 
1E-N-SP4 
IE-N-LP18 
IE-N-SP2 
lE-N-LPll 
DR-S-LP2 
JE-N-LP2 
lE-N-LPl 
lE-E-lPl 
lE-S-IPl 
1E-E-LP2 
DR-C-1P2 
SNPl 
(rs3813870) 
NA 
AA 
AG 
GO 
AA 
AA 
AA 
AA 
AA 
GG 
AG 
AG 
AA 
GG 
AA 
NA 
AA 
AA 
AG 
AG 
GG 
AA 
AG 
AA 
AA 
GG 
AG 
AA 
AA 
AG 
AA 
AA 
NA 
AA 
AA 
AG 
AA 
AA 
AA 
AG 
AA 
AG 
AA 
SNP2 
(1000252) 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GA 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
SNP3 
(rs8192775) 
NA 
GG 
GG 
GG 
GG 
NA 
GG 
GG 
GA 
GG 
GG 
GG 
NA 
GG 
GG 
NA 
GG 
GG 
AA 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
NA 
GG 
GA 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
SNP4 SNPS 
(rs6413432) (rs2864984) 
NA 
TT 
TT 
TT 
TT 
NA 
TT 
TT 
TT 
TT 
TT 
TT 
NA 
TT 
TT 
TT 
TT 
NA 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TT 
TA 
TT 
NA 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GT 
GG 
GG 
GG 
NA 
GG 
GG 
NA 
GG 
GG 
GT 
GT 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
NA 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GG 
GT 
GG 
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Table 2.4: Genotype and Minor Allele frequency (MAF) of SNPs of CYP2E1 gene in 
SNP Discovery Panel samples 
S.No. 
1 
2 
3 
4 
5 
SNPs 
SNPl 
(rs3813870) 
SNP2 
(i000252) 
SNP3 
(rs8192775) 
SNP4 
(rs6413432) 
SNPS 
(rs2864984) 
Nucleotide 
change 
A>G 
G>A 
G>A 
T>A 
O A 
Position 
from 
ATG 
5'UTR 
(-930) 
Exon6 
(6396) 
Intron 6 
(7126) 
Intron 6 
(7632) 
Intron 6 
(8057) 
AA 
24/40 
(0.74) 
GO 
42/43 
(0.99) 
GG 
35/38 
(0.95) 
TT 
38/39 
(0.99) 
CC 
35/39 
(0.95) 
Genotypes 
AG 
11/40 
(0.14) 
GA 
1/43 
(0.01) 
GA 
2/38 
(0.025) 
TA 
1/39 
(0.01) 
CA 
4/39 
(0.05) 
GG 
5/40 
(0.12) 
AA 
0/43 
(0.0) 
AA 
1/38 
(0.025) 
AA 
0/39 
(0.0) 
AA 
0/39 
(0.0) 
MAF 
(0.26) 
(0.01) 
(0.05) 
(0.01) 
(0.05) 
Table 2.5: CYP2E1 SNPs identified in different linguistic lineages of Indian 
population 
S.No. 
1. 
2. 
3. 
4. 
5. 
Linguistic families 
Austro-Asiatic 
Dravidian 
Indo-European 
Tibet-Burman 
Out-group 
SNPs 
SNP 1, 3, 5 
SNP 1,2, 3, 5 
SNP 1, 3, 4, 5 
SNPl 
— 
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Analysis of the sequencing data using primer pair 3, covering exon 6 and intron 6, 
revealed the presence of two polymorphisms at nucleotide positions 6396 and 7126. 
Polymorphism at nucleotide position 6396 results in the substitution of nucleotide G with 
A in exon 6 (6396G/A; novel) (Table 2.3 & 2.4). Details of this SNP are not available at 
NCBI as it has not been reported in other population. As seen in table 2.4, only one 
populations showed the presence of heterozygous genotype of CYP2E1 (6396G/A) 
polymorphism in 43 samples of Discovery Panel (Table 2.4). None of the DNA sample 
showed the presence of homozygous mutant genotype. The minor allele frequency i.e. A 
allele was found to be 0.01 (Table 2.4) and the expected genotype for 6396A/G 
polymorphic site was almost equal to that of the observed genotypes following the 
Hardy-Weinberg equilibrium (HWE). Likewise polymorphism at nucleotide position 
7126 results in the substitution of nucleotide G with A at intron 6 (7126G/A: rs8192775) 
(Table 2.3 & 2.4). As seen in table 2.4, two population showed the presence of 
heterozygous genotype of CYP2E] (7126G/A) polymorphism in 43 samples of Discovery 
Panel (Table 2.3 & 2.4) and only one DNA sample revealed the presence of homozygous 
mutant genotype (Table 2.3 & 2.4). The minor allele frequency i.e. A allele was found to 
be 0.05. The expected genotype for 7126G/A polymorphic site was almost equal to that 
of the observed genotypes following the HWE. 
Analysis of the sequencing data using primer pair 4, covering intron 6, also revealed 
the presence of two polymorphisms at nucleotide positions 7632 and 8057. 
Polymorphism at nucleotide position 7632 resulted in the substitution of nucleotide T 
with A in intron 6 (7632T/A; rs6413432) and this polymorphism has been identified as 
CYP2EI*6 and commonly referred to as Dral polymorphism of CYP2E1 (Table 2.3 & 
2.4). As evident from table 2.4, only one sub-population showed the presence of 
heterozygous genotype for 7632T/A polymorphism in 43 samples of Discovery Panel. 
None of the DNA sample revealed the presence of homozygous mutant genotype (Table 
2.4). The minor allele frequency i.e. A allele was found to be 0.01 and the expected 
genotype for 7632T/A polymorphic site was almost equal to that of the observed 
genotypes following the HWE. Polymorphism at nucleotide position 8057 resulted in the 
substitution of nucleotide G with T (8057C/A; rs2864984). As seen in table 2.4, four 
population showed the presence of heterozygous genotype of CYP2E1 (8057C/A) 
polymorphism in 43 samples of Discovery Panel (Table 2.4). None of the DNA sample 
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revealed the presence of homozygous mutant genotype. The minor allele frequency i.e. T 
allele was found to be 0.05 and the expected genotype for 8057C/A polymorphic site was 
almost equal to that of the observed genotypes following the HWE. Sequence analysis of 
PCR products using primer pair 5, covering exon 7 and 8, did not reveal the presence of 
any polymorphic sites. 
As evident from table 2.5, the SNPs in CYP2E1 were found to be distributed 
throughout the Indian population except for Out group. Indo-European and Dravidians 
language group were found to carry majority of the SNPs identified in CYP2E1 gene. The 
SNPs identified in Indo-European group were -930A/G, 7126G/A, 7632T/A and 
8057C/A whereas SNPs present in Dravidians groups were -930A/G, 6396G/A, 
7126G/A, and 8057C/A while Austro-Asiatic were found to carry -930A/G, 7126G/A 
and 8057C/A. Tibeto-Burmans group were found to carry only -930A/G SNP. Our results 
show that -930A/G was found to be conserved throughout the Indian population with 
minor allele frequency of 0.26. 
2.3.2 Validation of SNPs in CYP2E1 Gene 
SNPs identified in the representative samples of discovery panel were validated in 
larger sample size to demonstrate that they are polymorphic and not due to the artifact. 
CYP2E1 (-930A/G), CYP2E1 (6396G/A), CYP2E1 (7126G/A), CYP2E1 (7632T/A) and 
CYP2E1 (8057C/A) were validated in 552 samples from 24 sub-populations of India 
using Sequenom mass array technique. Data obtained after validation revealed that all the 
five SNPs were polymorphic in all the linguistic groups of India. The genotypes and 
minor allele frequency (MAP) of these SNPs in CYP2E1 in 24 different Indian sub-
populations are summarized in tables 5 to 9. All the SNPs were found to be in the Hardy 
Weinberg equilibrium (HWE) in all the sub-populations. 
Table 2.6.1 summarizes the genotype and MAP of SNPl (rs3813870) in the 
different Indian sub-populations of Validation Panel. As observed in SNP Discovery 
Panel, this polymorphism was found to be present in all the populations included in the 
Validation Panel. This polymorphism was distinct in our population as almost all the sub-
populations exhibited even the presence of homozygous mutant genotype of SNPl of 
CYP2E1. Only five sub-population of IE lineage, out of which three, present in northern 
region and two, present in western region and two TB population did not showed the 
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Table 2.6.1: Genotype & MAF of SNPl (rs3813870) of CYP2E1 gene in Indian sub-
populations from Validation Panel 
S.No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
Population code 
AA- C-IP5 
AA-E-IP3 
DR- C-1P2 
DR-S-IP4 
DR-S-LP2 
DR-S-LP3 
lE-E-IPl 
IE-E-LP2 
IE-E-LP4 
IE-N-IP2 
lE-N-LPl 
IE-N-LP5 
1E-N-LP9 
IE-N-SP4 
lE-NE-IPl 
lE-NE-LPl 
lE-W-LPl 
IE-W-LP2 
IE-W-LP3 
IE-W-LP4 
TB-N-IPl 
TB-N-SPl 
TB-NE-LPl 
OG-W-IP 
Genotype frequency 
AA 
0.56 
0.23 
0.35 
0.25 
0.50 
0.35 
0.30 
0.33 
0.52 
0.68 
0.59 
0.71 
0.70 
0.60 
0.64 
0.68 
0.46 
0.77 
0.57 
0.33 
0.70 
0.65 
0.68 
0.36 
AG 
0.33 
0.50 
0.45 
0.60 
0.46 
0.48 
0.35 
0.61 
0.39 
0.27 
0.41 
0.29 
0.26 
0.40 
0.32 
0.27 
0.45 
0.23 
0.43 
0.62 
0.30 
0.30 
0.32 
0.59 
GG 
0.1] 
0.27 
0.20 
0.15 
0.04 
0.17 
0.35 
0.06 
0.09 
0.05 
0 
0 
0.04 
0 
0.04 
0.05 
0.09 
0 
0 
0.05 
0 
0.05 
0 
0.05 
MAF 
0.28 
0.52 
0.42 
0.45 
0.28 
0.41 
0.58 
0.34 
0.28 
0.28 
0.20 
0.14 
0.17 
0.20 
0.20 
0.18 
0.32 
0.11 
0.22 
0.36 
0.15 
0.16 
0.16 
0.34 
Table 2.6.2: Average Genotype & MAF of SNPl (rs3813870) CYP2E1 in different 
linguistic lineages of Indian population 
S.No. 
1. 
2. 
3. 
4. 
5. 
Linguistic families 
Austro-Asiatic 
Dravidian 
Indo-European 
Tibet-Burman 
Out-group 
Genotype frequency 
AA 
0.40 
0.36 
0.56 
0.68 
0.36 
AG 
0.41 
0.50 
0.38 
0.31 
0.59 
GG 
0.19 
0.14 
0.06 
0.01 
0.05 
MAF 
0.40 
0.39 
0.25 
0.16 
0.34 
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presence of homozygous mutant genotype of this polymorphism (Table: 2.6.1). As 
showed in table 2.6.2, the average MAF was similar in sub-populations from AA (0.40), 
DR (0.39) and OG (0.34) lineage and relatively higher than sub-population from IE 
(0.25) and TB (0.16) lineage. 
As evident from table 2.7.1, the heterozygous genotype (GA) of SNP2 (novel) were 
found in both the sub-populations of AA lineage and three sub-population of DR lineage 
which belonged to southern region while no homozygous variant genotypes was observed 
in any sub-populations of India. The isolated and small sub-populations of DR lineage 
present in the Central zone and included in the study did not show the presence of this 
polymorphism ofCYP2El. This SNP was also found in population of IE lineages and out 
of fourteen sub-population of IE lineages, it was found to be present in eight sub-
population which were distributed evenly in all the sub-population of IE lineages. When 
this SNP was compared within the different language family it was found that the MAF 
was similar in the AA, DR and IE population (0.02), while this SNP was not found to be 
present in TB and OG lineage (Table: 2.7.2). 
Table 2.8.1 summarizes the distribution of genotypes and minor allele frequency 
of SNP3 in Indian populations stratified on linguistic basis. In contrast to the SNP 
Discovery Panel almost all DNA samples from validation panel exhibited polymorphic 
genotypes of SNP3. As evident from the table, heterozygous genotype (GA) were found 
in all the 24 sub-population of validation panel where as homozygous mutant were also 
found in most of the sub-population except for few IE and TB lineages. The population of 
IE and TB lineages which did not carry the homozygous mutant allele mostly belongs to 
northern region. When this SNP was compared within the different language family it 
was found that the MAF was similar in the AA (0.20), IE (0.20) and OG (0.18) 
population which was slightly lower than DR (0.28) but slightly higher than TB (0.10) 
lineages (Table: 2.8.2). 
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Table 2.7.1: Genotype and MAF of SNP2 0000252) ofCYP2El in 
S.No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
Population 
AA- C-IP5 
AA-E-IP3 
DR- C-IP2 
DR-S-IP4 
DR-S-LP2 
DR-S-LP3 
lE-E-IPl 
IE-E-LP2 
IE-E-LP4 
IE-N-IP2 
lE-N-LPl 
IE-N-LP5 
IE-N-LP9 
IE-N-SP4 
lE-NE-IPl 
lE-NE-LPl 
lE-W-LPl 
IE-W-LP2 
IE-W-LP3 
IE-W-LP4 
TB-N-IPl 
TB-N-SPl 
TB-NE-LPl 
OG-W-IP 
populations of Validation Panel 
code Genotype frequency 
GG 
0.95 
0.95 
1.00 
0.96 
0.87 
0.96 
0.96 
1.00 
0.96 
1.00 
1.00 
0.91 
0.91 
0.91 
1.00 
0.86 
0.86 
1.00 
1.00 
0.96 
1.00 
1.00 
1.00 
1.00 
GA 
0.05 
0.05 
0 
0.04 
0.13 
0.04 
0.04 
0 
0.04 
0 
0 
0.09 
0.09 
0.09 
0 
0.14 
0.14 
0 
0 
0.04 
0 
0 
0 
0 
AA 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Indian sub-
MAF 
0.03 
0.02 
0 
0.02 
0.07 
0.02 
0.02 
0 
0.02 
0 
0 
0.04 
0.04 
0.04 
0 
0.07 
0.07 
0 
0 
0.02 
0 
0 
0 
0 
Table 2.7.2: Average genotype and MAF of SNP2 (1000252) of CYP2E1 in 
different linguistic lineages of Indian population 
S.No. 
1. 
2. 
3. 
4. 
5. 
Linguistic families 
Austro-Asiatic 
Dravidian 
Indo-European 
Tibet-Burman 
Out-group 
Genotype frequency 
GG 
0.95 
0.95 
0.95 
1.00 
1.00 
GA 
0.05 
0.05 
0.05 
0 
0 
AA 
0 
0 
0 
0 
0 
MAF 
0.02 
0.02 
0.02 
0 
0 
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Table 2.8.1: Genotype and MAF of SNP3 (rs8192775) of CYP2E1 in Indian sub-
populations of Validation Panel 
S.No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16, 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
Population code 
AA- C-IP5 
AA-E-IP3 
DR- C-IP2 
DR-S-IP4 
DR-S-LP2 
DR-S-LP3 
lE-E-IPl 
IE-E-LP2 
IE-E-LP4 
IE-N-IP2 
lE-N-LPl 
IE-N-LP5 
IE-N-LP9 
IE-N-SP4 
lE-NE-IPI 
lE-NE-LPl 
lE-W-LPl 
IE-W-LP2 
IE-W-LP3 
IE-W-LP4 
TB-N-IPl 
TB-N-SPl 
TB-NE-LPl 
OG-W-IP 
Genotype frequency 
GG 
0.78 
0.48 
0.55 
0.33 
0.64 
0.43 
0.55 
0.38 
0.83 
0.76 
0.87 
0.78 
0.83 
0.43 
0.61 
0.77 
0.46 
0.91 
0.52 
0.48 
0.91 
0.81 
0.79 
0.65 
GA 
0.17 
0.48 
0.36 
0.62 
0.36 
0.48 
0.36 
0.57 
0.17 
0.10 
0.13 
0.22 
0.17 
0.29 
0.39 
0.18 
0.50 
0.09 
0.38 
0.48 
0.09 
0.19 
0.26 
0.35 
AA 
0.05 
0.04 
0.09 
0.05 
0 
0.09 
0.09 
0.05 
0 
0.14 
0 
0 
0 
0.28 
0 
0.05 
0.04 
0 
0.10 
0.04 
0 
0 
0.04 
0 
MAF 
0.14 
0.28 
0.27 
0.36 
0.18 
0.32 
0.27 
0.33 
0.09 
0.19 
0.07 
0.11 
0.01 
0.43 
0.20 
0.13 
0.30 
0.04 
0.29 
0.28 
0.04 
0.10 
0.17 
0.18 
Table 2.8.2: Average genotype and MAF of SNP3 (rs8192775) of CYP2E1 in 
different linguistic lineages of Indian population 
S.No. 
1. 
2. 
3. 
4. 
5. 
Linguistic families 
Austro-Asiatic 
Dravidlan 
Indo-European 
Tibet-Burman 
Out-group 
GG 
0.63 
0.49 
0.66 
0.81 
0.65 
Genotype frequency 
GA 
0.32 
0.45 
0.29 
0.18 
0.35 
AA 
0.05 
0.06 
0.05 
0.01 
0.00 
MAF 
0.21 
0.28 
0.20 
0.10 
0.18 
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Table 2.9.1, summarizes the genotype and MAF of SNP4 (rs6413432) in the larger 
samples of Indian sub-populations. As evident from the table, this SNP were found to be 
present in all the sub-population of AA and DR lineages where as only eight sub-
population of IE lineages carried this SNP and most of these sub-population belonged to 
Eastern and North-Eastem region of IE lineages. However, only two sub-population of 
TB lineages shows this SNP while this SNP was not found to be present in OG lineages. 
When this SNP was compared within the different language family it was found that 
MAF was similar in AA (0.07) and DR (0.07) population which was slightly higher than 
IE (0.04) and TB (0.03) population (Table: 2.9.2). 
As evident from table 2.10.1, the heterozygous genotype (GT) of SNP5 (rs2864984) 
were found in all the 24 sub-population where as homozygous mutant genotype (TT) of 
this SNP were also present in most of the sub-population except for one population 
belonging to AA, DR, OG lineages, two of TB and seven of IE lineages. Most of the 
population of IE lineages which do not show the homozygous mutant genotype belonged 
to northern region. As shown in table 2.10.2 the average MAF of AA (0.21) and IE (0.18) 
was lower than DR (0.30) and OG (0.26) but higher than TB (0.09) lineages. 
2.3.3 Haplotype Analysis o{CYP2El Gene in Indian Sub-Populations 
As evident from table 2.11.1, a total of nine haplotypes (haplotype 1-9) were 
formed using five SNP sets i.e. Cr/'2£7(-930A/G), CYP2Eli6396G/A), 
CYP2E1{1\26GIA), CYP2E1{7632T/A) and CYP2E1(S057C/A). Out of nine, six 
haplotypes 1 to 6 were most frequent in all the linguistic groups of India i.e. Austro-
Asiatic, Dravidian, Indo-European, Tibeto-Burman and Out-group. Haplotypes 7 to 9 was 
found to be rare and observed in few populations only. The frequency of Haplotype 1 
(AGGTG), consisting wild type alleles from all the five SNPs i.e. -930A, 6396G, 7126G, 
7632T and 8057C was observed to be 0.52 in Austro-Asiatics, 0.55 in Dravidians, 0.69 in 
Indo-Europeans, 0.78 in Tibeto-Burmans, and 0.69 in Out-group. Likewise, the haplotype 
2 (GGGTG) which consists of alleles from -930G, 6396G, 7126G, 7632T and 8057C was 
also common in the five major linguistic groups with the frequency of 0.24 in Austro-
Asiatics. The frequency of this haplotype was found to be 0.15 in Dravidians, 0.11 in 
Indo Europeans, 0.13 in Tibeto-Burmans and 0.10 in Out-group. The frequency of 
haplotype 3 (GGATT) which consist of alleles from -930G, 6396G, 7126 A, 7632T & 
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Table 2.9.1: Genotype and MAF of SNP4 (rs6413432) of CYP2E1 in Indian sub-
populations of Validation Panel 
S.No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
Population code 
AA- C-IP5 
AA-E-IP3 
DR- C-IP2 
DR-S-IP4 
DR-S-LP2 
DR-S-LP3 
lE-E-IPl 
IE-E-LP2 
IE-E-LP4 
IE-N-IP2 
lE-N-LPl 
IE-N-LP5 
IE-N-LP9 
IE-N-SP4 
lE-NE-IPl 
lE-NE-LPl 
lE-W-LPl 
IE-W-LP2 
IE-W-LP3 
IE-W-LP4 
TB-N-IPl 
TB-N-SPl 
TB-NE-LPl 
OG-W-IP 
Genotype frequenc> 
TT 
0.89 
0.92 
0.89 
0.77 
0.94 
0.92 
0.88 
0.85 
1.00 
0.94 
0.95 
1.00 
1.00 
1.00 
0.94 
0.85 
0.78 
1.00 
0.92 
1.00 
0.96 
1.00 
0.94 
1.00 
TA 
0.11 
0 
0.11 
0.23 
0.06 
0 
0 
0.15 
0 
0 
0.05 
0 
0 
0 
0.06 
0.10 
0.17 
0 
0 
0 
0.04 
0 
0 
0 
r 
AA 
0 
0.08 
0 
0 
0 
0.08 
0.12 
0 
0 
0.06 
0 
0 
0 
0 
0 
0.05 
0.05 
0 
0.08 
0 
0 
0 
0.06 
0 
MAF 
0.06 
0.08 
0.06 
0.12 
0.03 
0.08 
0.12 
0.08 
0 
0.06 
0.02 
0 
0 
0 
0.03 
0.10 
0.14 
0 
0.08 
0 
0.02 
0 
0.06 
0 
Table 2.9.2: Average genotype and MAF of SNP4 (rs6413432) of CYP2E1 in 
different linguistic lineages of Indian population 
S.No. 
1. 
2. 
3. 
4. 
5. 
Linguistic families 
Austro-Asiatic 
Dravidian 
Indo-European 
Tibet-Burman 
Out-group 
TT 
0.90 
0.88 
0.94 
0.97 
1.00 
Genotype frequency 
TA 
0.06 
0.10 
0.04 
0.01 
0 
AA 
0.04 
0.02 
0.02 
0.02 
0 
MAF 
0.07 
0.07 
0.04 
0.03 
0 
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Table 2.10.1: Genotype and MAF of SNP5 (rs2864984) of CYP2E1 in 
S.No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
Population 
AA- C-IP5 
AA-E-IP3 
DR- C-IP2 
DR-S-IP4 
DR-S-LP2 
DR-S-LP3 
lE-E-IPl 
IE-E-LP2 
IE-E-LP4 
IE-N-IP2 
lE-N-LPl 
IE-N-LP5 
IE-N-LP9 
IE-N-SP4 
lE-NE-IPl 
lE-NE-LPl 
lE-W-LPl 
IE-W-LP2 
IE-W-LP3 
IE-W-LP4 
TB-N-IPl 
TB-N-SPl 
TB-NE-LPl 
OG-W-IP 
populations of Validation Panel 
code Genotype frequency 
CC 
0.72 
0.50 
0.50 
0.30 
0.61 
0.43 
0.55 
0.36 
0.83 
0.76 
0.87 
0.78 
0.83 
0.60 
0.65 
0.77 
0.41 
0.96 
0.57 
0.48 
0.91 
0.81 
0.78 
0.48 
CA 
0.28 
0.45 
0.41 
0.65 
0.39 
0.48 
0.36 
0.55 
0.17 
0.10 
0.13 
0.22 
0.17 
0.40 
0.35 
0.18 
0.54 
0.04 
0.38 
0.48 
0.09 
0.19 
0.17 
0.52 
AA 
0 
0.05 
0.09 
0.05 
0 
0.09 
0.09 
0.09 
0 
0.14 
0 
0 
0 
0 
0 
0.05 
0.05 
0 
0.05 
0.04 
0 
0 
0.05 
0 
Indian sub-
MAF 
0.14 
0.28 
0.30 
0.37 
0.20 
0.32 
0.28 
0.37 
0.09 
0.19 
0.07 
0.11 
0.09 
0.20 
0.18 
0.14 
0.32 
0.02 
0.24 
0.28 
0.04 
0.10 
0.13 
0.26 
Table 2.10.2: Average genotype and MAF of SNP5 (rs2864984) of CYP2E1 in 
different linguistic lineages of Indian population 
S. No. 
1. 
2. 
3. 
4. 
5. 
Linguistic families 
Austro-Asiatic 
Dravidian 
Indo-European 
Tibet-Burman 
Out-group 
CC 
0.61 
0.46 
0.67 
0.83 
0.48 
Genotype frequency 
CA 
0.36 
0.48 
0.29 
0.15 
0.52 
AA 
0.03 
0.06 
0.04 
0.02 
0 
MAF 
0.21 
0.30 
0.18 
0.09 
0.26 
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Table 2.11.1: CYP2E1 Haplotypes Frequencies in Different Indian sub-populations 
of Validation Panel 
S. Populations Haplotype Haplotype Haplot^pe Haplotype Uaplotype Haplotype Haplotype Haplotypc Haplotype 
No. 1 2 3 4 5 6 7 8 9 
(AGGTC) (GGGTC) (GGATA) (GGAAA) (AGAAA) (AGATA) (AAGTC) (GAGTC) (AAATA) 
1. AA-C-1P5 0.56 0.26 0.03 - 0.07 0.04 0.01 - 0.02 
2. AA-E-IP3 0.47 0.22 - 0.28 - - 0.02 
3. DR-C-IP2 0.52 0.20 0.21 - 0.06 . . . -
4. DR-S-1P4 0.44 0.17 0.02 0.24 0.03 0.08 - 0.02 
5. DR-S-LP2 0.67 0.12 0.08 0.08 - - 0.02 - 0.02 
6. DR-S-LP3 0.57 0.09 0.16 0.16 - - 0.02 
7. lE-E-lPl 0.46 0.25 0.16 0.11 - - - 0.02 
8. IE-E-LP2 0.58 0.05 0.24 0.10 - 0.03 
9. IE-E-LP4 0.70 0.20 0.04 0.04 - - 0.02 
10. IE-N-IP2 0.72 0.10 - 0.09 0.09 . . . . 
11. lE-N-LPl 0.80 0.13 - 0.07 . . . . . 
12. IE-N-LP5 0.80 0.05 0.06 0.05 - - 0.04 
13. IE-N-LP9 0.76 0.13 0.01 0.04 - 0.04 0.01 
14. 1E-N-SP4 0.64 0.13 - 0.04 - 0.08 - - 0.05 
15. lE-NE-lPl 0.72 0.10 0.13 - 0.05 . . . . 
16. lE-NE-LPl 0.70 0.08 - 0.08 0.07 - 0.05 0.02 
17. lE-W-LPl 0.53 0.10 0.13 0.13 0.03 - 0.07 
18. IE-W-LP2 0.86 0.10 0.02 - - 0.02 
19. IE-W-LP3 0.69 0.03 0.16 0.03 0.02 0.07 
20. 1E-W-LP4 0.65 0.05 0.28 . . . . 0.02 
21. TB-N-IPl 0.78 0.18 - - 0.02 0.02 
22. TB-N-SPl 0.80 0.11 0.09 . . . . . . 
23. TB-NE-LPl 0.75 0.09 - 0.07 0.06 0,02 
24. OG-W-IP 0.69 0.10 0.20 . - . . - -
Table 2.11.2: Average CYP2E1 haplotypes frequencies in Different Linguistic 
Lineages of Indian population 
S. Populations Haplotjpe Haplotj'pe Haplotjpe Haplotjpe Haplotjpe Haplotjpe Haplotjpe Haplotype Haplotype 
No. 1 2 3 4 5 6 7 8 9 
(AGGTC) (GGGTC) (GGATA) (GGAAA) (AGAAA) (AGATA) (AAGTC) (GAGTC) (AAATA) 
Austro-
1. Asiatic 0.52 0.24 0.01 0.14 0.03 0.02 0.02 - 0.01 
2. Dravidian 0.55 0.15 0.12 0.12 0.02 0.02 0.01 0.005 0.005 
Indo-
3. European 0.69 0.11 0.08 0.06 0.02 0.02 0.01 0.004 0.003 
Tibet-
4. Burman 0.78 0.13 0.03 0.02 0.03 0.01 
5. Out-group 0.69 0.10 0.20 - - . . . . . 
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8057A was observed to be 0.01 in Austro-Asiatics, 0.12 in Dravidians, 0.08 in Indo-
Europeans, 0.03 in Tibeto-Burmans, and 0.20 in Out-group. Likewise, the frequency of 
haplotype 4 (GGAAT) which corresponds to alleles from -930G, 6396G, 7126A, 7632A 
and 8057A was observed to be 0.14 in Austro-Asiatics, 0.12 in Dravidians, 0.06 in Indo-
Europeans, and less than 0.10 in Tibeto-Burman population. The frequency of haplotype 
5 (AGAAT) which correspond to alleles from -930A, 6396G, 7126A, 7632A and 8057A 
were present in frequency of less than 0.10 in one Austro-Asiatics, two Dravidians, five 
Indo-European and two Tibeto-Burmans sub-population. Similarly the haplotype 6 
(AGATT) which correspond to alleles from -930A, 6396G, 7126A, 7632T and 8057A 
was found to be present in frequency of less than 0.10 in one Austro-Asiatics, Dravidians, 
five Indo-Europeans and two Tibeto-Burmans sub-population. Haplotype 7 (AAGTG) 
was observed in frequency of less than 0.10 only in Austro-Asiatics, Dravidians, and few 
sub-population of Indo-European. Haplotype 8 (GAGTG) which constitutes variant 
alleles from -930G, 6396A, 7126G, 7632T and 8057C was found to be present only in 
Dravidians and few populations of Indo-European group with the frequency less than 
0.05. Similarly the Haplotype 9 (AAATT) was found to be present one sub-population of 
Austro-Asiatic, Dravidians and Indo-European group with the frequency less than 0.05 
(Table 2.11.1 & 2.11.2). 
2.4 DISCUSSION 
The development of molecular genetic technology has led to the discovery of 
large number of polymorphic loci in the human genome and provided the necessary tools 
to understand the genetic basis of diversity among individuals, the most common familial 
traits, evolutionary processes, complex and common diseases such as diabetes, obesity, 
hypertension and psychiatric disorders, and to develop genome-based medicinal drugs 
(Emilien et al., 2000). Recent studies have emphasized the need for identifying SNPs in 
disparate global populations in an attempt to investigate their association with complex 
diseases (Carlson et al., 2003; Reich et al., 2003). Various SNP databases exist containing 
polymorphism information on worldwide populations, e.g., dbSNP (Sherry et al., 2001), 
HGVBase (Fredman et al., 2004), HapMap (The International HapMap Consortium 
2003), Celera (Kerlavage et al., 2002) etc. and specific populations, e.g., JSNP (Hirakawa 
et al., 2002). 
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India, due to its unique population structure has a leading edge on the global scene in 
studies related to population genetic, particularly in disease association studies, 
pharmacogenetic studies. The Indian population is subdivided into large number of 
endogamous ethnic groups and is genetically less heterogeneous than worldwide 
populations. The ethnic groups in general, follow similar life-styles including dietary 
habits which might lead to greater success in genomic and epidemiological studies. 
Indian ethnic groups harbor SNPs that remain unreported in the major SNP databases. On 
the contrary, some reported SNPs are monomorphic in the Indian population. The wide 
diversity of Indian sub-populations have revealed extensive variations in frequencies of 
alleles and haplotypes of common polymorphisms (Bhattacharyya et al., 1999; Roy et al., 
2001, Chandak et al., 2002; Nagarkatti and Ghosh, 2002; Pasha et al., 2002; Roy et al., 
2003; Nagarkatti et al., 2004a, 2004b; Batra et al., 2005) as well as occurrence of some 
specific and unique polymorphisms and mutations (Pramanik et al., 2000; Mukherjee et 
al., 2004; Sengupta et al., 2004). Several studies on Indian sub-populations have helped 
in understanding the origins of monogenic diseases in India (Saleem et al., 2000, 2002, 
2003; Bahl et al., 2005; Mittal et al, 2005). These findings have indicated the 
significance of population stratification in designing case-control association studies. 
Case-control studies carried out in the Indian population sometimes reveal observations 
distinct from other world populations (Ramana et al., 2000; Nagarkatti et al., 2002; 
Thangaraj et al., 2002; Sengupta et al., 2004; Batra et al., 2005b; Rajput et al., 2005, 
Sharma et al., 2005). SNPs studies have been successful in identifying at-risk markers or 
haplotypes for particular diseases (Choudhry et al., 2001; Ahsan et al., 2004; Nagarkatti 
et al., 2004a, 2004b; Sharma and Ghosh, 2004; Sharma et al., 2004; Verma et al., 2004; 
Verma et al., 2005a; Verma et al., 2005b). Thus the analysis of sequence in the context of 
genomic diversity would help in identifying genetic substructures, which in turn would 
be invaluable for identification of markers for linkage or association studies, detecting 
candidate susceptibility regions for many common and complex diseases as well as drug 
response studies. It is likely that the SNPs found in the genes involved in the toxication-
detoxication pathways may be conserved and these could be exploited to identify the risk 
factors for the environment induced diseases. 
The present study was initiated to identify as well as discover novel SNPs in the 
CyF2£7gene in different Indian sub-population, which represent the four major linguistic 
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families-Austro-Asiatic (AA), Dravidians(DR), Indo-European (IE), Tibeto-Burman (TB) 
and an Out-group (OG) and six geographical zones i.e. North-N, North-East- NE, East-
E, South-S, West-W, Central-C and different socio-cultural strata (caste which include 
large population- LP, tribe i.e. isolated population- IP and religious group i.e. special 
population-SP exhibiting diverse populations of India. The study initially involved the 
identification of the SNPs in CYP2E1 gene in SNP Discovery Panel of representative 43 
samples, representing the major linguistic families, geographical zones and different 
socio-cultural strata, by DNA sequencing to maximize the scopes of discovery of novel 
and reported SNPs in diverse populations of India. Our data using sequencing analysis 
revealed that CYP2E1 gene is highly polymorphic in Indian population. Five 
polymorphic sites (-930A/G, 6396G/A, 7126G/A, 7632T/A and 8057C/A) including 
novel one (6396G/A) were found in CYP2E1 gene in the samples of Discovery Panel. 
SNPs identified in Discovery Panel were found to be distributed differentially in the 
Indian population which is consistent with the literature indicating the diversity of the 
Indian population (Majumder, 1998, 2001; Raj et al., 2007). Since majority of Indian 
population belongs to Indo-European and Dravidian language group, most of the SNPs 
identified in CYP2E1 gene were found in the Indo-European and Dravidian population. 
Using primer pair one, which covers the 5'UTR, where one of the functionally 
important SNP, designated as Rsal or CYP2E1 *5B is known to exist and its variant form 
to be associated with various diseases such as alcoholic liver disease and cancer 
(Tsutsumi et al., 1994; Tanaka et al., 1997; Danko and Chaschin, 2005). The frequency of 
this SNP in the Indian population was found to be less than 1% (Mittal et al., 2005; Soya 
et al., 2005) as a result this SNP was not detected in the 43 samples of SNP discovery 
panel therefore it was not considered for further validation. Primer pair one revealed the 
presence of SNPl at 5'UTR (-930A/G; rs3813870) which was found to be polymorphic 
in all the four major sub-populations (AA DR, IE, TB) with minor allele frequency 
(MAP) of 0.26. This SNP was also found to be present in the Austro-Asiatic language 
group in the Discovery Panel. The Austro-Asiatic speakers are exclusively tribals and 
molecular diversity studies have revealed that the Austro-Asiatic speakers are likely to 
have been the most ancient inhabitants of India (Majumder, 2001; Roychoudhury et al., 
2001). As the -930A/G was present in most of the population of India, it can be 
concluded that this SNP was conserved in almost all the population of India. Perhaps, it 
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must be the oldest SNP present in CYP2E1 gene in Indian population. This SNP has not 
been reported to be of any functional consequence in any population worldwide. 
Interestingly, Rsal polymorphism was not present in any of the representative 43 DNA 
sample. Since the frequency of this polymorphism is very rare in Indian population (1%) 
as reported earlier (Mittal et al., 2005; Soya et al., 2005), it may be possible that this 
polymorphism may not be present in the representative 43 DNA sample sequenced in the 
present study. 
SNP2 (6396G/A; Novel) sequenced in exon 6 was found to be polymorphic in only 
one sub-populations of DR family with very low minor allele frequency (0.01) and found 
to be novel SNP. As this SNP is novel and is present in the exon and leads to amino acid 
substitution of Glycine to Serine at codon 288 it might have some functional significance 
and was therefore considered for validation in the different sub-populations using larger 
sample size. 
SNP3 (rs8192775) which is present in intron-6 (7126G/A) was found to be 
polymorphic in the three sub-population AA, DR and IE with the minor allele frequency 
of 0.05. Even though this SNP is intronic, due to its high frequency in the different Indian 
population it was considered for validation in the larger sample size. Likewise the SNP4 
(rs64I3432), also found at intron-6 (7632T/A) and known as Dral polymorphism or 
CYP2E1*6, was found to be polymorphic only in IE population with minor allele 
frequency of 0.01. As this SNP is reported in Caucasian population and is functionally 
important in various case control studies (Danko and Chaschin, 2005; Stickel and 
Osterreicher, 2006), it was considered for validation in the different sub-populations. 
Similarly the SNP5 (rs2864984) is also located at intron-6 (8057C/A) was found to be 
polymorphic in three sub population AA, DR and IE with minor allele frequency of 0.05. 
Even though this SNP was also intronic, but because of its relatively higher frequency 
and its presence in different population globally, it was considered for validation using 
larger sample size. 
Our validation data in 24 different sub-populations, which represented the population 
diversity of India, revealed that these five SNPs in CYP2E1 gene were polymorphic in 
the Indian population and not the artifact. SNPl (-930A/G; rs3813870) is present in all 
the linguistically and geographically diverse population of India. Minor allele frequency 
of this SNP was found to be 0.40 in Austro-Asiatic and Dravidian population which is 
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slightly higher than Out-group (0.34). In Indo-European the minor allele frequency was 
found to be 0.25 which is lower than that observed in Austro-Asiatic, Dravidian and Out-
group but slightly higher that Tibet-Burman (0.16). As this SNP was present in almost all 
the Indian sub-populations it can be concluded that this SNP was conserved in almost all 
the Indian population and might be the oldest SNP present in CYP2E1 gene in Indian 
population. This SNP has also been shown to be present in other populations of world 
though there is no frequency data available in NCBI or HapMap databases nor there is 
any information available on its functional significance. 
SNP2 (6396G/A; Novel) located at exon 6 that resulted in amino acid substitution 
from Glycine to Serine was also found to be polymorphic in Austro-Asiatic, Dravidian 
and Indo-European lineages. Heterozygous genotype was observed in all the sub-
populations of India except in one Dravidian and few sub-population of Indo-European 
language group. Homozygous mutant genotype was not observed in any of the sub 
populations. Minor allele frequency of this SNP was found to be 0.02 in Austro-Asiatic, 
Dravidian and Indo-European population. As this SNP is novel therefore no allele or 
genotype frequency data is available in the HapMap or NCBI database. However, this 
SNP is located at coding region and resulted in amino acid substitution from Glycine to 
Serine and might be responsible for alteration in protein activity. Even though the allele 
frequency of this polymorphism is very low, studies are needed to investigate the 
functional consequence in other world population. 
Our validation results also provided evidence that SNP3 (7126G/A; rs8192775) is 
present in all linguistically and geographically diverse populations of India. Heterozygous 
genotype was observed in all the sub-populations of India where as homozygous mutant 
genotype was also observed in majority of sub populations. Minor allele frequency observed 
in Indo-European (0.20) was quite similar to observed in Austro-Asiatic (0.21) and Out-
group (0.18) but lower than Dravidian (0.28). Minor allele frequency in Tibet-Burman 
(0.10) was found to be lower than that observed in all the lineages of Indian population. 
This polymorphism has been reported in Caucasians with MAP (0.14) which is 
comparable with population of Indo-European lineages (www.ncbi.nlm.nih.gov) 
interestingly, the MAP observed in Oriental population (Chinese and Japanese) was 
reported to be 0.31 which is almost similar to Dravidian but higher than other sub 
population of India (www.ncbi.nlm.nih.gov). However, the minor allele frequency of this 
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polymorphism was found to be 0.08 in Sub-Saharan African which is lower than MAF 
observed in all the sub population of India (www.ncbi.nlm.nih.gov). 
Likewise, our data have shown that Dral polymorphism of CYP2E1 (SNP4 or 
rs6413432) was found to be polymorphic in most of the sub-populations of India except 
for few Indo-European and one Tibet-Burman lineages. Similar MAF of this 
polymorphism was observed in Austro-Asiatic and Dravidian population (0.07) which is 
slightly higher than that observed in Indo-European (0.04) and Tibet-Burman (0.03) 
population. When compared with NCBl data, the frequency of Dral minor allele observed in 
various sub population of India was comparable to Caucasian (0.065) population 
(www.ncbi.nlm.nih.gov). MAF of Dral polymorphism was also reported in African with 
frequency of 0.167 which is quite higher than found in different lineages of India. MAF 
of Hispanic and Pacific Rim was found to be 0.174 and 0.152 respectively which is also 
higher than found in different sub population of India (www.ncbi.nlm.nih.gov). 
Functional consequence of this polymorphism is not yet well understood, disease 
association studies have reported an association of variant allele of CYP2E1*6 with 
nasopharyngeal carcinoma (Hildesheim et al., 1997). 
SNP5 (8057C/A; rs2864984) was also found to be polymorphic in all the sub 
population of India. Heterozygous genotype was observed in all the sub-populations of India 
where as homozygous mutant genotype was also observed in majority of sub populations 
except for few sub population of Indo-European and Tibet-Burman. MAF observed in 
Indo-European was found to be 0.18 which is similar to the Austro-Asiatic (0.21) but 
lower than Dravidian (0.30) and Out-group (0.26). MAF found in Tibet-Burman (0.09) 
was found to be lower than other lineages of Indian population. This polymorphism has 
also been reported in Caucasian, African American and Chinese population 
(www.ncbi.nlm.nih.gov). MAF observed in Caucasian and African American was found 
to be 0.06 which is quite lower than found in different sub population of India whereas 
MAF found in Chinese population (0.23) is similar to the frequency found in Austro-
Asiatic (0.21) and Out-group (0.26) population but higher than Indo-European (0.18) and 
Tibet-Burman (0.09) population (www.ncbi.nlm.nih.gov). However, MAF of Dravidian 
(0.30) is higher than reported Chinese population (0.23). As this polymorphism is found 
on intron therefore no functional consequence of this polymorphism has been i)enot^d. 
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Haplotype analysis of the CYP2E1 gene showed almost similar common haplotypes 
with differences in haplotype frequencies between different Indian sub-populations. 
Haplotype analysis in all the 24 sub-populations revealed that haplotype 1 (AGGTG), 2 
(GGGTG), 3 (GGATT), 4 (GGAAT), 5 (AGAAT) and 6 (AGATT) are common in all the 
four major linguistic groups of India (AA, DR, IE, and TB) with differences in their 
frequencies. Haplotype 7 (AAGTG) was found to be absent in the TB and OG whereas 
haplotype 8 (GAGTG) was present only in one DR and few populations of Indo-Europeans 
and haplotype 9 (AAATT) was found to be present only in one sub population of Austro-
Asiatic, Dravidians and Indo-Europeans. Haplotype analysis of SNPs of CYP2E1 revealed 
that SNP3 (7126G/A; rs8192775) and SNP5 (8057C/A; rs2864984) exhibit Linkage 
Disequilibrium (LD) in all the Indian sub populations. However, few sub population of 
Indo-Europeans and Tibet-Burman exhibit LD between SNPI (-930A/G; rs3813870) and 
SNP3. LD is also found between SNP3 and SNP4 in few sub population of Indo-
Europeans and Dravidians. Studies in European, Taiwanese (Persson et al., 1993; Hildesheim 
et al., 1995; Yu et al., 1995), and Mexican American populations (Wu et al., 1998) have 
shown LD between the Rsal and Dral polymorphism. However as Rsal polymorphism is not 
detected in 43 sample of SNP discovery panel due to its smaller frequency LD association 
studies between Rsal {CYP2E1*5B) and Dral (CYP2EI*6) polymorphism in different sub 
population of India could not be carried out in the present studies. These findings support 
earlier studies that LD is population specific (Stephens et al., 2001a; Gabriel et al., 2002). 
Haplotype structure may provide valuable information to identify genetic variants that 
increase susceptibility to human diseases through linkage disequilibrium (LD) (Zhao et al., 
2003). Identifying LD is one major aspect of haplotype analysis. The extent of LD between 
functional alleles and surrounding markers plays a critical role in detecting associations 
between marker alleles and disease (Long et al., 2004). Other studies have also suggested 
that haplotype data is more helpful in predicting the risk to disease when compared to 
single SNPs (Chang et al., 2003). 
In conclusion, our data after stratification of Indian population according to linguistic and 
geographical regions show that CYP2E1 is highly polymorphic among the diverse sub-
populations of India. Differences exist in the distiibution of allelic frequency of SNPs in 
CYP2E1 gene in all tiie four major linguistic groups and geographical zones of India. SNPI, 
SNP3, SNP4 and SNPS were found to be present in all the Indian sub-populations 
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irrespective of the stratification based on linguistic and geographic considerations. SNP2 
which is novel was found to be present in AA, DR and IE population three major sub-
populations of India. Identification of SNPs in CYP2E1 gene is of importance as it is 
involved in alcoholic liver diseases and certain forms of cancers. Knowledge of these allelic 
variants in different linguistic groups and geographical regions could be of significance in 
designing case-control or any association studies in specific sub-populations and in 
identifying susceptibility of these specific populations to environment induced diseases. 
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3.1 INTRODUCTION 
0vi 'tudies in the preceding ciiapter have shown that cytochrome P4502E1 
(CYP2E1), a major component of the microsomal ethanol oxidizing system in the liver 
(Takahashi et al., 1993), is highly polymorphic in Indian populations. Using the primer 
pairs, which are known to cover the functionally important polymorphism, several SNPs 
were identified in Indian population. CYP2E1*6 (Dral) was found to be present in 
different Indian population. Likewise SNPs at position -930A/G, 6396G/A, 7126G/A, 
and 8057C/A were also observed in different Indian population. Interestingly Rsal one of 
the major functionally important SNPs was not identified in the SNP Discovery panel 
consisting of 43 samples collected from individual belongs to different linguistic groups 
and geographical zones of India. The inability to detect Rsal (CYP2EI *5B) polymorphism 
could be due to rare occurrence of this SNP in Indian population (Mittal et al, 2005; Soya et 
al., 2005). Previous studies have shown that Rsal polymorphism is rare in the Indian 
population (Mittal et al., 2005; Soya et al., 2005), though this SNP is widely distributed in 
Oriental population (20% - 30%) (Chao et al, 1997; Hildesheim et al., 1997). Because of 
this rare occurrence in Indians, it may be possible that the 43 representative DNA sample 
from different sub-population (one sample from each sub-population) of India may not be 
carrying this SNP and it may be possible that if larger samples are screened this SNP could 
be identified. 
Disease association studies have suggested that polymorphism in the genes coding 
for enzymes that catalyze the oxidative metabolism and detoxification of ethanol such as 
CYP2E1 and glutathione S-transferases (GSTs) could be involved in determining the 
susceptibility to alcoholic liver disease (ALD) including liver cirrhosis (Tsutsumi et al., 
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1994; Savolainen et al., 1996; Tanaka et a!., 1997; Degoul et al., 2001; Ladero et al., 
2005). Though the exact pathogenesis of alcoholic liver injury is still not well 
understood, both immune and free radical mediated liver injury have been suggested to 
be important in alcoholic liver cirrhosis (Walsh and Alexander, 2000). The association 
between polymorphisms in CYP2E1, GSTs and alcoholic liver diseases has shown 
though, it has been found to be inconsistent particularly in the Caucasian population 
(Pirmohamed et al., 1995; Vidal et al, 2004; Cichoz-Lach et al., 2006). Studies in 
Oriental populations have shown that polymorphism in CYP2E1 leads to increased 
formation of reactive oxygen species (ROS) and is associated with increased 
susceptibility to alcoholic cirrhosis (Tsutsunii et al., 1994; Tanaka et al., 1997). Likewise, 
polymorphism in genes coding for enzymes such as GSTs and manganese superoxide 
dismutase (MnSOD), responsible for detoxifying electrophilic intermediates including 
free radicals generated as by the products of ethanol metabolism and lipid peroxidation, 
could also be potential risk factors involved in alcoholic liver diseases including cirrhosis 
(Savolainen et al., 1996; Degoul et al, 2001; Burim et al., 2004; Ladero et al., 2005). 
As mentioned in the preceding chapter, Indian population exhibits a great genetic 
diversity than any other comparable global region. However, not much information is 
available on association of polymorphic variant of CYP2E1 and other anti-oxidant 
enzymes with susceptibility to alcoholic cirrhosis in Indian population. The candidate 
therefore in present case control study attempted to investigate the association of 
polymorphism in CYP2E1, GSTs and MnSOD genes with alcoholic liver cirrhosis in 
North Indian population. As liver cirrhosis has been shown to be of multifactorial origin, 
attempts were also made by the candidate to investigate the interaction of CYP2E1 with 
other genetic risk factors such as GSTs and MnSOD in determining the susceptibility to 
alcoholic liver cirrhosis. 
3.2 MATERIALS AND METHODS 
3.2.1 Study group: 
The study group consisted of 175 patients suffering from alcoholic liver cirrhosis 
and 140 number of patients suffering from non-alcoholic liver cirrhosis visiting the OPD 
facility of Gastroenterology Department of Sanjay Gandhi Post Graduate Institute of 
Medical Sciences (SGPGIMS), Lucknow, India was included in the study. Patients with 
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alcoholic liver cirrhosis were diagnosed on the basis of their liver biopsy. All the 
alcoholic cirrhosis patients were negative for serum antinuclear and anti-mitochondrial 
antibodies and negative for antibodies to the hepatitis C virus. The hepatitis B surface 
antigen was also negative in all the alcoholic cirrhotic patients. Patients with non-
alcoholic liver cirrhosis were also diagnosed on the basis of their liver biopsy and 
hepatitis B surface antigen and antibodies against hepatitis C virus. AH the non-alcoholic 
liver cirrhotic patients were positive for either hepatitis B surface antigen or antibodies 
against hepatitis C virus. Control group consisted of non-alcoholic (n=255) and alcoholic 
(n=140) healthy men having no evidence of liver disease as judged by physical 
examination and normal liver function test. All the patients and controls included in the 
study belonged to same geographical location (Northern India) and same ethnicity. 
The protocol for research work was approved by the human ethics committee of 
Indian Institute of Toxicology Research (IITR), Lucknow and it conforms to the 
provisions of the declaration of Helsinki in 1995. Informed consent was obtained from 
the study subjects for inclusion in the study and before the collection of blood samples it 
was ensured that the subject anonymity was preserved. All study subjects completed a 
questionnaire covering medical, residential and occupational history. The questionnaire 
also included details such as frequency of alcohol intake. Subjects who consumed less 
than 10 g/day of alcohol were classified as non-alcoholics. Subjects who consumed more 
than 80 g/day of alcohol for more than 10 years were considered as alcoholics 
(Savolainen et al., 1997; Tanaka et al., 1997; Grove et al., 1998). 
3.2.2 Genomic DNA isolation 
About 500^1 of blood was drawn into citrate containing tubes from all patients as 
well as controls. DNA was isolated from whole blood with the QIAamp DNA mini kit 
(Qiagen, CA) following the manufacturer's protocol. In brief 20|il QUIAGEN protease or 
proteinase K was taken into the bottom of a 1.5ml microcentrifuge tube. 200^1 blood 
sample was added to the microcentrifuge tube and mixed properly. 200|a.l buffer AL was 
added to the sample followed by pulse-vortexing for 15 seconds and Incubated at 56°C 
for 10 min. 200|il ethanol was added to the sample and mixed again by pulse vortexing 
for 15 seconds. The resulting mix from previous step was added to the QIAamp spin 
column and then centrifuged for 8000 rpm for 1 minute at room temperature. 500^1 buffer 
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AWl was added in the QIAamp spin column and centrifuged at 8000 rpm for 1 minute at 
room temperature. Then 500|il buffer AW2 was added in the QIAamp spin column and 
centrifuged at 14,000 rpm for 3 minutes at room temperature. The QIAamp spin column 
was placed in a clean 1.5 ml microcentriilige tube then 200^1 buffer AE or distilled water 
was added and incubated at room temperature (15-25°C) for 1 to 5 minutes. 
Centrifugation at 8000 rpm for 1 minute at RT was carried out. Finally the filtrate (DNA) 
was collected the in a fresh 1.5ml eppendorf tube. The extracted DNA was quantified and 
checked for purity spectrophotomitrically (CARY 300 Bio-UVA^isible 
Spectrophotometer). Integrity of these DNA was analyzed by 0.8% agarose gel 
electrophoresis. 
3.2.3 Detection of CYP2E1*5B (Rsal) Polymorphism 
Rsal polymorphic site present in 5'UTR (C-1053T) of CYP2E1 gene was identified 
by the methods of Liu et al. (2001). The primer sequences used for identifying 
polymorphic sites in CYP2E1 are shown in Table 3.1. The reaction mixture in 50 [i\ 
contained IX buffer (10 mM Tris-HCl, pH 8.3, 1.5 mM MgCb, 25 mM KCl), 200 nM of 
each dNTPs, 200nM of each primers, 1.5 unit of Taq polymerase (MBI Fermentas, 
Germany), 100 ng of genomic DNA and sterile milliQ water. Amplification was 
performed on Gene Amp PCR system 9700 of Applied Biosystem using the following 
protocol: 94°C for 5 minutes for initial denaturation followed by 35 cycles of 94''C for 30 
sec, 64°C for 30 sec. and 72°C for 1 min and a final elongation step of 72''C for 10 min. 
PCR reaction resulted in a 410 bp product, which was further digested with lOU of Rsal 
restriction enzyme (MBI Fermentas, Germany), for the identification of genotypes. The 
digested PCR product were separated by electrophoresis using 2% agarose gel containing 
ethidium bromide and DNA bands were visualized on VERSA DOC Imaging System 
(Model 1000, Bio-Rad). Genotypes were determined based on the size of the respective 
DNA fragments. RFLP resulted in two fragments of 290 and 120 bp which were 
indicative of wild type genotype. The digestion of PCR product into three fragments of 
410, 290 and 120 bp, showed the presence of heterozygous genotype. In case of 
homozygous mutant single band of 410bp would be formed with the Rsal restriction 
enzyme digestion (Figure 3.1). 
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Table 3.1: Sequence of the primers used for amplification of polymorphic sites 
Gene Locus Sequences References 
CyP2El*5B FP: 5'-CCA GTC GAG TCT ACA TTG TCA- 3' 
RP: 5'-TTC ATT CTG TCT TCT A AC TGG-3' 
CYP2E1 *6 FP: 5'-AGT CGA CAT GTG ATG GAT CCA-3' 
RP: 5'-GAC AGG GTT TCA TCA TGT TGG-3' 
Mspl 
GSTMl & 
GSTTl 
FP: 5'-GTG CTG AAC ACC TGG TAC TCT-3' 
RP: 5'-CTG ACT GGC CTG TTT GCA TG-3' 
GSTMl FP: 5'-GAA CTC CCT GAA AAG CTA AAG C-3 
GSTMl RP: 5'-GTT GGG CTC AAA TAT AGG GTG G-3' 
GSTTl FP: 5'-TTC CTT ACT GGT CCT CAC ATC TC -3' 
GSTTl RP: 5'-TCA CCG GAT CAT GGC CAG CA-3' 
Albumin FP: 5'-GCC CTC TGC TAA CAA GTC CTA C-3' 
Albumin RP: 5'-GCC CTA AAA AGA AAA TCG CCA ATC-3' 
GSTPl *B FP 5'-ACC CCA GGG CTC TAT GGG AAA-3 
RP 5'-TGA GGG CAC AAG AAA GCC CCT-3' 
MnSOD FP: 5' - ACC AAC CAG CAG GCA GCT GGC GCC GG -3' 
RP: 5'- GCG TTG ATG TGA GGT TCC AG -3' 
Liu etal., 2001 
Vidal et al., 2004. 
Savolainen et al., 1997 
Arandetal., 1996 
Harries etal., 1997 
Akyol et al., 2004. 
84 
410bp 
290bp 
120bp 
SOObp 
Figure 3.1: Genotyping of CYP2EliRsal) polymorphism by PCR-RFLP. 
Lane 1: PCR product; Lane 2: Homozygous wild type genotype;, Lane 3: 
Heterozygous genotype; Lane 4: Homozygous mutant; Lane 5: lOObp 
ladder 
SOObp 
- 375bp 
-210bp 
-165bp 
Figure 3.2: Genotyping of CYP2El{Dral) polymorphism by PCR-RFLP. 
Lanel: 100 bp ladder; Lane 2: PCR product; Lane 3: Homozygous wild 
type genotype; Lane 4: Heterozygous genotype; Lane 5: Homozygous 
mutant 
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3.2.4 Detection oiCYP2El*6 (Dral) Polymorphism 
Dral polymorphic site present in intron 6 (T7632A) of CYP2E1 gene was identified 
by the method of Vidal et al. (2004). The primer sequences used for identifying Dral 
polymorphism is shown in Table 3.1. The reaction mixture in 50 [x\ contained IX buffer 
(10 mM Tris-HcCl pH 8.3, 1.5 mM MgCh, 25 mM KCl), 200 ^M of each nucleotides, 
200nM of each primers, 1.5 unit of Taq polymerase (MBI Fermentas, Germany), 100 ng 
of genomic DNA and sterile milHQ water. Amplification was performed on a thermal 
cycler using the following protocol: 94°C for 5 minutes for initial denaturation followed 
by 35 cycles of 94^0 for 30 seconds, 63°C for 30 seconds and 72°C for 1 minutes and a 
final elongation step of 72°C for 10 minutes. PCR reaction resulted in a 375 bp product. 
20|J1 of the PCR product was digested with 10 U of Dral (MBI Fermentas, Germany), in 
a final volume of 30 f^ l. This reaction mixture was incubated overnight at 37°C. 
Electrophoresis was carried out in a 3% agarose gel containing ethidium bromide and 
analyzed on VERSA DOC Imaging System (Model 1000, Bio-Rad). Digestion of 375 bp 
PCR product into two fragments of 210bp & 165bp indicated the presence of wild type 
genotype. In case of homozygous mutant single band of 375bp would be formed with the 
Dral restriction enzyme digestion. A mixture of all three sizes of fragments (375bp, 
210bp & 165bp) was indicative of the heterozygous genotype (Figure 3.2). 
3.2.5 Detection of Mspl Polymorphism 
Mspl polymorphic site located at intron 6 (A6827G) of CYP2E1 gene was 
identified by the method of Savolainen et al. (1997). The primer sequences used are 
shown in Table 3.1. The reaction mixture in 50 \i\ contained IX buffer (10 mM Tris-HCl, 
pH 8.3, 1.5 mM MgCb, 25 mM KCl), 200 \iU of each nucleotides, 200nM of each 
primers, 1.5 unit of Taq polymerase (MBI Fermentas, Germany), 100 ng of genomic 
DNA and sterile MilliQ water. Amplification was performed on a thermal cycler using 
the following protocol: 94°C for 3-5 minutes for initial denaturation followed by 35 
cycles of 94''C for 1 minute, 60''C for 1 minute and 72°C for 1.5 minutes and a final 
elongation step of 72°C for 10 minutes. PCR reaction resulted in a 480 bp product. 20 |il 
of the PCR product was further digested with 10 units of Mspl (MBI Fermentas, 
Germany), in a final volume of 30 ^1. This reaction mixture was incubated overnight at 
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37°C. Electrophoresis was carried out in a 2% agarose gel containing ethidium bromide 
and analyzed on VERSA DOC Imaging System (Model 1000, Bio-Rad). An undigested 
480 bp PCR fragment was indicative of wild type genotype. The digestion of 480 bp PCR 
fragment into two fragments of 301bp and 179 bp, was indicative of homozygous mutant 
genotype. A mixture of all three sizes of fragments was indicative of the heterozygous 
genotype (Figure 3.3). 
3.2.6 Detection of GSTMl and GSTTl polymorphism by multiplex PCR method 
Genotypes of GSTMl and GSTTl were identified by the multiplex PCR method 
(Arand et al., 1996). In brief, the PCR reaction was carried out with IX buffer (10 mM 
Tris-HCl pH 8.3, 2.5mM MgCl2, 25mM KCl), 200^M of each nucleotides, 200nM of 
each of the primers of GSTMl, GSTTl and albumin taken as internal control described in 
table 3.1, 1.5 units of Taq polymerase (MBI Fermantas, Germany), lOOng of genomic 
DNA and sterile MilliQ water in a final volume of 25|il. Amplification was performed on 
Gene Amp PCR system 9700 of Applied Biosystem using the following protocol: 94°C 
for 5 minutes for initial denaturation followed by 35 cycles of 94°C for 1.0 minutes, 64°C 
for 1.0 minutes, 72°C for 1.0 minutes and a final elongation step of 72°C for 10 minutes. 
5 |j,l of PCR product was analyzed on 2.5% agarose gel containing ethidium bromide on 
VERSA DOC Imaging System (Model 1000, Bio-Rad) for the presence of positive or 
null genotype of GSTMl or GSTTl. A PCR product of 215 bp indicates the positive 
genotype of GSTMl and absence of band indicates the null genotype of GSTMl. 
Similarly the band of GSTTl formed at 480bp indicated the positive genotype of GSTTl 
and absence of band indicates the null genotype of GSTTl. In this muhiplex PCR band at 
350bp is of albumin, an internal control (Figure 3.4). 
3.2.7 Detection oiGSTPl*B (Ile/Val) Polymorphism 
A 176 bp region of the GSTPl gene containing Ilel04Val mutation in exon-5 was 
amplified using the method of Harries et al. (1997). In brief, the reaction mixture in 25|j,l 
contained 0.5^M of each primers described in table 3.1, 0.2mM dNTPs, l.SmM MgCl2, 
0.75 units Taq DNA polymerase (MBI Fermantas, Germany) and 100 ng DNA. PCR 
condition used was as follows: initial denaturation at 94°C for 5 minutes followed by 35 
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Figure 3.3: Genotyping of CYP2EliMspl) polymorphism by PCR-RFLR 
Lane 1: PCR product; Lane 2: Homozygous wild type genotype;, Lane 3: 
Heterozygous genotype; Lane 4: Homozygous mutant; Lane 5: lOObp 
ladder 
GSTTl (480bp) -
Albumin (350bp)-
GSTMl (215bp)-
SOObp 
Figure 3.4: Genotyping of GSTs (GSTMl & GSTTl) by Multiplex-PCR. 
Lane 1: GSTMl(+)/GSTTl(+); Lane 2: GSTMl(+)/GSTTl(-); Lane 3: 
GSTMl(-)/GSTTl(-); Lane 4: GSTMl(-)/GSTTl(+); Lane 5: lOObp 
ladder 
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cycles of 94°C for 30 seconds, 60 °C for 1 minute, 72°C for 1.5 minutes and final 
extension at 72°C for 10 minutes. Amplified PCR products were digested with 8 units of 
restriction enzyme, Alw261 (New England Biolabs, UK) for 16 hourst at 37°C. The 
fragments of digested PCR products (wild type: 176bp; polymorphic heterozygous: 
176bp, 91bp and 85 bp; and homozygous variant: 91bp and 85bp) were analyzed either 
by 8% PAGE or 4% agarose stained with ethidium bromide on VERSA DOC Imaging 
System (Model 1000, Bio-Rad) (Figure 3.5). 
3.2.8 Detection of MnSOD (AIa-9Val) Polymorphism 
Polymorphism in the MnSOD or SOD2 gene was evaluated by the method of Akyol 
et al. (2004), to amplify a 107bp fragment followed by digestion with NgoMIV. PCR 
reaction was performed in a total volume of 50 \i\, containing 50 ng of genomic DNA, 20 
pmol/^ il of each primer (Table 3.1), 1.25 units Taq polymerase (in 50 mM Tris-HCl [pH 
8.0], 100 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 50% glycerol and 1% Triton X-100), 2 
mM dNTP, 25 mM MgCb, IX PCR buffer containing 50 mM KCl, 10 mM Tris-HCl 
(pH 8.3 at 25°C). The PCR reaction conditions involved an initial denaturation of DNA at 
95°C for 5 minutes, followed by 35 cycles of amplification at 95°C for 1 minutes 
(melting), 61°C for 1 minutes (annealing) and 72° C for 2 minutes, and final extension at 
72° C for 10 minutes. The resulting 107 bp PCR product was digested with the restriction 
endonuclease NgoMlV at 37°C for 16 hours according to the manufacturer's 
recommendations and digestion products were analyzed following electrophoresis in 3% 
agarose gel stained with ethidium bromide (0.5 Ag/ml). Restriction enzyme digestion 
results in a 107 bp product (allele 1 Val-9) or 89 and 18 bp products (allele 2 Ala-9) 
(Figure 3.6). 
3.2.9 Statistical Analysis 
All statistical analysis was performed using the software Statistical Package for the 
Social Sciences (SPSS Version 13.0, Chicago, IL) for windows. The Chi-square-
goodness-of-fit test was used to test the distribution of genotypes and allele frequencies 
for deviations from Hardy-Weinberg equilibrium between the patients group and 
controls. Odds ratios (ORs) and 95%confidence intervals (CI) were calculated to measure 
the risk associated with variant genotypes by unconditional logistic regression method. 
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Figure 3.5: Genotyping of GSTPlille-\al) polymorphism by PCR-RFLR 
Lanel: Heterozygous genotype; Lane 2: Homozygous wild type, Lane 3: 
Homozygous mutant genotype, Lane 4: PCR product, lane 5: lOObp ladder 
SOObp 
107bp 
89bp 
Figure 3.6: Genotyping of MnSOD{Ala-9yal) polymorphism by PCR-RFLP. 
Lane 1: Homozygous wild type genotype (Ala-9); Lane 2: Heterozygous 
genotype. Lane 3: Homozygous mutant genotype (Val-9) ; Lane 4: PCR product, 
LaneS: lOObp ladder 
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Age adjusted risks were also calculated using multivariate logistic regression model. The 
haplotype analyses were carried out using the software Haploview 
(www.broad.mit.edu/mpg/haploview/). Statistical significance for the difference in the 
haplotype frequencies between cases and controls were determined by the X^-test. The 
differences were considered significant if the p-value did not exceed 0.05. 
3.3 RESULTS 
The main characteristics of the study populations are summarized in table 3.2. 
The four populations were similar in ethnic origin. The mean ages were 42 ± 13.6, 47 ± 
14.2, 49 ± 11.4, 52 ± 12.5 for non-alcoholic controls, non-alcoholic cirrhosis, alcoholic 
controls and alcoholic cirrhosis respectively. Similarly, the mean alcohol consumption for 
non-alcoholic controls, non-alcoholic cirrhosis, alcoholic controls and alcoholic cirrhosis 
were found to be 8 ± 2.6, 2 ± 3.4,102 ± 12, 140 ± 32 g/day respectively. 
Both the genotype and allele frequency of CYP2E] in alcoholic and non-alcoholic 
controls were found to be in Hardy-Weinberg equilibrium. As the frequency of the 
homozygous mutant genotype of CYP2E1 {CYP2E1*5B, CYP2E1*6 and Mspl 
polymorphism) were very rare, the heterozygous and homozygous genotypes were 
clubbed together and are referred as variant genotypes. Table 3.3 summarizes both the 
genotype and allele frequencies of Rsal polymorphism {CYP2E1 *5B) of CYP2E1 genes. 
The frequency of variant (heterozygous and homozygous mutant) genotypes of 
CYP2E1 *5B was higher (8%) in alcoholic cirrhotic patients (ACP) when compared with 
non-alcoholic controls (2%), or alcoholic controls (2%) or non-alcoholic cirrhotic 
patients (NACP, 2%). The crude odds ratio (OR) for variant genotypes was found to be 
significantly increased (OR: 4.3; 95%CI: 1.5-12.3; p: 0.006) when the frequency of 
variant genotype in ACP was compared with non-alcoholic controls (Table 3.3). 
Similarly, when the frequency of the variant genotype of CYP2E1*5B in ACP was 
compared with NACP, an increased risk was observed in ACP (OR; 3.9; 95%C1: 1.11-
14.10; p: 0.03) which was statistically significant. Likewise, when the frequency of 
variant genotype of CYP2E1*5B in ACP was compared with alcoholic controls, a 
statistically significant increase in risk (OR: 4.0; 95%CI: 1.11-14.10; p: 0.03) was 
observed in the patients (Table 3.3). However, no risk was observed when the frequency 
of variant genotype of CYP2E1 *5B in either alcoholic controls or NACP (OR: 1.1; 
88 
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Table 3.2: Demographic data for cirrhotic patients and controls 
Non-alcoholic Non-alcoholic Alcoholic Alcoholic 
controls cirrhosis controls cirrhosis 
Population 255 140 140 175 
Alcohol 
consumption 
(mean ± SD) 
g/day 8 ±2.6 2 ±3.4 102 ±12 140 ±32 
Years — — 11 ±2.5 14 ±3.6 
Mean age 42 ±13.6 47 ±14.2 49 ±11.4 52 ±12.5 
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95%CI: 0.25-4.65; p: 0.90) was compared with non-alcoholic controls. Likewise, when 
the frequency of variant genotypes of CYP2E1 *5B in alcoholic controls was compared 
with NACP, no significant increase in risk (OR: 1.0; 95%CI: 0.20-5.04; p: 1.0) was 
observed (Table 3.3). 
As evident from table 3.4, the frequency of variant genotype of CYP2EJ*6 (Dral 
polymorphism) in ACP (27%) was almost similar to that observed in non-alcoholic 
controls (27%) or NACP (28%) but slightly lower than in alcoholic controls (30%). No 
significant change was observed in the OR associated with the variant genotype of 
CYP2E1*6 in ACP when compared with non-alcoholic controls (OR: 0.99; 95%C1: 0.64-
1.52; p: 0.96) or NACP (OR: 0.95; 95%CI: 0.58-1.56; p: 0.84) or alcoholic controls (OR: 
0.86; 95%)CI: 0.52-1.4; p: 0.54) (Table 3.4). Similarly, when comparing the frequency of 
variant genotype of CYP2E1 *6 in alcoholic controls with non-alcoholic controls (OR: 
1.15; 95%CI: 0.73-1.82; p: 0.53), or NACP (OR: 1.1; 95%CI: 0.66-1.86; p: 0.69) no 
significant change in OR was observed. Likewise, on comparing the frequency of variant 
genotype of CYP2E1 *6 in NACP with non-alcoholic controls, no significant change in 
OR (OR: 1.05; 95%C1: 0.66-1.65; p: 0.86) was observed (Table 3.4). 
Table 3.5 summarizes both the genotype and allele frequencies of Mspl 
polymorphism of CYP2E1 genes. Similar to the Dral polymorphism of CYP2E1, the 
frequency of variant genotype of Mspl polymorphism in ACP (13%) was similar to that 
observed in non-alcoholic controls (12%)), NACP (11.5%)) and alcoholic controls (12%) 
and no significant risk was observed in ACP when the frequency of variant genotype was 
compared with non-alcoholic controls (OR: 1.1; 95%)CI: 0.61-1.94; p: 0.76) or NACP 
(OR: 1.2; 95%CI: 0.59-2.3; p: 0.65) or alcoholic controls (OR: 1.1; 95%CI: 0.56-2.14; p: 
0.79) (Table 3.5). Likewise, on comparing the frequency of variant genotype of Mspl 
polymorphism in alcoholic controls with either non-alcoholic controls (OR: 1.0; 95%C1: 
0.53-1.87; p: 0.99) or NACP (OR: 1.1; 95%C1: 0.52-2.21; p: 0.85), no risk was observed 
(Table 3.5). Similarly, when the frequency of variant genotypes of Mspl polymorphism 
in NACP was compared with non-alcoholic control, no significant increase in risk (OR: 
0.93; 95%CI: 0.49-1.77; p: 0.83) was observed (Table 3.5). 
Haplotype approach was also followed to study the association of combined effect 
of three SNPs of CYP2E1 with cirrhosis. Out of 8 possible haplotypes, only 7 were 
observed in the patients and the controls (Table 3.6). The haplotype, C-A-T was 
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considered to be the reference carrying wild type alleles. The frequency of haplotype T-
A-T, carrying variant allele of CYP2E1 *5B, was higher in ACP (3%) when compared 
with non-alcoholic controls (0.6%) or NACP (0.7%) or alcoholic controls (0.7%)). The 
higher frequency of T-A-T haplotype in ACP resulted in 5.0 fold increase in OR (OR: 
5.0; 95%CI: 1.36-18.33; p: 0.007) when compared with non-alcoholic controls. This 
increase in risk was found to be statistically significant (Table 3.6). Similarly, almost 4-
fold increase in risk was also found in ACP carrying T-A-T haplotype when compared 
with alcoholic controls (OR: 3.4; 95%CI: 0.86-18.39; p: 0.056) or NACP (OR: 4.0; 
95%)CI: 0.88-18.73; p: 0.052). However, this increase in risk was not found to be 
statistically significant (Table 3.6). Though the frequency of other haplotypes (C-A-A, C-
G-T and T-A-A) were also higher in ACP when compared with non-alcoholic controls or 
NACP or alcoholic controls, the OR associated with these Haplotypes were not found to 
be statistically significant. Likewise, all the four haplotypes (C-A-A, C-G-T, T-A-T and 
T-A-A) in NACP and alcoholic controls exhibited slightly increased OR, though not 
statistically significant when compared with non-alcoholic controls. 
Table 3.7 summarizes the distribution of genotype frequency of GSTMl in 
controls and patients suffering from alcoholic and non-alcoholic liver cirrhosis. The null 
genotype of GSTMl was found to be present in increased frequency (44%)) in alcoholic 
cirrhotic patients (ACP) when compared with non-alcoholic controls (31.4%), or 
alcoholic controls (31.5%)) or non-alcoholic cirrhotic patients (NACP, 34.3%)). The crude 
odds ratio (OR) for null genotypes was found to be significantly increased (OR: 1.7; 
95%oCI: 1.15-2.56; p: 0.008) when the frequency of null genotype in ACP was compared 
with non-alcoholic controls (Table 3.7). A statistically significant increase in the risk to 
alcoholic liver cirrhosis was observed in ACP when the frequency of null genotype of 
GSTMl in alcoholic liver cirrhotic patients was compared with the alcoholic controls 
(OR: 1.7; 95%)CI: 1.07-2.73; p: 0.02). Likewise, when the frequency of null genotype of 
GSTMl in ACP was compared with NACP, an increase in the risk (OR: 1.5; 95%C1: 
0.95-2.38; p: 0.08) was observed in the patients which, however, was not found to be 
statistically significant (Table 3.7). No risk to the disease was observed when the 
frequency of null genotype of GSTMl in non-alcoholic controls was compared to the 
alcoholic controls (OR: 1.0; 95%oCI: 0.64-1.56; p: 0.99) or NACP (OR: 1.1; 95%C1: 0.73-
1.76; p: 0.55). Likewise, when the frequency of null genotypes of GSTMl in alcoholic 
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controls was compared with NACP, no increase in risk (OR: 0.88; 95%CI: 0.53-1.44; p: 
0.61) was observed (Table 3.7). 
The distribution of genotype frequencies of GSTTl in controls and patients 
suffering from alcoholic and non-alcoholic liver cirrhosis is summarized in table 3.8. As 
evident from table, the frequency of null genotype of GSTTl in ACP (19%) was almost 
similar to that observed in non-alcoholic controls (17%) or NACP (16.5%) or alcoholic 
controls (16.5%)). No significant change was observed in the OR associated with the null 
genotype oi GSTTl in ACP when compared to non-alcoholic controls (OR: 1.1; 95%CI: 
0.69-1.89; p: 0.59) or alcoholic controls (OR: 1.2; 95%CI: 0.65-2.12; p: 0.58) or NACP 
(OR: 1.2; 95%CI: 0.65-2.12; p: 0.58) (Table 3.8). When the frequency of null genotype 
of GSTTl in alcoholic controls was compared with either non-alcoholic controls (OR: 
0.97; 95%CI: 0.55-1.68; p: 0.91) or NACP (OR: 1.0; 95%CI: 0.53-1.88; p: 1.0), no 
significant increase in risk was observed. Likewise, on comparing the frequency of null 
genotype of GSTTl in NACP with non-alcoholic controls, no significant change in OR 
(OR: 0.97; 95%CI: 0.55-1.68; p: 0.91) was also observed (Table 3.8). 
The genotype and allele frequency of GSTPl in alcoholic and non-alcoholic 
controls were found to be in Hardy-Weinberg equilibrium. As the frequency of the 
homozygous mutant (VaWal) genotype of GSTPl was very rare, the heterozygous and 
homozygous mutant genotypes were clubbed together and are referred to as variant 
genotypes (Ile/Val + Val/Val) of GSTPL The frequency of the variant genotype of 
GSTPl was found to be higher in ACP (52%) when compared to the non-alcoholic 
controls (39.6%) or NACP (45%) or alcoholic controls (43%) (Table 3.9). The increase in 
frequency of the variant genotypes of GSTPl resulted in a significant increase in risk 
(OR: 1.65; 95%CI: 1.12-2.43; p: 0.01) in ACP when compared with non-alcoholic 
controls (Table 3.9). A slightly increased OR, though not statistically significant, was 
also observed when the frequency of variant genotype of GSTPl in ACP was compared 
with NACP (OR: 1.3; 95%CI: 0.84-2.06; p: 0.22) or alcoholic controls (OR: 1.44; 
95%.CI: 0.92-2.26; p: 0.11). No risk was however, observed on comparing the frequency 
of the variant genotype of GSTPl in alcoholic controls with either non-alcoholic controls 
or NACP. Similarly, no risk was found in NACP when frequency of the variant genotype 
of GSTPl was compared with non-alcoholic controls (Table 3.9). 
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The distribution of genotype and allele frequencies of MnSOD gene in controls 
and patients suffering from alcoholic and non-alcoholic liver cirrhosis is summarized in 
table 3.10. The frequency of the variant genotype (Ala/Ala + Ala/Val) of MnSOD was 
found to be higher in ACP (74.3%) when compared with non-alcoholic controls (64.7%) 
or NACP (68%) but was almost similar to that observed in alcoholic controls (71.5%). 
When the frequency of variant genotype of MnSOD in ACP was compared with non-
alcoholic controls the crude odds ratio was increased to 1.57 (95%C1: 1.03-2.41; p: 0.03), 
which was found to be statistically significant. A slight increase in risk to cirrhosis was 
also observed in ACP when the frequency of variant genotype of MnSOD was compared 
with NACP (OR: 1.36; 95%C1: 0.83-2.23; p: 0.21) or alcoholic controls (OR: 1.15; 
95%CI: 0.70-1.90; p: 0.57), though the increase in risk was statistically not significant. 
No risk to the disease was observed when the frequency of variant genotype of MnSOD 
in non-alcoholic controls was compared to the alcoholic controls (OR: 1.36; 95%CI: 
0.87-2.13; p: 0.17) or NACP (OR: 1.2; 95%C1: 0.71-1.97; p: 0.52) (Table 3.10). 
Similarly, when the frequency of variant genotypes of MnSOD in NACP was compared 
with non-alcoholic control, no significant increase in risk (OR: 1.15; 95%CI: 0.74-1.78; 
p: 0.53) was observed (Table 3.10). 
The risk to alcoholic liver cirrhosis associated with multiple at-risk genotypes of 
GSTs is summarized in table 3.11 & 3.12. When the genotypes of GSTMl and GSTTJ 
were combined, four combinations were observed. About 11.5% of the alcoholic cirrhotic 
patients carried the combination of null genotype of both GSTMl and GSTTJ, which 
increased the risk upto 2.8-fold (95% CI: 1.3-6.06; p: 0.006) when compared to non 
alcoholic controls or alcoholic controls (OR: 2.7; 95% CI: 1.07-6.70; p: 0.03). About 2.0 
fold increase in risk (OR: 2.0; 95% CI: 0.87-4.74; p: 0.09) was also observed in ACP 
when compared to NACP, though this increase in risk was not found to be statistically 
significant (Table 3.11). Likewise, about 24.5% of the alcoholic cirrhotic patients carried 
the combination of null genotype of GSTMl and variant genotype (Ile/Val + Val/Val) of 
GSTPl, which significantly increased the risk upto 2.8-fold (95% CI: 1.58-4.90; p: 0.000) 
when compared with non alcoholic controls or alcoholic controls (OR: 2.7; 95% CI: 1.35-
5.30; p: 0.004). However, slightly lower risk, though statistically significant was 
observed in ACP carrying the combination of null genotype of GSTMl and variant 
genotype (IleA^al + ValA^al) of GSTPl when compared with NACP (OR: 1.9; 95% CI: 
100 
o u 
c o 
u 
-a 
C3 
i 
S O 
s 
I 
J5 
i I 
^ 
u 
a 
o 
B 
CD 
B 
_o 
' • * i < 
9 £ 
• mm 
Q 
H 
T3 U a 
< 
O U 3 
'•a v? ^ 
•T3 "-^  5 
o 
r-
m 
• * 
oo 
d 
1> 
r^  
o u I 
a *^  > 
U ^ 
°0 ^ I') n 
If 
U I 
•a vo •« 
' !5 Q, 
as ^ 
05 es 
C/3 
as 
Pi 
a; 
m 
-
0 0 
' 
m 
"O 
d 
»—1 
o 
o 
'T 
VO 
ro iX 
o _ 
•S ^ --^ 
i i -g >« 
i u 
o 
Z. 
• * • » ! ^ 
z 
OS 
OS 
d 
OS 
•5 o ^^ 
O L. o 
U O ^ 
i n 
0 0 
a 
so 
-
OS 
' 1 
o 
<ri 
<ri 
d 
o 
OS 
• t - -
• o 
-^  
o 
1 
0 0 d 
so 
ro 
d 
OS 
d 
o 
r- (N g 
o 
I—1 
>n 
• * 
T f 
r^  
r-; 
ITS 
J3 ^ >-^  
•a 
O 
c 
00 
o V 
D. 
c u 
•a 
c o o 
U 
I 
1 
I 
,^ 
o 2 
ai B 
z 
S ^ ^ 
= i © NS 
o S -
^ " 
t a 
l l I !f? ? 
<« o 
o 
Z 
o 
o 
I 
I 
a; 
00 m 
o 
•^ ^' o 
oo I r^  
o 
- i 
rr f^  <) 
^ o o 
oo "-^  
p t p 
d 
^ 
o 
• * 
t/1 f^ V^ 
^ . — - : >^  o 
00 ^ d 
t^ 
f ^ ^ S 
r4 S d 
—^ 
OO t ^ 
— ^ '^ vb 
f- ? 
O w-i 
-^ ^ (^  
d i e d 
Tf (N 2 
"";;: d 
S S 
o 
2 ^ O yri 
d 
r^ oo 
00 U-1 
00 irt 
o 
— P 
in o 
; lA Q 
o 
5? 
— O 
^ V O 
- S d 
- g o 
o 
Qo __; —' 
d 
ov Tj- — 
— >0 d 
i i t P 
s? ^ i-« 
Vj JO 
I J O 
=8 
is IE 
tn >1 
l i l i 
2| 
i^ : K K 1>5 So ( i l i 
22 
§? 
^ (> 03 CO 
l i ^ 
§?: f> K |>3 fn 
^ l i 
1 
+ 
5l "^  
K h. CO Co 
;3 e) 
»8 S~ 
^5. 
2 "^  
h, f^ 
Co CO 
l i O 
s 
+ 
i?: ^ t^ 
CO Co 
i^^S 
"8 3^  II 
??: h^ ^ 
so to 
o ; ? 
1 
+ 
it 
p? t^ K 
1>3 =0 
^ e> 
"3^  
cs: h, (^ 
Co Co 
l i l i 
+ 
«8l 
(^  ^ Co to 
1^ l i 
(Potymorpfdsm in CY<P2fEl and msceptibiSky to dcofwGc twer cirrhosis 
1.01-3.57; p: 0.04) (Table 3.11). Similarly, when genotype combinations of GSTTl and 
GSTPl were studied, it was found that 12.5% of the alcoholic cirrhotic patients carried 
the combination of null genotype of GSTTl and variant genotype (Ile/Val + ValA'al) of 
GSTPl, which significantly increased the risk upto 2.16-fold when compared with non-
alcoholic controls (95% CI: 1.08-4.28; p: 0.02) (Table 3.11). The increase in risk was 
also observed in ACP when compared to alcoholic controls (OR: 1.6; 95% CI: 0.75-3.47; 
p: 0.21) or NACP (OR: 1.9; 95% CI: 0.85-4.37; p: 0.11) though this increase was not 
found to be statistically significant (Table 3.11). Further, no significant risk was observed 
in NACP and alcoholic controls carrying the various combination of null genotype of 
GSTMl, GSTTl or variant genotype of GSTPl when compared with non alcoholic 
controls. 
When the genotypes of GSTMl, GSTTl and GSTPl were combined, eight 
possible combinations were observed (Table 3.12). As evident from table, individuals 
with combination of the null genotypes of GSTTl, GSTMl and the variant genotype of 
GSTPl were at significantly higher risk to alcoholic cirrhosis when compared with non-
alcoholic controls (OR: 5.8; 95% CI: 2.17-15.80; p: 0.000) or alcoholic controls (OR: 4.6; 
95% CI: 1.44-14.65; p: 0.006) or NACP (OR: 3.5; 95% CI: 1.2-10.30; p: 0.01) (Table 
3.12). Further, no significant risk was observed in NACP and alcoholic controls carrying 
the various combination of null genotype of GSTMl, GSTTl or variant genotype of 
GSTPl when compared with non alcoholic controls. 
The distribution of genotype combinations of CYP2E1*5B with GSTMl or, 
GSTTl or GSTPl are summarized in table 3.13. Several fold statistically significant risk 
was observed in the ACP carrying the combination of null genotype of GSTMl and 
variant genotype of CYP2E1*5B when compared to non-alcoholic controls (OR: 7.2; 
95%CI: 1.98-26.17) or alcoholic controls (OR: 4.0; 95%CI: 1.08-14.47) or NACP (OR: 
11.0; 95%CI: 1.43-88.28) (Table 3.13). Likewise, upto 6-fold increase in the risk was 
observed in ACP carrying combination of null genotype of GSTTl and variant genotype 
of CYP2E1*5B when compared to non alcoholic controls (OR: 6.1; 95%CI: 1.28-29.38) 
or alcoholic controls (OR: 6.7; 95%CI: 0.83-54.89). An increase in risk was also 
detected in ACP carrying combination of null genotype GSTTl and variant genotype of 
CYP2E1*5B when compared to NACP (OR: 3.4; 95%CI: 0.71-16.38), though this 
increase was not found to be statistically significant. Several fold statistically significant 
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increase in the risk was also observed in the ACP carrying variant genotype combination 
of CYP2E1*5B and GSTPl when compared to non-alcoholic controls (OR: 11.0; 95%C1: 
2.4-50.56) or alcoholic controls (OR: 5.7; 95%CI: 1.25-26.56) or NACP (OR: 11.0; 
95%CI: 1.4-86.25) (Table 3.13). However, no significant increase in OR was observed in 
alcoholic controls or NACP carrying the combination of variant genotype of CYP2E1 *5B 
and null genotype of GSTMl or GSTTl or variant genotype of GSTPl when compared 
with non-alcoholic controls. 
The distribution of genotype combinations of CYP2E1*5B and MnSOD are 
summarized in table 3.14. Almost 8-fold statistically significant increase in the risk (OR: 
8.0; 95%CI: 2.19-30.54; p: 0.000) was observed in the ACP carrying variant genotype 
combination of CYP2E1 *5B and MnSOD when compared with non-alcoholic controls. 
Likewise, the 5.5-fold increase in the risk (OR: 5.4; 95%CI: 1.14-25.85; p: 0.02) was 
found in ACP carrying variant genotype combination of CYP2E1 *5B and MnSOD when 
compared with alcoholic controls. Similarly, a significant increase in OR (OR: 4.2; 
95%CI: 1.10-15.86; p: 0.02) was also observed in ACP carrying variant genotype 
combination of CYP2E1 *5B and MnSOD when compared with NACP. However, no 
significant increase in OR was observed in alcoholic controls or NACP when the 
genotype combination of variant of CYP2E1 *5B and MnSOD in these groups were 
compared with non-alcoholic controls. 
The distribution of genotype combinations of MnSOD either with GSTMl or 
GSTTl or GSTPl are summarized in table 3.15. Statistically significant increase in risk 
was observed in ACP carrying the combination of null genotype of GSTMl and variant 
genotype of MnSOD when compared with non-alcoholic controls (OR: 2.65; 95%CI: 
1.47-4.78) or alcoholic controls (OR: 1.9; 95%CI: 0.99-3.8) or NACP (OR: 2.0; 95%CI: 
1.03-3.98) (Table 3.15). Similarly, 2-fold increase in the risk was observed in ACP 
carrying the combination of null genotype of GSTTl and variant genotype of MnSOD 
when compared to non-alcoholic controls (OR: 2.0; 95%CI: 1.02-4.10). Likewise, 2.5-
fold increase in the risk was observed in ACP carrying the combination of variant 
genotype of GSTPl and MnSOD when compared to non-alcoholic controls (OR: 2.5; 
95%CI: 1.38-4.52) (Table 3.15). No significant increase in risk was observed in alcoholic 
controls or NACP carrying the combination of variant genotypes of MnSOD with null 
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genotype of GSTMl, GSTTl or variant genotype of GSTPl when compared to non-
alcoholic controls. 
3.4 DISCUSSION 
Cirrhosis, a chronic liver disease, is mainly caused by heavy alcohol consumption 
or hepatitis B and C viral infections (Walsh and Alexander, 2000; Choi and Ou, 2006). 
While nearly all heavy alcohol drinkers reveal fatty liver, only 10% - 20% of alcoholics 
develop cirrhosis (Savolainen et al., 1995; Mann et al., 2003). Though the exact 
pathogenesis of alcoholic liver injury is still not well understood, oxidative stress has 
been suggested to be important in alcoholic liver cirrhosis (Walsh and Alexander, 2000). 
Polymorphism in the genes coding for enzymes that catalyze the oxidative metabolism of 
ethanol such as CYP2E1 and those involved in detoxification of free radicals generated 
during the metabolism of ethanol such as GSTs, MnSOD etc could be involved in 
determining the susceptibility to ALD. CYP2E1 is particularly of interest as chronic 
ethanol intake increases its activity up to 10 to 20-fold (Kessova and Cederbaum, 2003). 
This induced CYP2E1 results in accumulation of toxic acetaldehyde and reactive oxygen 
species (ROS) in the cell which induces mitochondrial damage, DNA modification and 
lipid peroxidation which may leads to alcoholic liver cirrhosis. Polymorphism in CYP2E1 
gene, particularly of CYP2E1 *5B is known to further increase enzyme activity which 
leads to increased formation of ROS when compared to wild type genotype (Hayashi et 
al., 1991; Tsutsumi et al., 1994; Watanabe et al., 1994). These liver cells respond to the 
CYP2E1 induced oxidative stress by transcriptionally inducing various antioxidant 
enzymes such as GSTs, Manganese superoxide dismutase (MnSOD) via their antioxidant 
response elements. As polymorphism in GSTs (GSTMl, GSTTl and GSTPl) and MnSOD 
genes are known to have reduced and increased enzyme activity respectively, the 
individuals with gene deletion in GSTMl, GSTTl or variant genotypes of GSTPl and 
MnSOD may be at the increased risk to alcoholic liver diseases including cirrhosis. 
Consistent with the studies mentioned in the preceding chapter, our data have 
shown that polymorphisms exist in the CYP2E1 gene in North Indian population. 
Interestingly, Rsal (CYP2E1*5B) polymorphism not found in the 43 representative 
sample of Indian population was found to be present in the North Indian population. Due 
to the rare occurrence of the CYP2E1 *5B polymorphism, it may be possible that this 
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minor allele of CYP2E1 *5B could not be identified in the 43 representative samples. The 
frequency of minor allele of CYP2E1 *5B (Rsal) was found to be very rare (1 %) and 
supports our hypotheses that due to the rare occurrence of the CYP2E1*5B 
polymorphism, this minor allele of CYP2E1*5B was not identified in the 43 
representative samples. The frequency of minor allele of CYP2E1 *5B was found to be 
similar to that reported in earlier reports in North Indian and South Indian controls (Mittal 
et al., 2005; Soya et al., 2005). Similar frequency of the minor allele of CYP2E1*5B is 
also reported in the Caucasians (1% - 4%) (Pirmohmed et al., 1995; Grove et al., 1998; 
Wong et al., 2000). Similar to that seen in the preceding chapter, the minor allele 
frequency (16%) of CYP2E1*6 (Dral) in North Indian controls was quite similar to that 
observed in different population or reported earlier in the North Indian (19%) or South 
Indian (14%) population (Mittal et al., 2005; Soya et al., 2005). Likewise, our data further 
revealed that Mspl polymorphism, which was not present in 43 representative DNA 
sample was also found to be present in North Indian population. The minor allele 
frequency (6%) of this polymorphism was quite higher than reported in Caucasians (2%) 
population (Savolainen et al., 1997). 
Similar to the CYP2E1, our data showed polymorphism also exist in the GSTs and 
MnSOD, the phase II genes, involved in the detoxification of reactive oxygen species, in 
North Indian population. The frequency of null genotype of GSTMI (31.5%) was found 
to be similar to that reported earlier in the North Indian population (28%-33%) (Sobti et 
al., 2004; Singh et al., 2008). However, this was much lower than found in other Asian 
populations (33-63% in Japanese, Chinese and Koreans), Caucasians (38-67%) (Geisler 
et al., 2001) and Pacific-Rims (approx. 75%). Likewise, the GSTTl null genotype 
frequency was found to be 17% in the controls which was similar to that seen in other 
North Indian, Caucasians and African- Americans (Geisler et al., 2001; Sobti et al., 2004; 
Ladero et al., 2005; Singh et al., 2008) but lower than reported in Oriental (approx. 42-
58% in Chinese, Japanese and Korean) and Pacific Rim (33%) populations. Similarly the 
frequency of minor alleles of GSTPl was found to be 22% which was equal to that 
observed with other North Indian and Caucasians (Garte et al., 2001; Jain et al., 2006; 
Singh et al., 2008) but more than that reported with Japanese and African-Americans and 
less than Hispanics and Pacific-Rim population (Geisler et al., 2001) 
(www.snp500cancer.nci.nih.gov). Likewise, the frequency of Alanine encoding allele of 
10 
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MnSOD in our study was found to be 43% which is slightly lower than that reported in 
Caucasian (50%) but much higher than that found in Chinese (30%)) and Japanese (13%) 
population (Shimoda-Matsubayashi et al., 1996; Van Landeghem et al., 1999). 
The present study has provided evidence that polymorphism in CYP2E1 modifies 
susceptibility to alcoholic liver cirrhosis. Significant increase in the frequency of variant 
genotype of CYP2E1 *5B was observed in alcoholic cirrhotic patients when compared 
with non-alcoholic controls. As the variant genotype of CYP2E1*5B is known to increase 
the CYP2E1 enzyme activity, this increase in frequency of the variant genotype of 
CYP2E1 *5B may lead to an increased formation of reactive oxygen species (ROS) in 
alcoholics that may help in explaining the increased risk observed in alcoholic liver 
cirrhotic cases when compared with non-alcoholic controls (Hayashi et al., 1991; 
Tsutsumi et al., 1994; Watanabe et al., 1994). Significant association of CYP2E1*5B with 
alcoholic cirrhosis and other alcoholic liver diseases has been shown in the Oriental 
population though there are few reports which do not show the association of 
CYP2EI*5B polymorphism with alcoholic liver disease in Orientals (Tsutsumi et al., 
1994; Yamauchi et al., 1995b; Carr et al., 1996; Tanaka et al., 1997; Lee et al., 2001; 
Piao et al., 2003; Stickel and Osterreicher, 2006). Minor allele of CYP2E1*5B (c2) was 
found to be more frequent in alcoholic liver diseases and alcoholic liver cirrhotic patients 
when compared to the controls and this increase in frequency was associated with higher 
CYP2E1 activity in CYP2E1 c2 homozygotes as reflected by acetaminophen elimination 
test (Tsutsumi et al., 1994; Tanaka et al., 1997). Piao et al. (2003) reported that the minor 
allele frequency of CYP2E1 *5B in Chinese population play a key role in the pathogenesis 
of fatty liver and CYP2E1 c2 allele frequency in patients with alcoholic or non-alcoholic 
fatty liver was much higher than that observed in controls. Yamauchi et al. (1995b) also 
found the association of variant genotype of CYP2E1 *5B with alcoholic liver disease in 
Japanese population. However, this association of CYP2E1*5B with alcoholic liver 
cirrhosis was not found to be consistent in the Caucasians as well as in few studies with 
Oriental populations (Pirmohmad et al, 1995; Carr et al., 1996; Parsian et al., 1998; Lee 
et al., 2001) with few studies showing significant association of CYP2E1*5B with 
alcoholic liver diseases in Caucasian population (Pirmohmad et al., 1995; Cicho-Lach et 
al., 2006) though, most of the studies in Caucasians does not show any significant 
association of CYP2E1 *5B with alcoholic cirrhosis and other alcoholic liver disease. 
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(Carr et al., 1995; Parsian et al., 1998; Wong et al., 2000; Vidal et al., 2004). Pirmohmad 
et al. (1995) reported that the minor allele frequency of CYP2E1*5B is strongly 
associated with development of alcoholic liver disease in Caucasians. This inconsistency 
in the association of the alcoholic cirrhosis or other alcoholic liver diseases with 
CYP2El*5B may be partly due to the smaller sample size in the study group, lower 
frequency of CYP2E1 *5B variant genotype and ethnic variations amongst the Caucasians 
(Carr et al., 1995; Parsian et al., 1998; Wong et al, 2000; Vidal et al., 2004). 
That the increased CYP2E1 activity associated with variant genotype of 
CYP2E1*5B leads to an increased oxidative stress was further shown by statistically 
significant increase in risk in alcoholic cirrhotic cases (OR: 4.7; 95%C1: 1.66-13.74; p: 
0.004) when compared with non-alcoholic cirrhotic cases carrying the variant genotype 
of the same. Non-alcoholic cirrhosis has been primarily attributed to hepatitis B and C 
virus infections which are known to increase the expression of CYP2EI in liver (Choi 
and Ou. 2006) but not to the extent as observed in alcoholics due to excess alcohol intake 
(Takahasi et al., 1993). Further evidence that the increased frequency of the variant 
genotypes (Rsal) of CYP2E1 may lead to increased oxidative stress in alcoholic liver 
cirrhosis was demonstrated by significant increase in risk (OR: 4.0; 95%CI: 1.11-14.10; 
p: 0.03) in cases when compared with the alcoholic controls. Further, almost similar 
frequency of variant genotype (Rsal) of CYP2E1 in alcoholic and non-alcoholic controls 
have suggested that the variant genotype (Rsal) of CYP2EI is involved in alcoholic liver 
diseases (Vidal et al., 2004; Loza et al., 2006). 
Multivariate logistic regression model after adjustment for age, showed no 
significant association of CYP2E1*6 or Mspl polymorphisms with alcoholic cirrhosis. 
This is consistent with the earlier report indicating no association between CYP2E1*6 
with alcoholic liver cirrhosis or other alcoholic liver diseases (Lucas et al., 1996; Frenzer 
et al., 1997; Savolainen et al., 1997; Parsian et al., 1998; Wong et al, 2000; Pasturelli et 
al., 2001; Vidal et al., 2004; Loza et al., 2006). Loza et al (2006) reported a higher 
frequency of the variant genotype of CYP2E1*6 in alcoholic of Otomie population. 
However, this observation needs to be interpreted with caution as the control population 
for this polymorphism was not in HWE. In contrast, Iwahashi et al. (1998) suggested that 
the mutant (C) allele of CYP2E1 *6 may be associated with a higher risk to develop 
alcoholism in Japanese population. However, most of the studies in Oriental as well as 
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Caucasians failed to show any association between CYP2E1*6 genotype with alcoholic 
liver disease or alcoholism (Lucas et al., 1996; Frenzer et al., 1997; Savolainen et al., 
1997; Parsian et al., 1998; Wong et al., 2000; Pasturelli et al., 2001; Vidal et al., 2004; 
Loza et al., 2006). 
Haplotype analysis has revealed that Rsal and Dral polymorphism of CYP2E1 do 
not exhibit linkage disequilibrium (LD) in either controls or cases. Similar results were 
also observed in American, Japanese (Kato et al., 1994) and African American 
populations (Wu et al., 1998), though studies in European, Taiwanese (Persson et al., 
1993; Hildesheim et al., 1995; Yu et al., 1995), and Mexican American populations (Wu 
et al., 1998) have shown LD between the Rsal and Dral polymorphism. These findings 
support that LD is population specific (Stephen et al., 2001a ; Gabriel et al., 2002). 
Haplotype data also demonstrated that the frequency of haplotype C-A-A, C-G-T, T-A-T 
and T-A-A are increased in the alcoholic cirrhotic patients. The haplotype T-A-T, which 
contains variant genotype of CYP2E1 *5B was found to be associated with several fold 
increased risk (OR: 5.0; 95%CL- 1.36-18.33; p: 0.007) for alcoholic cirrhosis. However, 
haplotype studies in Caucasian population showed that CYP2E1 plays no substantial role 
in susceptibility to alcoholic liver cirrhosis or alcoholism (Parsian et al., 1998). 
As observed with CYP2E1 *5B the results of the present study also demonstrated 
that polymorphism in GSTs modifies the susceptibility to alcoholic liver cirrhosis. An 
elevated risk to alcoholic liver cirrhosis was observed in the patients with null genotype 
of GSTMl when compared with the non-alcoholic controls. No significant increase in the 
frequency of null genotype of GSTMl in patients with non-alcoholic liver cirrhosis or 
alcoholic controls when compared with non alcoholic controls have suggested that 
GSTMl null genotype may be an risk factor important in the development of alcoholic 
liver diseases associated with chronic ethanol intake. Since null genotype of GSTMl 
results in enzyme deletion, reactive oxygen species generated during the excess ethanol 
intake by CYP2E1 particularly in alcoholics, cannot be detoxified leading to the liver 
damage (Seidegard et al., 1986). Null genotype of GSTMl was also found to occur more 
frequently among patients with different features of alcoholic liver disease (Harada et al., 
1987, 1993; Baranov et al., 1996; Savolainen et al., 1996; Ladero et al., 2005) though 
several studies, lacking sufficient sample size, have failed to find such an association 
(Groppi et al., 1991; Rodrigo et al., 1999; Frenzer et al., 2002; Burim et al., 2004). 
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Savolainen et al. (1996) have reported statistically significant association of GSTMl null 
genotype with alcoholic liver cirrhosis. Ladero et al. (2005) also detected 4 times higher 
frequency of GSTMl null genotype in patients suffering from advanced alcoholic liver 
disease compared with healthy controls. Likewise significant association of null genotype 
of GSTMl with cryptogenic cirrhosis has implicated this polymorphism as a risk factor 
for the occurrence of the disease (Ghobadloo et al., 2004). 
Consistent with earlier reports (Frenzer et al., 2002; Brind et al., 2004), no 
significant increase in the frequency of null genotype in GSTTl was observed in 
alcoholic cirrhotic patients when compared with the non-alcoholic controls or non-
alcoholic cirrhotic patients or alcoholic controls. Ladero et al. (2005), however, reported 
increase in the frequency of GSTTl null genotype in advanced alcoholic liver disease 
patients when compared with the healthy controls. Burim et al (2004) also reported an 
increase in the frequency of GSTTl null genotype in alcoholics with pancreatitis than that 
of the controls or alcoholics without disease. Interestingly GSTTl gene is better 
conserved in humans and has been suggested to have a more relevant functional role for 
GSTTl enzyme than for GSTMl enzyme (Ladero et al., 2005). 
The increase in the frequency of variant genotype of GSTPl in alcoholic cirrhosis 
patients when compared with non-alcoholic controls is in agreement with the earlier 
reports (Burim et al., 2004; Ghobadloo et al., 2004), indicating that GSTPl 
polymorphism is associated with the development of alcoholic cirrhosis. Burim et al 
(2004) earlier reported higher frequency of the VaWal genotype of GSTPl in patients 
with alcoholic liver disease or chronic pancreatitis when compared to alcoholics without 
disease or the healthy controls. GSTPl Wa\fVa\ genotypes were also found to be 
associated with the development of cirrhosis in patients with hereditary hemochromatosis 
(Stickel et al., 2005). Likewise significant association of Val/Val genotype of GSTPl 
with cryptogenic cirrhosis has implicated this polymorphism as a risk factor for the 
occurrence of the disease (Ghobadloo et al., 2004). Experimental studies have shown that 
GSTPl polymorphism alters the protein function. Biochemical studies have demonstrated 
a lower thermal stability of GSTPl Val compared with GSTPl He (Nelson et al., 1995; 
Alves-Silva et al., 2000) and also lower conjugating activity of Val homozygous 
compared with lie homozygous, with heterozygous displaying intermediate activity 
(Watson et al., 1998). In vitro studies in human tissues revealed that ValA^al genotype is 
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associated with a lower enzyme activity compared to that of the heterozygous and the 
Ile/Ile genotype. No significant association of variant genotype of GSTPl with non 
alcoholic cirrhosis or in alcoholic controls when compared to non-alcoholic controls has 
further suggested that ethanol derived free radicals are not generated to an extent 
observed in patients suffering from alcoholic cirrhosis (Takahashi et al., 1993). 
As observed with GSTs, a statistically significant risk was observed in alcoholic 
cirrhotic patients with variant genotype of MnSOD, an enzyme specifically involved in 
the detoxification of mitochondrial reactive oxygen species such as superoxide anion, 
when compared with non-alcoholic controls. The variant form of MnSOD (Ala/Ala + 
Val/Ala) is known to facilitate the enhanced translocation of MnSOD into mitochondria 
than the wild form (Val/Val). This enhanced translocation of MnSOD may result in 
increased detoxification of reactive oxygen species which are generated during chronic 
ethanol intake in the alcoholics. The detoxification of reactive oxygen species, in turn 
may lead to increased formation of hydrogen peroxide, which may not be efficiently 
detoxified by glutathione peroxidase and catalases, thus causing increased lipid 
peroxidation and mitochondrial damage in alcoholic cirrhotic patients (Li et al., 1998; 
Wallace, 1999; Sutton et al., 2003). Similar increase in the risk in alcoholic cirrhotic 
patients with variant genotypes of MnSOD when compared with non-alcoholic controls 
has been reported in earlier studies (Degoul et al., 2001; Nahon et al., 2005). Degoul et al. 
(2001) reported that the homozygosity for alanine in the mitochondrial targeting 
sequence of MnSOD does not change alcohol consumption in alcoholics but increases the 
risk of developing microvesicular steatosis by 3-fold, and that of alcoholic hepatitis and 
cirrhosis by 6 to 10 fold. Nahon et al. (2004) found higher Ala/Ala homozygous 
frequency in alcoholic cirrhotic and hepatocellular carcinoma patients than controls and 
presence of this Alanine allele increases the risk for developing cirrhosis in alcoholics. 
However, there are few reports which do not show the significant association of variant 
genotype of MnSOD with alcoholic liver disease (Steward et al., 2002; Brind et al., 
2003). 
Interestingly, our data demonstrating significantly elevated risk (OR: 2.8; 95%C1: 
1.3-6.06; p: 0.006) of alcoholic cirrhosis in patients with both the GSTMJ and GSTTl 
null genotypes is consistent with the hypothesis that combinations of various unfavorable 
deletion genotypes may theoretically confer an even higher risk to alcoholic cirrhosis. 
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Ladero et al (2005) have shown that individuals with deletions of both genes, GSTMl and 
GSTTl are at increased risk of developing the alcoholic liver diseases. The presence of 
both, GSTMl and GSTTl null genotypes was 3 times more frequent in cases with severe 
alcoholic liver diseases when compared to the controls. Since GSTs exhibit overlapping 
substrate specificity (Eaton, 2000), it is possible that simultaneous lack of both GSTMl 
and GSTTl enzyme activity may significantly reduce the ability of neutralizing the toxic 
effects of lipid peroxidation products or other end product of ethanol metabolism. Similar 
increase in risk to alcoholic cirrhosis cases was observed in cases who simultaneously 
carried the variant genotype ofGSTPl (IleA^al or Val/Val) and null genotype of GSTMl 
(OR: 2.8; 95%CI: 1.58-4.90; p: 0.000) or GSTTl (OR: 2.16; 95%CI: 1.08-4.28; p: 0.02) 
when compared to non-alcoholic controls, demonstrating significance of the genotypic 
combinations in the development of alcoholic liver cirrhosis. That the combination of 
deletions in GST isoforms could be involved in increasing the susceptibility to alcoholic 
liver cirrhosis was further evident in our study indicating approximately 6-fold increased 
risk (OR: 5.8; 95%CI: 2.17-15.80) to alcoholic liver cirrhosis in cases carrying 
combination of null genotypes of GSTMl, GSTTl and variant genotype of GSTPl 
(Ile/Val or VaWal) when compared to non-alcoholic controls. 
Our study further provided evidence that individuals who simultaneously carried 
polymorphism in CYP2E1, a phase I enzyme, involved in generating free radicals and 
GSTs, which detoxify there free radicals are at greater risk to alcoholic liver cirrhosis. 
Several fold increase in risk was observed in the alcoholic liver cirrhosis patients with the 
combination of variant genotypes of CYP2E1*5B and GSTPl or null genotype of GSTMl 
or GSTTl. This increase in risk is due to increased formation of reactive oxygen species 
and ethanol derived free radicals by the CYP2E1 polymorphic variants, which may not be 
detoxified because of deletion or variant genotype of GSTs. Though the number of cases 
who simultaneously carried variant genotypes of GSTs and CYP2E1 *5B was much higher 
when compared to the controls, greater magnitude of risk (upto-11-fold) observed in 
alcoholic cirrhosis patients could be attributed to the rare (1-2%) frequency of 
CYP2E1*5B in the controls because of which the number of individuals with the 
combination of variant genotypes was very low. Similarly, several fold increase in the 
risk in patients with alcoholic liver cirrhosis carrying combination of variant genotypes of 
CYP2E1*5B and MnSOD when compared with non-alcoholic controls or alcoholic 
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controls or non-alcoholic cirrhotic patients have further shown that increased frequency 
of CYP2E1 *5B leads to an increase in reactive oxygen species generation and because of 
the presence of the variant genotype of MnSOD, these individuals may not be able to 
detoxify them leading to their accumulation in alcoholic cirrhotic patients which 
eventually leads to enhanced mitochondrial damage and lipid peroxidation (Degoul et al., 
2001). 
Further evidence for the importance of genotypic combinations in the 
development of alcoholic liver cirrhosis was provided by the present study indicating 
significantly increased risk in the cases simultaneously carrying the null or variant 
genotypes of GSTs and MnSOD when compared to the patients with the risk genotypes of 
GSTs or MnSOD alone. Although the combination of MnSOD and GSTs allows the 
detoxification of mitochondrial ROS, an optimal balance must exist between these 
enzymes. It is well established that when there is more of MnSOD, or not enough GSTs, 
ie reactive oxygen species are being detoxified to hydrogen peroxide by MnSOD, but 
hydrogen peroxide not being detoxified by GSTs, thus MnSOD may becomes a toxifying 
rather than a detoxifying enzyme (Li et al., 1998; Esposito et al., 2000). As 
polymorphism in MnSOD has been shown to result in increased activity while a depletion 
of GSTs activity is reported with null genotype of GSTMl or GSTTl or different variant 
form of GSTPl, it may be possible that combination of the variant genotype of these two 
enzymes in individuals may result in increase in accumulation of reactive oxygen species 
rather than its detoxification. Alcoholics already have a basal imbalance in these 
enzymes. Ethanol on one hand, shown to induce the level of MnSOD but is also known to 
decrease the activity of GSTs (Femandez-Checa et al., 1991; Koch et al., 1994; Perera et 
al., 1995). Polymorphism in these two enzymes may further increase the imbalance with 
the increase in the level of Ala/Ala MnSOD homozygotes resulting in more of reactive 
oxygen species accumulation, mitochondrial damage or more of lipid peroxidation which 
may not be detoxified because of reduced activity of GSTPl or deleted enzyme activity 
due to null genotype of GSTMl or GSTTl in alcoholic cirrhotic patients. 
In conclusion, our data suggests that polymorphism in phase I enzyme such as 
CYP2EI particularly CYP2E1*5B and GSTs, MnSOD, the phase II enzymes are 
associated with an increased susceptibility to alcoholic cirrhosis. Haplotype analysis 
revealed that haplotype T-A-T, carrying variant allele of CYP2E1*5B, was associated 
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with increased risk for alcoholic cirrhosis. Risk to alcoholic cirrhosis was further found to 
increase in alcoholic cirrhotic patients carrying the combination of null or variant 
genotypes of GSTs. Likewise, several fold increased risk in the alcoholic cirrhotic cases 
carrying combinations of risk genotype of GSTs or CYP2E1*5B or MnSOD have 
suggested that interaction amongst the genes involved in ethanol metabolism and 
detoxification of reactive oxygen species may affect the balance between the generation 
of ROS and their detoxification and may be important in determining the susceptibility to 
alcoholic liver cirrhosis. 
CHAPTER-4 
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4.1 INTRODUCTION 
0xvi 'tudies in preceding chapter have shown that polymorphism in genes responsible 
for ethanol metabolism and detoxification such as CYP2E1, GSTs and MnSOD modifies 
the susceptibility to alcoholic liver cirrhosis. However, in contrast, to measuring genetic 
polymorphism and correlating them with other determinants of risk, another approach has 
been to measure interindividual variation in the expression of CYPs, involved in 
xenobiotic metabolism (Hayashi et al., 1994; Willey et al., 1997; Raucy et al., 1999). In 
recent years there has been great interest in developing assays that can be used as 
biomarkers of the extent and persistence of effects caused by exposure to toxic agents. 
Lymphocytes have obvious advantages for use in the development of non-invasive assays 
to screen human population for toxicant exposure and the applicability of these cell types 
as indicative of toxicant exposure has been well documented (Lucier et al., 1987; Harris, 
1989). Lymphocytes have been shown to express several members of CYP gene family, 
whose protein products are involved in the oxidative metabolism of wide variety of drugs 
and chemicals (Raucy et al., 1997; Dey et al., 2001, 2002). Recent studies from our 
laboratory have demonstrated the expression of xenobiotic metabolizing CYPs in freshly 
isolated unstimulated rat blood lymphocytes (Dey et al., 2001, 2002, 2005). 
Studies have shown that freshly isolated PBLs of human and laboratory animal 
express measurable levels of CYP2E1 mRNA and protein (Song et al., 1990; Raucy et 
al., 1997, 1999; Dey et al., 2002, 2005; Haufroid et al., 2003). Dey et al. (2002, 2005), 
earlier characterized CYP2E1 activity in freshly isolated and uncultured rat blood 
lymphocytes and reported significant increase in CYP2E1 dependent NDMA-J activity 
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and lipid peroxidation in freshly prepared lymphocytes isolated from ethanol pretreated 
rats. The increase in NDMA-i/ activity in rat blood lymphocytes was further found to be 
associated with increase in mRNA and protein expression of CYP2E1 (Dey et al., 2002, 
2005). RT-PCR studies showed that as observed in liver, acute treatment of ethanol 
resulted in increase in the mRNA expression of CYP2E1 in freshly isolated rat blood 
lymphocytes. Western blotting studies using polyclonal antibody raised against rat liver 
CYP2E1 demonstrated significant immunoreactivity, comigrating with the liver 
isoenzymes, in freshly isolated control rat blood lymphocytes. Thus these studies 
demonstrating similarities of the blood lymphocyte CYP2E1 with the liver enzyme 
suggest that lymphocyte CYP2E1 levels in freshly isolated rat blood lymphocytes could 
be used to monitor tissue enzyme levels (Dey et al., 2005). 
Since expression of CYP2E1 is altered by many factors affecting chemical 
metabolism and toxicity, monitoring of CYP2E1 levels in individuals, who are regular 
alcohol users or are exposed to environmental chemicals or carry certain 
pathophysiological changes which result in induction of CYP2E1, could help in 
identifying individuals who are at risk. The candidate in the present study therefore aimed 
to develop peripheral blood lymphocyte CYP2E1 expression as a possible biomarker of 
alcoholic cirrhosis by investigating mRNA and protein expression of CYP2E1 and 
associated catalytic activity in freshly prepared blood lymphocytes isolated from non-
alcoholic healthy controls, non-alcoholic cirrhotic and alcoholic cirrhotic patients. 
4.2 MATERIALS AND METHODS 
4.2.1 Chemicals 
N-nitrosodimethylamine (NDMA), NADPH, bovine serum albumin (BSA) 
and Histopaque 1077 were procured from Sigma-Aldrich, St. Louis, MI, U.S.A. 
Polyclonal rabbit anti-human CYP2E1 antibodies was procured from Chemicon, U.S.A. 
Oligo (dT)2o, RNAse out, dNTP mix, Reverse Transcriptase (RT), Taq DNA polymerase 
and all other reagent for PCR were procured from Fermentas, CANADA. All other 
chemicals used were of highest purity commercially available and procured either from 
E. Merck, India or Sisco Research Laboratories Pvt. Ltd., India. 
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4.2.2 Study group 
The study group consisted of eight patients suffering from alcoholic liver cirrhosis 
(non-cholestatic) and equal number of patients suffering from non-alcoholic liver 
cirrhosis visiting the OPD facility of Gastroenterology Department of Sanjay Gandhi Post 
Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India was included in the 
study. Eight healthy non-alcoholic individuals were also enrolled in the study and served 
as controls. Patients with alcoholic liver cirrhosis were diagnosed on the basis of their 
liver biopsy. All the alcoholic cirrhosis patients were negative for serum antinuclear and 
anti-mitochondrial antibodies and negative for antibodies to the hepatitis C virus. The 
hepatitis B surface antigen was also negative in all the eight alcoholic cirrhotic patients. 
Alcoholic cirrhotic patients were actively drinking alcohol prior to inclusion in the study. 
Patients with non-alcoholic liver cirrhosis were also diagnosed on the basis of their liver 
biopsy and out of the eight non-alcoholic cirrhotic patients three were positive for 
hepatitis B surface antigen and five were positive for antibodies against hepatitis C virus. 
Non-alcoholic control group did not showed any evidence of liver disease as judged by 
physical examination and normal liver function test. It was ensured that the alcoholic and 
non-alcoholic cirrhotic patients and non-alcoholic controls belonged to the same ethnicity 
(Indo-European community) of North India. Table 4.1 summarizes the main 
characteristics of the individuals enrolled in the study. 
The protocol for research work was approved by the human ethics committee of 
Indian Institute of Toxicology Research (IITR), Lucknow and it conforms to the 
provisions of the declaration of Helsinki in 1995. Informed consent was obtained from 
the study subjects for inclusion in the study and before the collection of blood samples it 
was ensured that the subject anonymity was preserved. All study subjects completed a 
questionnaire covering medical, residential and occupational history. The questionnaire 
also included details such as frequency of alcohol intake. Subjects who consumed less 
than 1 Og/day of alcohol were classified as non-alcoholics. Approximately 4 ml of blood 
was collected from each subject. RNA was isolated from 0.5ml of whole blood while 3ml 
of blood was used for preparing lymphocytes. Lymphocytes were used for enzyme 
estimation and ELISA studies while RT-PCR and semi-quantitative RCR studies were 
carried out with total RNA isolated from whole blood. Though correlation has been 
reported for CYP2E1 mRNA and protein in blood lymphocytes of alcoholic and non-
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Table 4.1: Main characteristics of study group 
Non-alcoholic Non-alcoholic Alcoholic 
controls cirrhosis cirrhosis 
Number of sample 
Mean age 
Alcohol consumption 
(mean ± SD) 
gm/day 
Duration (Years) 
Histology 
8 
39 ±9.2 42 ± 7.6 
Non-cholestatic 
early stage 
cirrhosis 
45 ±9.8 
135 ±12 
14 ±3.6 
Non-cholestatic 
early stage 
cirrhosis 
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alcoholics (Raucy et al., 1999), CYP2E1 is known to be regulated at various levels such 
as pre-transcription, transcription, pre-translation, translation and post-translation (Ronis 
et al., 1996). Therefore in the present study, CYP2E1 mRNA, protein and activity of 
NDMA-t/, a marker of CYP2E1 catalyzed reaction, were investigated in freshly isolated 
blood lymphocytes. ELISA was preferred over western immunoblotting as it required 
lesser amount of lymphocyte protein when compared to immunoblotting studies. 
4.2.3 RNA isolation 
Total RNA was extracted from whole blood by RiboPure-blood kit (Ambion 
USA) according to manufacturer protocol. 500 |al of anti-coagulated blood was centrifuge 
at 13,200rpm and pellet was lysed with 800|il of lyses solution and 50 ,^1 sodium acetate. 
500^1 of acid phenol: chloroform was added to separate the aqueous and organic phase. 
600|al of 100% ethanol was added to the aqueous phase and contents were transferred to 
the filter cartridge assembly supplied with kit. After centrifligation at 13,200 rpm the 
RNA was washed with wash solution 1 and wash solution 2/3 (supplied with kit). RNA 
was eluted with suitable amount of elution solution. Eluted RNA was used for cDNA 
synthesis. 
4.2.4 Semi-Quantitative RT-PCR analysis 
Total RNA isolated from whole blood of healthy controls and patients suffering 
from alcoholic and non-alcoholic cirrhotic patients were analyzed for CYP2E1 mRNA by 
RT-PCR analysis. cDNA was prepared from total RNA with Reverse Transcriptase (RT) 
enzyme (].5U/^1) in a reaction mixture containing cDNA synthesis buffer, 0.0IM DTT, 
4U/nl RNAse out, and 2mM dNTPs and incubating them at 50°C for 60min. 2)il of this 
RT product was used for subsequent PCR reactions. The reaction mixture for PCR of 
CYP2E1 in 25 ^1 contained lOX PCR buffer, 1.5 mM MgCb, 0.2 mM dNTP mix, 0.5 
\iU of each CYP2E1 primers, 2 ^1 of cDNA and 1 i^l Taq enzyme. The details of the 
sequence of primers used for CYP2E1 have been described earlier (Hakkola et al., 1994). 
PCR was carried out in Gene Amp PCR system 9700 of Applied Biosystem using 35 
cycles of denaturation at 94°C for 5 min, annealing of primers at 60°C for Imin, 
extension at 72^C for 1.5 min and final extension at 72°C for 10 min. Prior to 
amplification of CYP2E1, normalization was carried out with P-actin, the house keeping 
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gene. The PCR reaction for p-actin contains lOX PCR buffer, 1.5 mM MgCl2, 0.2mM 
dNTP mix, 0.5 |iM of each J3-actin primers (Hakkola et al., 1994), 2 \x\ of cDNA and 1 \i\ 
Taq enzyme. PCR was carried out using 35 cycles of denaturation at 94°C for 5 min, 
annealing of primers at 59°C for 1 min, extension at 72°C for 1.5 min and final extension 
at 72°C for 10 min. PCR products (365bp for CYP2E1 and 541bp for 13-actin) were 
analyzed by electrophoresis in 2.5% and 1.8% agarose gel respectively stained with 
ethidium bromide in VERSA DOC Imaging system. Model 1000 (Biorad, USA). 
Densitometric analysis of the bands was carried out using Quantity One Quantitation 
Software version 4.3.1 (Biorad, U.S.A). 
4.2.5 Quantitative Real Time PCR (RT-PCR) Analysis 
For Quantitative PCR, cDNA was synthesized by High-Capacity cDNA Reverse 
Transcription Kit provided by Applied Biosystems. For RT, the reaction mixture in 20^1 
contained 10^1 2X master mix [2X RT buffer (2^1), 0.8 mM dNTP Mix (0.8^1), 2X 
Random Primers (2^1), RNase Inhibitor (1^1), 1^ 1 MultiScribe Reverse Transcriptase and 
3.2|al Nuclease-free H2O] and an equal volume of diluted RNA sample. RT reaction was 
carried out in a thermal cycler consisting of 1 cycle of 25°C for 10 min, 37°C for 120 min 
and 85°C for 5 sec followed by placing the reaction vial at 4°C. The PCR reaction 
mixture for CYP2Eland B-actin in 20(xl contained IX TaqMan Universal PCR Master 
Mix provided by Applied Biosystems, 0.5nM of each primer, 0.2|iM of probe, l\i.\ cDNA 
and Nuclease-free H2O. TaqMan assays for each gene target were performed in triplicate 
on cDNA samples in 96-well optical plates on an ABI 7900HT Fast Real-Time PCR 
System (Applied Biosystems). PCR parameters were 50°C for 2 min, 95°C for 10 min, 40 
cycles of 95°C for 15 s and 60°C for 1 min. 
4.2.6 Lymphocyte isolation 
Lymphocytes were isolated from the blood by the method of Boyum (Boyum, 
1968) with slight modifications. In brief, 4.0 ml of whole blood was diluted with 4.0 ml 
of phosphate buffered saline (PBS), pH 7.4, and carefully layered over 2.0 ml of 
Histopaque 1077. After centrifugation at 400 x g for 30 min at room temperature, the 
upper layer was discarded and the opaque interface containing mononuclear cells was 
transferred into a clean centriftage tube. After repeated washing of the lymphocytes with 
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PBS and recentrifugation at 250 x g, the resulting pellet was resuspended in 0.5 ml of 
PBS and used for enzyme estimations. 
4.2.7 Protein estimation 
Protein content of the samples was estimated by the method of Lowry et al. 
(1951). Suitable volume of protein sample was diluted to 1.0 ml with distilled water and 
to 1.0 ml aliquot, 5.0 ml of alkaline copper reagent (2% copper sulphate, 2% sodium 
potassium tartarate, 2% sodium carbonate in 0.2N sodium hydroxide) was added. The 
solution was kept for 10 minutes at room temperature. The final color was developed by 
the addition of 0.5 ml of Folin Ciocalteau phenol reagent (IN). The intensity of the color 
developed 30 minutes later was measured at 660 nm in a spectrophotometer. The amount 
of protein in the sample was determined by comparing it with the standard protein curve 
ofBSA. 
4.2.8 Enzyme assay 
NDMA-d activity was assayed by the method of Dey et al. (2002). The assay 
mixture contained a suitable amount of lymphocytes, 70.0 mM Tris-HCl, pH 7.4, 10.0 
mM semicarbazide, 14.0 mM MgC12, 215.0 mM KCl, 1.0 mM NADPH and 4.0 mM 
NDMA in 1.0 ml final volume. The reaction mixture was incubated at 37°C for 30 
minutes and the reaction was stopped by the addition of 1.5ml of 12.5% TCA solution. 
After centriftigation at 2000 rpm for 10 minutes, 2 ml of the supernatant was mixed with 
an equal amount of Nash reagent. The tubes were then incubated at 70°C for 20 min and 
the HCHO formed was measured at 415 nm (Nash, 1953). 
4.2.9 Enzyme-linked immunosorbent assay (ELISA) 
Polyvinyl chloride 96-well plates (Falcon) were coated with poly L-lysine and 
washed twice with double distilled water. Protein were then bound on 96-well plates 
overnight at 4'^ C with sequentially increasing concentrations (from 0.001 ng to lOOng) in 
phosphate buffered saline (PBS, 0.1 M phosphate buffer, 150 mM NaCl, pH 7.2). The 
binding step(s) was followed by a blocking step by incubating of the plates with 4% 
BSA, 5% sucrose and 0.05% sodium azide (NaNs) in PBS for 2 hours at room 
temperature. The plates were then washed twice for 15 min with wash buffer (0.05% 
Tween 20 in PBS). Primary rabbit anti-human CYP2E1 antibodies and secondary 
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alkaline phosphatase (AP) conjugated anti-rabbit IgG antibodies were diluted 
appropriately with 20 mM Tris (pH 7.5), 2% BSA, 0.05% Tween 20, 150 mM NaCl. 
Plates were incubated with primary antibody for 1 h at ambient temperature, followed by 
two wash-steps. Incubation with secondary antibodies was also carried out for 1 h at 
ambient temperature. Two 15-min wash steps were done in the buffer described above, 
and a final 15-min step was done in PBS without additives. The bound AP conjugate was 
detected by adding lOO/il of p-nitrophenyl phosphate (PNPP). The alkaline phosphatase 
reaction was stopped after 20 min by the addition of 50^1 of 3 MNaOH. Optical densities 
at 405 nm were measured using an ELISA plate reader. The assay was performed in 
triplicates. 
4.2.10 Statistical analysis 
Students 't' test was employed to calculate the statistical significance between 
non-alcoholic control and cirrhotic patients. p<0.05 was considered to be significant 
when compared with the non-alcoholic controls. 
4.3 RESULTS 
Total RNA was isolated from blood of eight non-alcoholic controls and equal 
number of sex matched alcoholic and non-alcoholic liver cirrhotic patients, CYP2E1 
mRNA were quantified by RT-PCR and Real Time PCR, as described under Materials 
and Methods, using a set of forward and reverse primers that ensured a specific CYP2E1 
cDNA amplification. In order to improve the accuracy and precision of the correlation 
studies, mRNA expression of the P-actin, a house keeping gene, was also studied and the 
abundance of CYP2E1 mRNA was normalized against the house keeping gene. 
4.3.1 Semi-Quantitative PCR analysis 
PCR amplification of the RT product obtained from the RNA isolated from non-
alcoholic controls, with the primer pairs of P-actin, resulted in the formation of PCR 
products of expected band size of 541bp. As evident from figure 4.1 A almost equal 
intensity of the PCR product was obtained from the PCR amplification of the RT product 
isolated from RNA extract from blood lymphocytes of non-alcoholic control or non-
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alcoholic cirrhotic or alcoholic cirrhotic patients (Figure 4.1 A and 4.IB). Results of PCR 
amplification of RT products obtained from RNA isolated from the whole blood of non-
alcoholic controls or non-alcoholic cirrhotic or alcoholic cirrhotic patients, with primers 
specific for CYP2E1 are shown in figure 4.2A. As evident from the figure, PCR product 
of expected band size of 365 bp were formed with the RNA isolated from the blood of 
non-alcoholic controls or non-alcoholic cirrhotic or alcoholic cirrhotic patients. 
Densitometric analysis of the PCR products revealed that the intensity of the bands was 
higher in the PCR products obtained from blood lymphocytes of patients suffering from 
alcoholic liver cirrhosis when compared to non-alcoholic controls or non-alcoholic 
cirrhotic patients (Figure 4.2A). As evident from figure 4.2B, mRNA expression of 
CYP2E1 in alcoholic cirrhotic patients was found to be 1.9 and 1.6-folds higher than non-
alcoholic controls and non-alcoholic cirrhotic patient respectively which was found to be 
statistically significant. No significant change was however, observed in the mRNA 
expression of CYP2E1 in non-alcoholic cirrhotic patients when compared with non-
alcoholic controls (Figure 4.2A). 
4.3.2 Quantitative Real-Time PCR (RT-PCR) Analysis 
To validate the data of semi-quantitative PCR, RT-PCR was also carried out to 
study the mRNA expression of CYP2E1 in lymphocytes of non-alcoholic control, non-
alcoholic cirrhotic and alcoholic cirrhotic patients. The mRNA expression of 
housekeeping gene (P-actin) was used as an endogenous control. The expression of p-
actin was found to be uniform throughout all the samples (control and patients) analyzed 
confirming the integrity of RNA used in assays. RT- PCR clearly demonstrated that the 
mRNA expression of CYP2E1 in alcoholic cirrhotic patients increased 2-fold in blood 
lymphocytes when compared to the non-alcoholic controls. This increase in CYP2E1 
mRNA expression in the alcoholic cirrhotic patient was found to be statistically 
significant (Table 4.2). A 1.4-fold higher induction was also observed in the mRNA 
expression of CYP2E1 blood lymphocytes isolated from non-alcoholic cirrhotic patients 
when compared with non-alcoholic controls which was found to be statistically 
significant (Table 4.2). 
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Table 4.2: Fold induction of CYP2E1 by Real Time PCR analysis in 
blood lymphocytes of non-alcoholic cirrhotic patients and alcoholic 
cirrhotic patients when compared with non-alcoholic controls 
Fold Induction 
Non-alcoholic cirrhosis (NACP) 1.41 * + 0.06 (n=8) 
Alcoholic cirrhosis (ACP) 1.96* ± 0.09 (n=8) 
All the values are mean +.S.E. of eight NACP & ACP. 
* p<0.001 when compared with non-alcoholic controls. 
Figure in parenthesis indicate number of NACP & ACP. 
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4.3.3 N-nitrosodimethylamine demethylase (NDMA-d) activity 
The catalytic activity of CYP2E1 dependent NDMA-d in blood lymphocytes of 
healthy non-alcoholic controls and patients suffering non-alcoholic and alcoholic liver 
cirrhosis is summarized in table 4.3. As evident from the table the specific activity of 
CYP2E1 in the peripheral blood lymphocytes of alcoholic cirrhotic patients was found to 
be significantly higher (1.3 fold) when compared with non-alcoholic controls or non-
alcoholic cirrhotic patients. In contrast no significant change in the NDMA-d activity was 
observed in the blood lymphocytes of non-alcoholic cirrhotic patients when compared 
with non-alcoholic controls (Table 4.3). 
4.3.4 Enzyme-linked immunosorbent assay (ELISA) 
Figure 4.3 summarizes the CYP2E1 protein activity using ELISA at different 
protein concentration in non-alcoholic controls, non-alcoholic cirrhotic patients and 
alcoholic cirrhotic patients. Consistent with the mRNA expression studies, the results 
from ELISA also indicate that CYP2E1 protein was expressed in blood lymphocytes of 
non-alcoholic controls, non-alcoholic cirrhotic and alcoholic cirrhotic patients. As 
evident from figure 4.3, the level of CYP2E1 protein in blood lymphocytes of all the 
three groups gradually increased with the increase in protein concentration. Maximum 
activity was found at 100 |ag of protein concentration and the protein expression in blood 
lymphocytes of alcoholic cirrhotic patients was found to be higher when compared to 
non-alcoholic controls or non-alcoholic cirrhotic patients (Figure 4.3). As evident from 
the figure, the CYP2E1 protein activity in the peripheral blood lymphocytes of alcoholic 
cirrhotic patients was found to be 1.25-fold higher than non-alcoholic controls. However, 
no statistically significant change was observed in CYP2E1 protein in the blood 
lymphocytes of non-alcoholic cirrhotic patients when compared with non-alcoholic 
controls (Figure 4.3). The CYP2E1 protein expression in blood lymphocytes of alcoholic 
cirrhotic patients was found to be increased (1.15-fold) when compared with non-
alcoholic cirrhotic patients which however, was not found to be statistically significant 
(Figure 4.3). 
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Table 4.3: CYP2E1 dependent N-nitrosodimethylamine demethylase 
(NDMA-d) activity in blood lymphocytes of non-alcoholic controls, non-
alcoholic cirrhotic patients and alcohoUc cirrhotic patients 
Specific Activity 
Non-alcoholic Control 1.78 + 0.026 (n-8) 
Non-alcoholic cirrhosis (NACP) 1.90 + 0.038 (n=8) 
Alcoholic cirrhosis (ACP) 2.36* ± 0.123 (n-8) 
Values are expressed in n moles HCHO/min/mg protein. 
All the values are mean j^S.E. of eight control and patients. 
* p<0.001 when compared with control and non-alcoholic cirrhotic patients. 
Figure in parenthesis indicate number of non-alcoholic controls and patients 
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4.4 DISCUSSION 
Consistent with earlier reports (Song et al., 1990; Raucy et al., 1997, 1999; 
Haufroid et al., 2003, 2005), the present study has provided evidence for the mRNA 
expression of CYP2E1 in freshly isolated peripheral blood lymphocytes of healthy 
individuals. Though CYP2E] is primarily a hepatic enzyme, studies have shown that 
CYP2E1 mRNA is expressed in peripheral blood lymphocytes of human (Song et al., 
1990) and laboratory animals (Soh et al., 1996; Dey et al., 2002, 2005). The expression 
of CYP2E1 in these uncultured and unstimulated peripheral blood lymphocytes is 
regulated in a manner similar to that observed in the liver (Song et al., 1990; Raucy et al., 
1997, 1999). Our study using ELISA has further showed that CYP2E1 protein was 
expressed in control blood lymphocytes isolated from healthy individuals. As mRNA and 
protein were elevated concordantly in the peripheral blood lymphocytes following 
exposure to ethanol (Raucy et al., 1999) and western immunoblotting required larger 
amounts of blood sample, ELISA was used to study protein expression instead of 
blotting. Earlier studies using western immunoblotting have indentified the expression of 
CYP2E1 in blood lymphocytes isolated from humans (Song et al., 1990; Raucy et al., 
1997). Western immunoblotting with freshly prepared peripheral blood lymphocytes 
isolated from experimental animals also revealed constitutive as well as inducible 
expression of CYP2E1 protein (Raucy et al., 1995; Dey et al., 2002, 2005). 
CYP2E1 mRNA and protein expressed in blood lymphocytes was further found to 
be catalytically active as reflected by the present study indicating significant activity of 
NDMA-d in freshly prepared peripheral blood lymphocytes isolated from healthy 
individuals. Previous studies have also shown that freshly prepared blood lymphocytes 
were found to catalyse the demethylation of N-nitrosodimethyamine (NOMA) and 
NADPH dependent lipid peroxidation in Wistar rats. Similarities were observed in the 
NADPH dependent lipid peroxidation and NDMA-t/ activity in the blood lymphocytes 
with liver microsomes further suggesting that CYP2E1 lymphocytes levels in freshly 
isolated peripheral blood lymphocytes could be used to monitor tissue enzyme levels 
(Dey et al., 2002, 2005). Using chlorzoxazone as a substrate to monitor CYP2EI 
catalyzed reactions, Raucy et al. (1997, 1999) reported that freshly isolated peripheral 
blood lymphocytes catalyze the oxidation of chlorzoxazone in healthy individuals. Raucy 
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et al. (1999) have further reported that ethnicity does not play a major role in the 
constitutive expression of CYP2E1 in the lymphocytes as the levels of CYP2E1 mRNA 
and protein were found to be similar among the healthy Whites, Novajo and Mexican-
American ethnic groups. 
A significant increase in the CYP2E1 mRNA expression in freshly prepared 
peripheral blood lymphocytes isolated from alcoholic liver cirrhotic patients when 
compared to the non-alcoholic controls or non-alcoholic cirrhotic patients is in agreement 
with the earlier studies (Yano et al., 2001; Jones et al., 2002) indicating that CYP2E1 
expression increases significantly in patients suffering from alcoholic liver disease. 
Chronic ethanol consumption is known to increase the expression of CYP2E1 in liver 
which increases the formation of reactive oxygen species leading to the liver damage 
(Lieber, 1991, 1998). Yano et al., (2001) reported that CYP2E1 mRNA levels of 
mononuclear cells in alcoholic healthy controls increased almost 100-times compared 
with non-alcoholic healthy controls. Interestingly, when these subjects abstained from 
drinking, this increase in CYP2E1 mRNA decreased to the levels observed in non-
alcoholic healthy subjects by 4-days of abstinence (Yano et al., 2001). Further, CYP2E1 
mRNA levels in patients with alcoholic liver disease were found to be almost similar to 
that observed in alcoholic healthy subjects. However, progression of the disease to 
hepatic fibrosis and cirrhosis did not resulted in any significant difference in CYP2E1 
mRNA levels suggesting that CYP2E]mRNA in mononuclear cells may not be 
influenced by the progression of disease (Yano et al., 2001). Studies in laboratory 
animals have also shown that the expression of CYP2E1 mRNA and protein in the 
lymphocytes is influenced by the same factors that affect the concentration of hepatic 
enzymes. CYP2E1 induction by either ethanol or fasting occurred both in liver and 
lymphocytes in a parallel manner (Soh et al., 1996; Raucy et al, 1997, 1999; Dey et al., 
2002, 2005). 
That the increased mRNA expression of CYP2E1 in blood lymphocytes of 
alcoholic cirrhotic patients leads to increased protein expression and associated enzyme 
activity was demonstrated by an increase in the CYP2E1 immunoreactive protein and 
NDMA-c? activity in the blood lymphocytes of alcoholic liver cirrhotic patients when 
compared with non-alcoholic controls or non-alcoholic cirrhotic patients. Raucy et al., 
(1997) also reported a 2-fold increase in the CYP2E1 immunoreactive protein in 
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alcoholics when compared with non-alcoholic controls. This increase in lymphocyte 
CYP2E1 content in alcoholic subjects was associated with nearly 2-fold increase in 
chlorzoxazone clearance rate and a 2-fold decrease in the AUC for chlorzoxazone. Dey et 
al. (2002, 2005) who characterized CYP2E1 activity in freshly isolated and uncultured rat 
blood lymphocytes also reported significant increase in CYP2E1 dependent NDMA-<i 
activity and lipid peroxidation in freshly prepared lymphocytes isolated from ethanol 
pretreated rats. The increase in NDMA-c? activity in rat blood lymphocytes was further 
found to be associated with increase in mRNA and protein expression of CYP2E1 (Dey 
et al., 2002, 2005). The increase in CYP2E1 protein expression and associated NDMA-t/ 
activity observed in the blood lymphocytes of alcoholic cirrhotic patients in present study 
is in agreement with earlier reports demonstrating a higher chlorzoxazone oxidation in 
patients with alcoholic liver disease when compared with alcoholics without clinical and 
biochemical signs of liver disease suggesting the role of CYP2E1 in the development of 
alcoholic liver disease (Dupont et al., 1998). Dilger et al. (1997) also showed a 3-fold 
increase in chlorzoxazone oxidation in actively drinking patients with alcoholic liver 
disease when compared with abstaining patients with the disease. Elevated CYP2E1 
activity as measured by chlorzoxazone metabolism was found to rapidly decline during 
withdrawal of alcohol. The contribution of CYP2E1 inducibility as a risk factor for the 
development of alcoholic liver disease has also been shovsoi in experimental studies using 
chronic ethanol-fed rats, in which the modulation of CYP2E1 by treatments with 
diallylsulfide or phenylethylisothiocyanate, specific inhibitors of CYP2E1, reduced the 
extent of alcohol induced liver damage (Albano et al., 1996) 
A significant increase observed in the CYP2E1 mRNA expression in freshly 
isolated peripheral blood lymphocytes of non-alcoholic liver cirrhotic patients when 
compared to the non-alcoholic controls could be attributed to the hepatitis C virus 
infection. CYP2E1 activation has been proposed to be one potential factor responsible for 
the progression of fibrosis in chronic hepatitis C disease. In hepatitis C virus (HCV) 
infected patients, the presence of hepatic steatosis has been associated with the increased 
expression of CYP2E1 mRNA in the liver (Gochee et al., 2003), In contrast, Haufroid et 
al. (2005) did not observed induction in CYP2E1 activity either in liver or blood 
lymphocytes of chronic HCV patients, mainly without cirrhosis, suggesting absence of 
relationship between CYP2E1 induction and patients with early stages of hepatitis C 
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infection. However, as almost none of patients included in the study exhibited 
histological fibrosis, Haufroid et al. (2005) suggested that that the development of 
cirrhosis in chronic HCV patients may be associated with an increase in CYP2E1 
activity. 
Interestingly, our data indicating increase in CYP2E1 mRNA and protein 
expression and NDMA-d activity in the freshly isolated peripheral blood lymphocytes of 
alcoholic liver cirrhotic patients when compared with the non-alcoholic controls is in 
contrast to the earlier reports indicating a decrease in hepatic CYP2E1 activity in 
cirrhotic patients (George et al., 1995). CYP2E1 was found to be reduced in microsomes 
of cirrhotic livers from patients with cholestasis, but not in other non-cholestatic cirrhotic 
livers. The reasons for this inconsistency could be due to the fact that our study involved 
the actively drinking individuals with non-cholestatic early stage of alcoholic liver 
cirrhosis, whereas the study of George et al. (1995) included the non-drinking patients 
suffering from cholestatic end stage of cirrhosis. Cholestatic cirrhosis has been shown to 
lead to the accumulation of bile acids in the liver which induces cellular oncotic necrosis 
and apoptosis leading to cell death (Spivey et al., 1993). It is however not clear whether 
this oncotic necrosis and apoptosis leads to reduced CYP2E1 activity or whether necrosis 
and apoptosis is a consequence of altered CYP2E1 activity. Dilger et al. (1997) have also 
reported continuously decreasing CYP2E1 activity in non-drinking or abstaining patients 
with progressively severe manifestations of alcoholic liver disease. Using bile duct 
ligation and carbon tetrachloride (CCl4)-induced models of cirrhosis, Bastien et al. (2000) 
also reported that the CYP content and the individual CYP isoenzymes are differentially 
altered by cirrhosis in the rats. In rats with mild cirrhosis, CYP contents and the activity 
of CYP1A2, 2C and 3A isoenzymes were comparable with the controls while an increase 
in the activity of CYP2E1 was observed. In rats with more severe form of cirrhosis the 
contents of all the four CYPs were found to be reduced (Bastien et al., 2000). 
In conclusion, the results of the present study have shown the CYP2E1 mRNA is 
expressed in freshly prepared uncultured human blood lymphocytes. Significant increase 
in the CYP2E1 mRNA and protein expression and associated NDMA-d activity in the 
freshly prepared blood lymphocytes isolated from non-cholestatic alcoholic liver cirrhotic 
patients when compared to non-alcoholic controls and non-alcoholic cirrhotic patients 
have shown that blood lymphocytes CYP2E1 could possibly be used to predict alcohol 
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induced toxicity as reported in experimental animals (Raucy et al., 1995; Dey et al 2002, 
2005). Further this increase in CYP2E1 mRNA expression and protein activity in freshly 
prepared blood lymphocytes of alcoholic liver cirrhotic patients with early stage of 
alcoholic cirrhosis have indicated suitability of using blood CYP2E1 mRNA expression 
profile as a biomarker to detect the hepatic level of CYP2E1. 
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Summary 
Cytochrome P450 (CYP) is a multigene family of constitutive and inducible 
enzymes which catalyze oxidative metabolism of a wide variety of xenobiotics, of both 
endogenous and exogenous origin. Though several distinct CYP gene families are 
expressed in mammals, four of these CYP gene families (CYP 1-4) are recognized to be 
the major forms of CYPs that metabolize foreign chemicals including drugs, 
environmental chemicals and other xenobiotics. Alteration in the expression of these 
CYPs has been often found to be associated with exposure of drugs and environmental 
chemicals. Specific and selective expression profiles of these CYPs are observed 
following treatment of specific drugs and environmental chemicals. Genetic 
polymorphism is reported for several of the xenobiotic metabolizing CYPs and the 
susceptible genotypes are reported to be at increased risk to the toxicity of drugs and 
chemicals. Genetic variations in the CYPs are often an emerging resource for studying 
various complex diseases and have been identified as biomarker of susceptibility. Much 
of the variability in the CYPs is in the form of stable substitution of a single base termed 
as the single nucleotide polymorphism (SNP). Although SNPs in CYPs have been found 
to be present in all the population, the frequencies of these polymorphisms differ between 
populations. In general, SNPs occurring in the coding region have the potential to alter 
protein structure and function and therefore could be the causative factor influencing 
disease susceptibility, drug efficacy and xenobiotic response. SNPs in CYPs can cause 
abolished, quantitatively altered or enhanced xenobiotic metabolism leading to enhanced 
or diminished toxicity of a chemical or adverse drug effects. In addition, recent studies 
136 
Summary 
have shown that CYPs are expressed in blood lymphocytes and could be used as a 
phenotypic tool and biomarker to predict exposure of drugs and environmental changes. 
Cytochrome P450 2E1 (CYP2E1) is a major component of the microsomal ethanol 
oxidizing system in the liver. It exhibits a high degree of inter-individual variability in its 
catalytic activity. To date, several mutations have been described in CYP2E1 gene which 
are well characterized in the Caucasian as well as in Oriental population. Further, these 
SNPs in CYP2E1 play a major role in determining individual's susceptibility to alcoholic 
liver diseases such as alcoholic liver cirrhosis, a chronic liver disease results from 
damage to liver cells from heavy alcohol consumption. As compared to the data available 
in other population worldwide, not much is known about the SNPs in CYP2E1 in Indian 
population. Only few case-control studies are available while no population based study 
have been carried out to investigate the genotype status of CYP2E1 gene in Indian 
populations. Studies have shown that Indian population has more human diversity than 
any other comparable global population in the world. It is likely that the SNPs found in 
the genes involved in the ethanol metabolism pathway may be conserved and these could 
be exploited to identify the risk factors for the environment induced diseases. Further the 
CYP2E1 protein activity and mRNA expression is also known to increase several fold in 
the liver of experimental animals following alcohol administration suggesting that 
CYP2E1 is regulated at various levels such as pretranscriptional, pretranslational, 
translational, and posttranslational. This increase in CYP2E1 activity results in 
accumulation of toxic acetaldehyde and reactive oxygen species in the cell which may 
lead to mitochondrial damage, DNA modification and lipid peroxidation. Studies have 
also shown that freshly isolated peripheral blood lymphocytes of human and laboratory 
animal express measurable levels of CYP2E1 mRNA and protein. Expression of CYP2E1 
mRNA and protein in the peripheral blood lymphocytes is known to be influenced by the 
same factors that affect the concentration of hepatic enzymes including exposure to 
xenobiotics and certain physiological states particularly those associated with higher 
plasma cholesterol. Since expression of CYP2E1 is altered by many factors affecting 
chemical metabolism and toxicity, monitoring of CYP2E1 levels in individuals, who are 
regular alcohol users could help in identifying individuals who are at risk to develop 
alcohol induced toxicity. 
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The candidate in the present dissertation has therefore attempted to identify the 
SNPs, including novel ones in CYP2E1 gene in the different sub-population of India. 
Attempts were also made by the candidate in a case-control study to investigate 
association of functionally important SNPs in CYP2E1 gene identified in Indian 
population along with the other candidate genes such as glutathione S-transferases 
(GSTs) and manganese superoxide dismutase (MnSOD), responsible for detoxifying 
electrophilic intermediates including free radicals generated during the ethanol 
metabolism. Studies were also initiated by the candidate to develop peripheral blood 
lymphocyte CYP2EI expression as a possible biomarker of alcoholic liver cirrhosis by 
investigating mRNA and protein expression of CYP2E1 and associated catalytic activity 
in freshly prepared blood lymphocytes isolated from alcoholic cirrhotic patients. 
To identify SNPs in Indian population, different population were identified based 
on diverse geographical zones (North, South, East, West, Central and North-East) and 
linguistic backgrounds (Indo Europeans-IE, Dravidians-DR, Tibeto Burmans-TB and 
Austro Asiatics-AA) to maximize novel SNP discovery. Molecular diversity studies have 
revealed that Austro-Asiatic (AA) language speakers are exclusively tribals and are likely 
to have been the most ancient inhabitants of India. Populations of Indo-European (IE) and 
Dravidian (DR) lineage groups account for almost 85% of the total Indian population, 
while the Tibeto-Burman (TB) lineage groups are supposedly immigrants to India from 
Tibet and Burma. These diverse set of sub-population does increase the heterogeneity in 
terms of SNP discovery as compared to a set of samples from a single sub-population. 
These population were identified after consultation with the expert anthropologists. 
Blood samples were collected from different sub-population of India by the Indian 
Genome Variation (IGV) Consortium members including IITR, Lucknow. Genomic 
DNA samples were provided by IGV Consortium for identifying SNPs in CYP2E1. Five 
pairs of primers for CYP2E1 gene were designed with the aim to cover the exonic region 
as well as the regions carrying functionally important SNPs using the DNA Star software. 
The first step involved discovering SNPs in CYP2E1 gene in one representative 
DNA sample drawn from 43 different sub-populations and designated as SNP Discovery 
Panel. Though 43 individuals per se do not represent the entire Indian population, such a 
diverse set does increase the heterogeneity in terms of SNP discovery as compared to a 
set of samples from a single sub-population. The SNPs identified in these Discovery 
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panel samples were than validated in the second step in a larger sample size of these 
populations. SNPs in CYP2E1 gene in SNP Discovery Panel were identified by 
bidirectional sequencing of PCR products using primer pairs that covered functionally 
important polymorphism of CYP2E1 gene. Five polymorphic sites including a novel one 
were identified in CYP2E1 gene and were designated as SNPl (-930A/G; rs3813870) in 
5'UTR, SNP2 (6396G/A; Novel) in exon 6, SNP3 (7126G/A; rs8192775), SNP4 
(7632T/A; rs6413432) and SNP5 (8057C/A; rs2864984) in intron 6. Out of these five 
SNPs, SNP2 (6396G/A) was considered as novel because no information or any literature 
was available in any existing databases about this SNP. SNPl was found to be 
polymorphic in all the four major sub-population (AA DR, IE and TB) with minor allele 
frequency (MAF) of 0.26. SNP2 was found to be novel and polymorphic in only one sub-
population (DR) with very low minor allele frequency (0.01). SNP3 which is present in 
intron-6 was found to be polymorphic in the three sub-population (AA, DR and IE) with 
the minor allele frequency of 0.05. Similarly, SNP4 commonly known as Dral 
polymorphism or CYP2E1 *6, was found to be polymorphic only in IE population with 
minor allele frequency of O.OI. Likewise, SNPS also located at intron-6 was found to be 
polymorphic in three sub population (AA, DR and IE) with minor allele frequency of 
0.05. SNPs identified as SNPl-5 at -930A/G (5'UTR), 6396G/A (exon 6), 7126G/A 
(intron 6), 7632T/A (intron 6) and 8057C/A (intron 6) in CYP2E1 gene were considered 
for further validation in a larger sample size because of their higher minor allele 
frequency. Interestingly, one of the major functionally important SNP, designated as Rsal 
or CYP2E1 *5B was not present in any of the 43 representative DNA sample. Since the 
frequency of this polymorphism is very rare in Indian population (1%), it may be possible 
that the 43 representative DNA sample from different sub-population of India may not be 
carrying this SNP. It may be possible that if larger samples were screened, this SNP could 
have been identified. 
Validation data of SNPs in CYP2E1 gene in different Indian sub-population further 
provided evidence that CYP2EI gene is polymorphic in all the Indian sub-population. The 
five SNPs discovered in Discovery Panel were found to exist in Indian population with 
varied frequency. SNPl was found to be present in all the linguistically and 
geographically diverse population of India. As the SNPl was present in most of the 
population of India, it can be concluded that this SNP was conserved in almost all the 
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population of India and must be the oldest SNP present in CYP2E1 gene in Indian 
population. This SNP has also been shown to be present in other world population though 
there is no frequency data available in NCBI or HapMap databases. Similarly, SNP2 
which is novel and results in amino acid substitution from Glycine to Serine was also 
found to be polymorphic in AA, DR and IE lineages. Minor allele frequency of this SNP 
was found to be similar in AA, DR and IE population. As this SNP is novel, no allele or 
genotype frequency data is available in the HapMap or NCBI database. However, as this 
SNP is located at coding region and resulted in amino acid substitution from Glycine to 
Serine, it might be responsible for alteration in protein activity and need to be further 
studied. SNP3 was also found to be polymorphic in all sub-population of India belonging 
to different linguistic lineages. This polymorphism was found to be reported in 
Caucasians with comparable minor allele frequency with IE lineage. Interestingly, the 
MAP reported in Oriental population (Chinese and Japanese) was almost similar to 
Dravidian but found to be higher than other sub population of India. However, the minor 
allele frequency of this polymorphism in Sub-Saharan African is lower than minor allele 
frequency observed in all the sub population of India. Likewise, our validation data have 
shown that SNP4 (Dral polymorphism) of CYP2E] was found to be polymorphic in most 
of the sub-population of India except for few IE and one TB lineages. The MAP of Dral 
polymorphism observed in various sub-population of India was quite comparable to 
Caucasian population. However, this SNP was found to be present in African, Hispanic and 
Pacific Rim with higher minor allele frequency than found in different sub-population of 
India. Similarly, SNP5 was found to be polymorphic in all sub-population of India with 
varied frequency of minor allele. This polymorphism has also been reported in 
Caucasian, African American and Chinese population. Minor allele frequency reported in 
Caucasian and African American was found to be lower than found in different sub 
population of India whereas its frequency in Chinese population is similar to the found in 
AA and Out-group population but higher than IE and TB population. Haplotype analysis 
revealed the formation of nine major haplotypes. Some of these haplotypes were found to 
be present in all the four major linguistic groups and in one Out-group population though 
the frequency was found to vary between these groups. Haplotype analysis of SNPs of 
CYP2E1 also revealed that most of the SNPs did not exhibit Linkage Disequilibrium 
(LD) in majority of Indian population. However few SNPs (SNP3 & SNPS; SNPl & 
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SNP3; SNP3 & SNP4) exhibit LD in few sub-population of India. The differences in the 
frequencies of these haplotypes could be of significance in determining the individual's 
susceptibility towards the environment induced diseases. 
To further identify the involvement of these SNPs with alcoholic liver disease, a 
case-control study was carried out to investigate the association of functionally important 
SNPs in CYP2E1 gene and other candidate genes with alcoholic liver cirrhosis in North 
Indian population. Even though Rsal {CYP2E1 *5B) and Mspl polymorphism of CYP2E1 
gene were not identified in SNP Discovery Panel of 43 samples, they were also included 
in the study as they were reported to be functionally important in Caucasians and Oriental 
population. Due to their very rare frequency in Indian population, these SNPs were not 
detected in 43 representative samples of Discovery Panel. However, because of their 
clinical significance, they were included in the case-control study to investigate their 
association with the disease. Along with CYP2E1, polymorphism in glutathione S-
transferases (GSTs) and manganese superoxide dismutase {MnSOD), involved in 
scavenging free radicals, were also studied for their association with alcoholic liver 
cirrhosis. The study group consisted of 175 patients suffering from alcoholic liver 
cirrhosis and 140 number of patients suffering from non-alcoholic liver cirrhosis visiting 
the OPD facility of Gastroenterology Department of Sanjay Gandhi Post Graduate 
Institute of Medical Sciences (SGPGIMS), Lucknow, India was included in the study. 
Patients with alcoholic and non-alcoholic liver cirrhosis were diagnosed on the basis of 
their liver biopsy. Control group consisted of non-alcoholic (n=255) and alcoholic 
(n=140) healthy men having no evidence of liver disease as judged by physical 
examination and normal liver function test. All the patients and controls included in the 
study belonged to same geographical location (Northern India) and same ethnicity. 
It was found that the frequency of minor allele (1%) of CYP2E1*5B (Rsal) was 
almost similar to that reported earlier in North Indian population but slightly higher than 
South Indian controls. Similar frequency of the minor allele of CYP2E1 *5B was also 
reported in the Caucasians population while the Oriental population carry much higher 
frequency of the minor allele. Similarly, the minor allele frequency (16%) of CYP2E1*6 
(Dral) was quite similar to that reported earlier in the North Indian or South Indian 
population. This polymorphism is also reported in the Caucasians, though its frequency 
was relatively less when compared to our study or Oriental population. Our data further 
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revealed that Mspl polymorphism is present in North Indian population, though its minor 
allele frequency (6%) is quite higher than reported in Caucasians population. Similar to 
the CYP2E1, the frequency of null genotype of GSTMl (31.5%) was found to be similar 
to that reported earlier in the North Indian population. However, this was much lower 
than found in other Asian populations, Caucasians and Pacific-Rims. Likewise, the 
GSTTl null genotype frequency was found to be 17% in the controls which was similar 
to that seen in other North Indian, Caucasians and African- Americans but lower than 
reported in Orientals and Pacific Rim. Similarly the frequency of minor alleles ofGSTPl 
was found to be 22%) which was equal to that observed with other North Indian and 
Caucasians but more than that reported with Japanese and African-Americans and less 
than Hispanics and Pacific-Rim population. Likewise, the frequency of Alanine encoding 
allele of MnSOD in our study was found to be 43% which is slightly lower than that 
reported in Caucasian but much higher than that found in Orientals. 
It was also found that Rsal polymorphism (CYP2E1 *5B) of CYP2E1 gene were 
observed with higher frequency in alcoholic liver cirrhotic patients when compared with 
non-alcoholic controls or alcoholic controls or non-alcoholic cirrhotic patients. The 
higher frequency of Rsal polymorphism of CYP2E1 was found to be significantly 
associated with alcoholic liver cirrhosis risk. Interestingly, Dral and Mspl polymorphism 
of CYP2E1 did not show statistically significant risk for alcoholic liver cirrhosis. 
Haplotype analysis has revealed that Rsal and Dral polymorphism of CYP2E1 do not 
exhibit LD in either controls or cases. Haplotype approach further revealed that haplotype 
T-A-T was found to be associated with more than 5-fold increase in risk for alcoholic 
liver cirrhosis. As observed with CYP2E1 *5B, the present study also demonstrated that 
polymorphism in GSTs modifies the susceptibility to alcoholic liver cirrhosis. An 
elevated risk to alcoholic liver cirrhosis was observed in the patients with null genotype 
of GSTMl when compared with the non-alcoholic controls. Similar significant risk was 
also observed in alcoholic cirrhotic patients carrying variant genotype (Ile/Val + Val/Val) 
of GSTPl when compared with the non-alcoholic controls. Interestingly, no significant 
increase in the frequency of null genotype in GSTTl was observed in alcoholic cirrhotic 
patients when compared with the non-alcoholic controls or non-alcoholic cirrhotic 
patients or alcoholic controls. As observed with GSTs, a statistically significant risk was 
observed in alcoholic cirrhotic patients with variant genotype of MnSOD, an enzyme 
142 
Summary 
specifically involved in the detoxification of mitochondrial reactive oxygen species such 
as superoxide anion, when compared with non-alcoholic controls. 
It was also found that combination of null genotypes of GSTMl and GSTTl or 
variant genotype of GSTPl with null genotype of GSTMl or GSTTl confer an even 
higher risk to alcoholic liver cirrhosis. Likewise, a much greater risk for alcoholic 
cirrhosis was also detected in the patients carrying the combination of null genotype of 
GSTMl, GSTTl and variant genotype of GSTPl. Our data also demonstrated that 
combination of SNPs particularly those which are involved in generating free radicals 
such as CYP2E1, a phase I enzyme, and GSTs or MnSOD, which detoxify there free 
radicals increase the risk in alcoholic cirrhotic patients. Several fold increase in risk was 
observed in the alcoholic liver cirrhosis patients with the combination of variant 
genotypes of CYP2E1*5B and GSTPl or null genotype of GSTMl or GSTTl. Similarly, 
several fold increase in the risk was observed in patients with alcoholic liver cirrhosis 
carrying combination of variant genotypes of CYP2E1 *5B and MnSOD when compared 
with non-alcoholic controls or alcoholic controls or non-alcoholic cirrhotic patients. 
Further evidence for the importance of genotypic combinations in the development of 
alcoholic liver cirrhosis was provided by the present study indicating significantly 
increased risk in the cases simultaneously carrying the null or variant genotypes of GSTs 
and MnSOD when compared to the patients with the risk genotypes of GSTs or MnSOD 
alone. 
In addition to identify the association of susceptibility genotypes of CYP2E1 with 
alcoholic liver cirrhosis, attempts were also made to develop and validate CYP2E1 as a 
phenotypic marker which can eventually be used in monitoring studies to screen 
individuals for alcohol exposure. Since exposure to alcohol has been shown to result in 
increased hepatic and blood lymphocyte CYP2EI levels in laboratory animals, these 
studies have been extended to humans who are regular alcohol users and suffering from 
alcoholic liver cirrhosis with the aim to validate blood lymphocytes CYP2E] levels as a 
possible biomarker of exposure. Study was therefore initiated to investigate mRNA and 
protein expression of CYP2E1 and associated catalytic activity in freshly prepared blood 
lymphocytes isolated from non-alcoholic healthy controls, non-alcoholic cirrhotic and 
alcoholic cirrhotic patients. Eight patients suffering from alcoholic liver cirrhosis (non-
cholestatic) and equal number of patients suffering from non-alcoholic liver cirrhosis, 
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diagnosed on the basis of their liver biopsy and hepatitis B surface antigen and antibodies 
against hepatitis C virus, visiting the OPD facility of Gastroenterology Department of 
Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India 
was included in the study. Eight healthy non-alcoholic individuals were also enrolled in 
the study and served as controls. Semi-quantitative, quantitative RT-PCR, ELISA and 
NDMA-d activity were used for studying mRNA and protein expression of CYP2E1 and 
associated catalytic activity in freshly prepared blood lymphocytes of non-alcoholic 
healthy controls, non-alcoholic cirrhotic and alcoholic cirrhotic patients. Significant 
increase in the CYP2E1 mRNA and protein expression was observed in the freshly 
prepared blood lymphocytes isolated from non-cholestatic alcoholic liver cirrhotic 
patients when compared to non-alcoholic controls and non-alcoholic cirrhotic patients. 
This increase in blood lymphocyte CYP2E1 expression was associated with an increase 
in NDMA-d activity in blood lymphocytes isolated from alcoholic liver cirrhotic patients 
when compared to non-alcoholic controls and non-alcoholic cirrhotic patients. Our data 
indicating increase in CYP2E1 expression and catalytic activity in freshly prepared blood 
lymphocytes of alcoholic liver cirrhotic patients with early stage of alcoholic cirrhosis 
have suggested suitability of using blood CYP2E1 mRNA expression profile as a 
biomarker to detect the hepatic level of CYP2E1. 
In conclusion, the present dissertation had demonstrated that CYP2E1 is highly 
polymorphic in Indian population. Indian population when stratified either on language 
basis or on the basis of geographical zones, were found to exhibit polymorphism in 
CYP2E1. The presence of SNPs in CYP2E1 even in the tribal population, have fiarther 
provided evidence that these SNPs in CYP2E1 were conserved during evolution and may 
have a physiological role in addition to metabolizing drugs and environmental chemicals. 
Case-control studies have further shown that polymorphism in CYP2E1 particularly 
CYP2E1*5B and the phase II genes such as GSTs, MnSOD, are associated with an 
increased susceptibility to alcoholic cirrhosis. Risk to alcoholic cirrhosis was further 
found to increase several fold in the alcoholic cirrhotic cases carrying combinations of 
risk genotype of GSTs or CYP2E1 *5B or MnSOD demonstrating the role of gene-gene 
interactions in modulating the risk to alcoholic liver cirrhosis. The candidate in the 
present dissertation has further showed a significant increase in the CYP2E1 mRNA and 
protein expression and associated NDMA-d activity in the freshly prepared blood 
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lymphocytes isolated from non-cholestatic alcoholic liver cirrhotic patients indicating 
suitability of using blood CYP2E1 mRNA expression profile as a biomarker to predict 
the hepatic level of CYP2E1. 
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Polymorphism in Cytochrome P450 2E1 and interaction with other genetic 
risk factors and susceptibility to alcoholic liver cirrhosis 
Anwar Jamal Khan, Munindra Ruwali, Gourdas Choudhuri, Neeraj Mathur, Qayyum 
Husain, and Devendra Parmar 
ABSTRACT 
The association of polymorphism in cytochrome P450 2EI (CYP2E1), the major 
microsomal ethanol metaboHzing enzyme and its interaction with genes, involved in 
detoxification of reactive oxygen species (glutathione-S-Transferases M, GSTMl) and 
alcohol intake (gamma-aminobutyric acid receptor y2, GABRG2) was studied with the 
risk to alcoholic cirrhosis in a case control study. A total of 160 alcoholic cirrhotic, 125 
non-alcoholic cirrhotic cases, 250 non-alcoholic and 100 alcoholic controls having no 
evidence of liver disease were included in the study. PCR based RFLP methodology was 
followed for genotyping studies. Our data revealed that the variant genotypes of 
CYP2E1*5B exhibited significant association with the alcoholic liver cirrhosis when 
compared to non-alcoholic controls (OR; 4.3; 95%CI: 1.5-12.4) or non-alcoholic 
cirrhosis patients (OR: 5.4; 95%CI: 1.2-24.5) or alcoholic controls (OR: 4.3; 95%CI: 
0.95-19.62). Haplotype approach revealed that haplotype T-A-T was found to be 
associated with more than 5-fold increase in risk for alcoholic cirrhosis. Likewise, 
combination of variant genotype of CYP2E1 *5B with null genotype of GSTMl resulted 
in several fold increase in risk in alcoholic cirrhotic patients when compared with non-
alcoholic controls (OR: 7.4; 95%CI: 1.91-29.07) or non-alcoholic cirrhotic patients (OR: 
5.2; 95%C1: 1.07-25.7). Further, the combination of variant genotype of CYP2E1*5B 
with GABRG2, significantly increased the risk up to 9.0-fold in alcoholic cirrhotic 
patients (OR: 9.2; 95%CI: 1.4-72.03) when compared with non-alcoholic controls 
thereby suggesting the role of gene-gene interaction in alcoholic cirrhosis. 
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Polymorphism in glutathione-S-transferases: A risk factors in alcoholic liver 
cirrtiosis 
Anwar Jamal Khan, Gourdas Choudhuri, Qayyum Husain, and Devendra Parmar 
ABSTRACT 
The present case-control study attempted to investigate the association of polymorphism 
in glutathione-S-transferases (GSTMl, GSTTl, GSTPl), involved in detoxification of 
reactive oxygen species (ROS), with alcoholic liver cirrhosis. The study included 175 
alcoholic cirrhotic patients (ACPs) and 140 non-alcoholic cirrhotic patients (NACPs), 
visiting Gastroenterology Department, Sanjay Gandhi Post Graduate Institute of Medical 
Sciences (SGPGI), Lucknow, India. The controls included 255 non-alcoholic and 140 
alcoholic controls having no evidence of liver disease. The data showed an increase in 
risk to alcoholic cirrhosis in ACPs with null genotype of GSTMl when compared with 
non-alcoholic controls or alcoholic controls. Significant increase in risk was also 
observed in ACPs with variant genotype (Ile/Val + Val/Val) of GSTPl when compared 
with non-alcoholic controls. Our data further showed that combination of null genotypes 
of GSTMl and GSTTl or variant genotype of GSTPl with null genotype of GSTMl or 
GSTTl confer an even higher risk to alcoholic liver cirrhosis. Likewise, a much greater 
risk for alcoholic cirrhosis was observed in the patients carrying the combination of null 
genotype of GSTMl, GSTTl and variant genotype of GSTPl. Our data further showed 
that interaction of genotype of GSTs with variant genotype of manganese superoxide 
dismutase {MnSOD), which detoxifies free radical intermediate or CYP2E1, involved in 
generation of free radicals, resulted in several fold increase in risk to alcoholic liver 
cirrhosis in ACPs when compared with non-alcoholic controls thus demonstrating the 
role of gene-gene interactions in modulating the risk to alcoholic liver cirrhosis. 
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The Indian Genome Variation database (IGVdb): a project overview 
The Indian Genome Variation Consortium 
ABSTRACT 
Indian population, comprising of more than a billion people, consists of 4693 
communities with several thousands of endogamous groups, 325 functioning languages 
and 25 scripts. To address the questions related to ethnic diversity, migrations, founder 
populations, predisposition to complex disorders or pharmacogenomics, one needs to 
understand the diversity and relatedness at the genetic level in such a diverse population. 
In this backdrop, six constituent laboratories of the Council of Scientific and Industrial 
Research (CSIR), with funding from the Government of India, initiated a network 
program on predictive medicine using repeats and single nucleotide polymorphisms. The 
Indian Genome Variation (IGV) consortium aims to provide data on validated SNPs and 
repeats, both novel and reported, along with gene duplications, in over a thousand genes, 
in 15,000 individuals drawn from Indian subpopulations. These genes have been selected 
on the basis of their relevance as functional and positional candidates in many common 
diseases including genes relevant to pharmacogenomics. This is the first largescale 
comprehensive study of the structure of the Indian population with wide-reaching 
implications. A comprehensive platform for Indian Genome Variation (IGV) data 
management, analysis and creation of IGVdb portal has also been developed. The 
samples are being collected following ethical guidelines of Indian Council of Medical 
Research (ICMR) and Department of Biotechnology (DBT), India. This paper reveals the 
structure of the IGV project highlighting its various aspects like genesis, objectives, 
strategies for selection of genes, identification of the Indian subpopulations, collection of 
samples and discovery and validation of genetic markers, data analysis and monitoring as 
well as the project's data release policy. 
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Genetic landscape of the people of India: a canvas for disease gene 
exploration 
The Indian Genome Variation Consortium 
ABSTRACT 
Analyses of frequency profiles of markers on disease or drug-response related genes in 
diverse populations are important for the dissection of common diseases. We report the 
results of analyses of data on 405 SNPs from 75 such genes and a 5.2 Mb chromosome, 
22 genomic region in 1871 individuals from diverse 55 endogamous Indian populations. 
These include 32 large (>10 million individuals) and 23 isolated populations, 
representing a large fraction of the people of India. We observe high levels of genetic 
divergence between groups of populations that cluster largely on the basis of ethnicity 
and language. Indian populations not only overlap with the diversity of HapMap 
populations, but also contain population groups that are genetically distinct. These data 
and results are useful for addressing stratification and study design issues in complex 
traits especially for heterogeneous populations. 
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Polymorphism in environment responsive genes and association with 
Paridnson disease 
Madhu Singh, Anwar J. Khan, Parag P. Shah, Rakesh Shukla, V. K. Khanna, Devendra 
Parmar 
ABSTRACT 
Attempts were made in the present case-control study to investigate the association of 
polymorphism in the genes encoding proteins involved in toxication-detoxication and 
dopaminergic pathways and susceptibility to Parkinson's disease (PD). Seventy patients 
suffering from PD and one hundred healthy controls belonging to the same geographical 
location and same ethnicity were included in the study. PCR RFLP and allele-specific 
PCR-based methodology were used to identify the genotypes. Multivariate logistic 
regression analysis revealed that heterozygous genotypes of cytochrome 
P4502D6U(CYP2D6*4), CYP2E1*5B (Rsal) polymorphism and homozygous mutant 
genotypes of CYP2EI*6 (Dral) were found to be overrepresented in PD cases when 
compared to the controls. Risk was also found to be increased in patients carrying 
glutathione S-transferaseT 1 (GSTTl) null or homozygous variant genotypes of GSTPl. 
Significant association was observed for monoamine oxidase-B (MAO-B) variant allele G 
and PD, whereas no difference in genotype and allele frequencies was observed for 
manganese-superoxide dismutase (MnSOD), dopamine receptor-D2 (DRD2), and 
dopamine transporter (DAT) genes between controls and PD cases. Genotype 
combinations characterized by the presence of two variant genotypes on their 
corresponding loci revealed that four combinations of GSTTl null and MnSOD (-9Val) or 
GST null and MAOB-G or CYP2E1*5B and MAO-B-AG or CYP2E1*5B and DRD2 
(TaqlA-het) genotypes in the patients exhibited several fold higher and significant 
association with risk to PD. Our data suggest that polymorphism in the genes involved in 
detoxification and dopamine regulation may modulate the susceptibility to PD and could 
be important risk factors in the pathogenesis of PD. 
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